Exploring the use of synthetic delivery platforms and small molecule adjuvants to improve the efficacy of spinal interleukin-10 gene therapy for chronic neuropathic pain by Dengler, Ellen
University of New Mexico
UNM Digital Repository
Biomedical Sciences ETDs Electronic Theses and Dissertations
7-1-2012
Exploring the use of synthetic delivery platforms
and small molecule adjuvants to improve the
efficacy of spinal interleukin-10 gene therapy for
chronic neuropathic pain
Ellen Dengler
Follow this and additional works at: https://digitalrepository.unm.edu/biom_etds
Part of the Medicine and Health Sciences Commons
This Dissertation is brought to you for free and open access by the Electronic Theses and Dissertations at UNM Digital Repository. It has been
accepted for inclusion in Biomedical Sciences ETDs by an authorized administrator of UNM Digital Repository. For more information, please contact
disc@unm.edu.
Recommended Citation
Dengler, Ellen. "Exploring the use of synthetic delivery platforms and small molecule adjuvants to improve the efficacy of spinal
interleukin-10 gene therapy for chronic neuropathic pain." (2012). https://digitalrepository.unm.edu/biom_etds/62
 i 
ELLEN DENGLER 
       CANDIDATE  
      
     BIOMEDICAL SCIENCES- DEPT. OF NEUROSCIENCES 
     DEPARTMENT 
      
 
     THIS DISSERTATION IS APPROVED, AND IT IS ACCEPTABLE IN QUALITY 
AND FORM FOR PUBLICATION : 
 
     APPROVED BY THE DISSERTATION COMMITTEE: 
 
               
     ERIN D. MILLIGAN, PHD  , CHAIRPERSON 
  
 
     JAMES WALLACE, PHD 
 
 
     LEE ANNA CUNNINGHAM, PHD 
 
 
     C. JEFFREY BRINKER, PHD. 
 
 ii 
EXPLORING THE USE OF SYNTHETIC DELIVERY PLATFORMS AND 
SMALL MOLECULE ADJUVANTS TO IMPROVE THE EFFICACY OF 
SPINAL INTERLEUKIN-10 GENE THERAPY FOR CHRONIC NEUROPATHIC 
PAIN 
by 
Ellen C. Dengler 
B. S. Physical Therapy, University of Pennsylvania, 1975 
M. S. Biology, San Diego State University, 2007 
DISSERTATION 
Submitted in Partial Fulfillment of the 
Requirements for the Degree of  
Doctor of Philosophy 
Biomedical Sciences  
The University of New Mexico 
Albuquerque, New Mexico 
July, 2012 
 iii 
Dedication 
I’d like to dedicate this dissertation to my family. First, to my father who passed 
away from complications from brain trauma. He was my inspiration. A dedicated 
polymer researcher and wonderful father, his ability for precision and detail, and warmth 
and intelligence were to be envied. My mother is a rock, and without her I would surely 
falter. My three sisters have motivated me, aspired me, annoyed me but always loved me, 
surrounding me with rejuvenation, and validation that I am on the right path. My bother-
in-laws aspire me with their determination for success and energy. My husband, the 
organizer par excellence, has whole-heartedly supported me in this educational endeavor. 
His spirit is a delight and his intelligence astonishes me. My children now adult, are so 
dear to me. Their brightness and confidence are wonderful, and let me know my job as a 
single mom was a success. I want to thank them for understanding my need to pursue my 
dream and apologize for all the times I ignored them when I was buried in my books. I 
love you all. 
 iv 
Acknowledgements  
First, I would like to thank all my scholastic mentors, for providing me with the 
tools, advice and experiences to expand my world. You have all given me a means to 
think critically and logically. You have given me the strength, to know that I can achieve 
my inspirations and goals. During my career as a physical therapist, I have seen so many 
folks suffer from health problems and the consequences of disease. I’d like to commend 
you for your research and for all you do to educate the next generation.  
I want to thank my all my lab colleagues, office staff, animal facility staff and the 
folks in the microscopy, flow cytometry and DNA sequencing facilities for all their 
assistance in getting this research accomplished. I am forever grateful to all of you. 
I’d like to thank, my mentor Erin D. Milligan, PhD for all the time and effort she 
has put into my training as a scientist. She has always been available to help and offer 
support for my work. I am in awe of her energy, organizational skills and 
professionalism.  
 
 v 
EXPLORING THE USE OF SYNTHETIC DELIVERY PLATFORMS AND 
SMALL MOLECULE ADJUVANTS TO IMPROVE THE EFFICACY OF 
SPINAL INTERLEUKIN-10 GENE THERAPY FOR CHRONIC NEUROPATHIC 
PAIN 
by 
Ellen C. Dengler 
B.S Physical Therapy, University of Pennsylvania, 1975 
M.S. Biology, San Diego State University, 2007 
PhD Biomedical Sciences, University of New Mexico, 2012 
Abstract 
The focus of the work in this dissertation is to improve the efficiency of a gene 
therapy for the treatment of chronic pain. The introduction, Chapter 1, is intended to 
orient the reader to the underlying physiological principles and anatomical structures 
involved in general sensory and pain transmission in the peripheral and central nervous 
systems. Pain modulatory systems are described in detail. Also included, is a discussion 
of how peripheral nerve injury can provoke immune changes at the spinal level, including 
the activation of spinal macrophages and glial cells (microglia, astrocytes and 
oligodendrocytes) with the release of immune modulators, such as pro- and anti-
inflammatory cytokines, that can lead to the development of chronic pain. One of the 
most important of these is the anti-inflammatory cytokine, Interleukin-10 (IL-10). As a 
framework for the experiments described in the dissertation, earlier studies using spinal 
injections of IL-10 protein and DNA containing the gene for IL-10 for the treatment of 
neuropathic pain in a chronic constriction injury (CCI) rodent model are introduced. Also 
 vi 
presented in this dissertation, are some of the key problems of delivering DNA to cells 
(tranfection). The studies in Chapter 2, explore the use of one novel non-viral synthetic 
platform, a silica/lipid nanoparticle or “protocell,” as a potential platform for IL-10 
transgene delivery to the central nervous system (CNS). These particles had never before 
been examined in vivo in the CNS. The first objective was to determine if they simply 
would be tolerated by animals following peri-spinal injection. The second objective was 
to determine their biodistribution in the whole body following these injections and the 
cell type interacting with them near the spinal injection site. The final objective was to 
determine if the IL-10 transgene produced functional IL-10 protein following loading on 
protocells and if the gene loaded on protocells would produce a therapeutic pain reversal 
in neuropathic animals. The studies in Chapter 3 are based on previously published 
results72 of a critical interval following spinal injection of a transgene, the “sensitization 
period”, during which there is immune cell enrichment in the cerebral spinal fluid (CSF) 
in the subarachnoid matrix. This local enrichment of immune cells in the spinal CSF, is 
key to the development of the experimental approach used in Chapter 3, which is to 
prime improved cellular uptake of the IL-10 gene with small molecules as immune 
adjuvants. In Chapter 2 and Chapter 3, each experimental data set is presented in the form 
of the original manuscripts, submitted for external peer-review and publication. Chapter 4 
includes a discussion of the gene therapy approaches used in this work and by other 
investigators. Also considered are some future directions, including the use of a  different 
synthetic polymer, polylactic co-glycolic acid, PLGA, that is FDA approved and highly 
biodegradable in the body. A concluding statement completes the work of this 
dissertation. 
 vii 
Table of Contents 
Dedication ......................................................................................................................... iii	  
Acknowledgements .......................................................................................................... iv 
Abstract ............................................................................................................................. iv	  
List of Figures .................................................................................................................... x	  
Abbreviations .................................................................................................................. xii	  
1. Introduction ................................................................................................................... 1	  
1.1 Normal Pain Processing ........................................................................................................................ 1	  
1.1.1 The neuron ..................................................................................................................................... 1	  
1.2 Peripheral versus central sensory relay systems ................................................................................... 4	  
1.2.1 Sensory relay in the PNS ............................................................................................................... 5	  
1.3 Sensory relay in the CNS ...................................................................................................................... 7	  
1.3.1 Ascending pain transmission ......................................................................................................... 9	  
1.3.2 Descending modulation of pain ................................................................................................... 10	  
1.4 Pathological Pain ................................................................................................................................ 12	  
1.4.1 Peripheral Sensitization ............................................................................................................... 13	  
1.4.2 Central Sensitization .................................................................................................................... 14	  
1.4.3 Loss of inhibition ......................................................................................................................... 16	  
1.4.4 Glial cells ..................................................................................................................................... 16	  
1.5 Immunological interactions mediate pathological pain ...................................................................... 18	  
1.5.1 Innate and adaptive immunity ..................................................................................................... 18	  
1.5.2 Innate Immune Cells Display Two Distinct Activation Profiles ................................................. 19	  
1.6 Interleukin-10 a powerful anti-inflammatory cytokine ....................................................................... 21	  
1.6.1 IL-10 as a Therapeutic for Chronic Neuropathic Pain ................................................................ 22	  
1.6.2 Period of Sensitization and Cell Enrichment .............................................................................. 22	  
1.6.3 Strategies for intrathecal delivery of pDNA-IL-10 for long term expression of IL-10 .............. 25	  
1.7 Global Hypothesis Synthetic delivery platforms and small molecule adjuvants will improve the 
efficacy of spinal interleukin-10 gene therapy for chronic neuropathic pain. .................................... 29	  
1.8 Research objectives and aims: original and revised ............................................................................ 29	  
1.8.1 Original Aims .............................................................................................................................. 30	  
1.8.2 Revised Aims .............................................................................................................................. 31	  
1.9 Brief Summary of Each Chapter ......................................................................................................... 33	  
2. Mesoporous silica-supported lipid bilayers (protocells) for DNA cargo delivery to 
the spinal cord ............................................................................................................. 34	  
Abstract ............................................................................................................................ 35	  
2.1 Introduction ......................................................................................................................................... 35	  
 viii 
2.2 Materials And Methods ....................................................................................................................... 38	  
2.3 Results ................................................................................................................................................. 51	  
2.3.1 Characterization of protocells ..................................................................................................... 51	  
2.3.2 In vitro cellular viability .............................................................................................................. 54	  
2.3.3 Protocells are well tolerated in an animal model. ....................................................................... 55	  
2.3.4 Intrathecal (.i.t) DNA delivered by DOTAP:Chol or DOPC protocells remains closely 
associated with meninges. ........................................................................................................... 58	  
2.3.5 In vivo biodistribution of protocells. ........................................................................................... 61	  
2.3.6 Protocell IL-10 gene delivery leads to robust transgene expression. .......................................... 64	  
2.3.7 Protocells are functionally effective as gene delivery platforms. ............................................... 66	  
2.4 Discussion ........................................................................................................................................... 68	  
2.5 Conclusions ......................................................................................................................................... 74	  
3. Improvement of spinal non-viral IL-10 gene delivery using D-Mannose as a 
transgene adjuvant to control chronic neuropathic pain ....................................... 76	  
Abstract ............................................................................................................................ 77	  
3.1 Introduction ......................................................................................................................................... 78	  
3.2 Results ................................................................................................................................................. 83	  
3.2.1 Dexamethasone primes subsequent i.t. pDNA-IL-10 to produce transient and minimal 
behavioral reversal of allodynia ................................................................................................... 83	  
3.2.2 D-Mannose primes subsequent i.t. pDNA-IL-10 to produce long-term behavioral reversal of 
allodynia ...................................................................................................................................... 84	  
3.2.3 Characterization of D-mannose: short-term reversal of allodynia, M2-polarization, and 
increased IL-10 transgene expression. ......................................................................................... 86	  
3.2.4 Intrathecal D-mannose priming followed by i.t pDNA-IL-10 results in increased IL-10 and 
decreased IL1β expression in spinal cord and DRG .................................................................... 90	  
3.2.5 A single i.t. co-injection of D-Mannose with a very low dose of pDNA-IL-10 extends reversal 
of allodynia .................................................................................................................................. 94	  
3.3 Discussion ........................................................................................................................................... 96	  
3.4 Materials and methods ...................................................................................................................... 104	  
4. Discussion .................................................................................................................. 116	  
4.1 Gene delivery to the CNS ................................................................................................................. 116	  
4.1.1 Clinical uses .............................................................................................................................. 116	  
4.2 Approaches ....................................................................................................................................... 117	  
4.2.1 Viral vectors .............................................................................................................................. 117	  
4.2.2 Non-viral vectors ....................................................................................................................... 120	  
4.3 Mesoporous silica-supported lipid bilayers (protocells) for DNA cargo delivery to the spinal cord ( 
re-submitted to the Journal of Controlled Release) ........................................................................... 131	  
4.3.1 Investigation of toxicity and biocompatibility of protocells ..................................................... 131	  
4.3.2 Transfection capacity and efficiency of protocells .................................................................... 135	  
 ix 
4.4 Adjuvants to improve pDNA therapy ............................................................................................... 136	  
4.4.1 Adjuvants defined ...................................................................................................................... 136	  
4.4.2 Adjuvants to prime innate immunity ......................................................................................... 137	  
4.5 Improvement of spinal non-viral IL-10 gene delivery using D-mannose as a transgene adjuvant to 
control chronic neuropathic pain (re-submitted to Molecular Pain) ................................................. 139	  
4.5.1 Dexamethasone as an adjuvant .................................................................................................. 139	  
4.5.2 D-mannose as an adjuvant ......................................................................................................... 141	  
4.5.3 Mannose receptor in the CNS ................................................................................................... 146	  
4.6 Future directions ............................................................................................................................... 147	  
4.6.1 Protocells to deliver adjuvant .................................................................................................... 147	  
4.6.2 PLGA encapsulation .................................................................................................................. 149	  
4.7 Concluding remarks .......................................................................................................................... 150	  
5. References .................................................................................................................. 152	  
Appendix A: Figures ..................................................................................................... 172	  
 
 x 
List of Figures 
Figure 2.1 Characterizations of protocells. .................................................................................................... 53	  
Figure 2.2 Cells remain highly viable following application of DOTAP:Chol and DOPC protocells 
containing pDNA-IL-10-GFP. ........................................................................................................ 55	  
Figure 2.3 In vivo subtle differences in biocompatibility are revealed between DOTAP:Chol and DOPC 
protocells. ........................................................................................................................................ 57	  
Figure 2.4 Histological examination of DOTAP:Chol protocells with DNA cargo. ..................................... 60	  
Figure 2.5 The spread to brain following i.t. protocell injection is determined by the lipid bilayer 
formulation. ..................................................................................................................................... 63	  
Figure 2.6 DOTAP:Chol protocells improve cellular transfection of pDNA-IL10 transgene. ..................... 65	  
Figure 2.7 Intrathecal delivery of protocells loaded with pDNA-IL-10 causes therapeutic reversal of 
allodynia. ......................................................................................................................................... 68	  
Figure 3.1 Dexamethasone for improved pDNA-IL-10 uptake does not create robust pain reversal. .......... 84	  
Figure 3.2 The D-Mannose used to prime M2 polarization for improved pDNA-IL-10 uptake reverses 
allodynia greater than 90 days. ........................................................................................................ 85	  
Figure 3.3 D-Mannose generates short-term reversal of allodynia without pDNA-IL-10. ........................... 89	  
Figure 3.4 Spinal and DRG pro-and anti-inflammatory markers expression. ............................................... 93	  
Figure 3.5 A single co-injection of D-mannose with low dose pDNA-IL-10 produces enduring reversal of 
allodynia. ......................................................................................................................................... 95	  
Figure A.1 Characterizations of protocells. ................................................................................................. 172	  
Figure A.2 Cells remain highly viable following application of DOTAP:Chol and DOPC protocells 
containing pDNA-IL-10-GFP. ...................................................................................................... 173	  
Figure A.3 In vivo subtle differences in biocompatibility are revealed between DOTAP:Chol and DOPC 
protocells. ...................................................................................................................................... 174	  
Figure A.4 Histological examination of DOTAP:Chol protocells with DNA cargo. .................................. 176	  
Figure A.5 The spread to brain following i.t. protocell injection is determined by the lipid bilayer 
formulation. ................................................................................................................................... 177	  
Figure A.6 DOTAP:Chol protocells improve cellular transfection of pDNA-IL10 transgene. ................... 179	  
Figure A.7 Intrathecal delivery of protocells loaded with pDNA-IL-10 causes therapeutic reversal of 
allodynia. ....................................................................................................................................... 180	  
Figure A.8 Dexamethasone for improved pDNA-IL-10 uptake does not create robust pain reversal. ....... 181	  
Figure A.9 The D-Mannose used to prime M2 polarization for improved pDNA-IL-10 uptake reverses 
allodynia greater than 90 days. ...................................................................................................... 182	  
 xi 
Figure A.10 D-Mannose generates short-term reversal of allodynia without pDNA-IL-10. ...................... 183	  
Figure A.11 Spinal and DRG pro-and anti-inflammatory markers expression. .......................................... 185	  
Figure A.12 A single co-injection of D-mannose with low dose pDNA-IL-10 produces enduring reversal  
of allodynia. ................................................................................................................................................. 187 
Figure A.13 Scheme1- Schematic showing theoretical loading of 3 protocell cargos ................................ 189 
  
 xii 
	  
Abbreviations 
AAV adeno-associated virus 
AMPA α- amino-3-hydroxy-5-methyl-4-isooxazole-proionate 
AP-1 activator protein-1 
APCs antigen presenting cells 
BBB blood brain barrier 
CAMK calcium calmodulin dependent protein kinase 
CGRP calcitonin gene related peptide 
CHO chinese hamster ovary cells 
CNS central nervous system 
COX cyclooxygenase 
CpG cytosine-phosphate-guanine 
CR cytosine rich  
CREB cyclic AMP response element binding protein 
CRPS complex regional pain syndrome 
CSF cerebral spinal fluid 
CTAB cetyltrimethylammoniumbromide 
CTLD c-type lectin domain 
CTLs cytotoxic T lymphocytes 
DC-SIGN dendritic cell-specific intercellular adhesion molecule-3-grabbing 
non-integrin 
DCIR dendritic cell inhibitory receptor 
DCs dendritic cells 
Dex dexamethasone 
DH dorsal horn 
DNA deoxyribonucleic acid 
DOPC 1,2-dioleoyl-sn-glycero-3-phosphocholine 
DOPE dioleoylphosphatidylethanolamine 
DOTAP  1-(2,3-Dioleoyloxy)propyl]-N,N,N-trimethylammonium methyl-
sulfate 
DRG dorsal root ganglion 
dsDNA dsDNA 
DsREd Discosoma red fluorescent protein 
EH-1 ethidium homodimer-1 
EISA evaporation induced self assembly 
 xiii 
EPSP excitatory post synaptic potential 
ERK extracellular signal related kinase 
FDA Food and Drug Administration 
FITC fluorescein isocyanate 
GABA gamma amino butyric acid 
GC glucocorticosteroid 
GDNF glial derived neurotrophic factor 
GFP green fluorescent protein 
GR glucocorticosteroid receptor 
GRE glucocorticosteroid response element 
HEK human embryonic kidney cells 
HIV-1 human immunodeficiency virus-1 
I.T. intrathecal 
IB4 α-D-galactosyl-binding lectin 
IL-10 interleukin-10 
IL-13 interleukin-13 
IL-4 interleukin-4 
IL-6 interleukin- 6 
IL1-β interleukin1-beta 
IL1Ra interleukin1 receptor antagonist 
INF-γ interferon gamma 
IPSP inhibitory post synaptic potential 
IRAK interleukin-1 receptor-associated kinase 4 
IκB-2 inhibitor of nuclear factor kappa light chain enhancer of activated 
B cells 
JAK Janus kinase 
LVs lentivirus 
M1 classical pro-inflammatory macrophage activation 
M2 alternative anti-inflammatory macrophage activation 
MAPK mitogen activated protein kinase 
MHC major histocompatibily complex 
MINCLE macrophage-inducible C-type lectin 
MR mannose receptor 
MSNs mesoporous silica nanoparticles 
MTT 3-(4,5-dimethylthiozal-2-yl)-2,5-dipheyl-tetrazolium bromide 
NFκ-B nuclear factor kappa-light-chain-enhancer of activated B cells 
NGF nerve growth factor 
NK1 neurokinin receptor 
 xiv 
NMDA N-methyl-D-aspartate 
NO nitric oxide 
NPCs nuclear pore complexes 
ODN2006 oligodeoxynucleotide 
PAG peri-aqueductal grey 
PAMAM polyamidoamine 
PAMPS pathogen associated molecular patterns 
pDNA plasmid DNA 
PEG polyethylene glycol 
PEI polyethylenimine 
PKA protein kinase A 
PKC phosphokinase C 
PKC protein kinase C 
PLC phospholipase C 
PLGA poly-lactic-co-glycolic acid 
PMI phosphomannose isomerase 
PNS peripheral nervous system 
PRRs patterned recognition receptors 
RNA ribonucleic acid 
ROS reactive oxygen species 
RVM rostral ventral medulla 
siRNA silencing RNA 
ssDNA single stranded DNA 
ssRNA single stranded RNA 
STAT signal transducer and activator of transcription 
TEOS tetraethylorthosilicate 
TGF-β transforming growth factor 
Th1 T helper 1 cells 
Th2 T helper 2 cells 
TLR toll like receptor 
TNF-α tumor necrosis factor alpha 
WDR wide dynamic range
 1 
1. Introduction 
1.1 Normal Pain Processing 
1.1.1 The neuron 
The primary and basic unit of the nervous system is a specialized cell, the neuron, 
composed of a cell body or soma from which extend many processes known as dendrites 
that receive incoming signals, and axons, which are long extensions of cytoplasm ending 
in nerve terminals for signal transmission. Some neuronal axons are myelinated by a 
layer of insulating myelin protein, while others are unmyelinated and lack this covering. 
Neurons communicate with other neurons across the synapse or space between them by 
releasing chemicals known as neurotransmitters. The cell body or soma houses the 
nucleus containing chromosomal DNA and the transcriptional machinery for cellular 
replication and protein synthesis. The cell soma also contains the subcellular organelles 
responsible for metabolic and neuronal nutritional support and the formation of the 
neurotransmitters. 1 
There are three types of morphologically distinct neurons. The classically 
depicted neuron is multi-polar, with many branching dendrites emanating from the cell 
body. From this neuron projects only one long axon that ends in multiple branched 
terminals. Bipolar neurons have two long processes, one a dendrite and one an axon, with 
a cell soma in the middle. Both ends are composed of many branches. These are found in 
the visual, auditory and vestibular systems. One category of sensory neurons is composed 
of nociceptors, having specialized receptors on their peripheral terminal endings that to 
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respond to and transmit painful stimuli that can cause tissue damage (harsh chemicals, 
high or low temperatures or hard pressure). Nociceptors have one axon with two terminal 
endings, one in the periphery, in the skin or viscera, and the other end synapsing onto 
neurons in the spinal cord or brainstem. All sensory neurons entering the spinal cord, 
including nociceptive neurons, have cell bodies outside the CNS in a structure referred to 
as the dorsal root ganglia (DRG).2  
The resting membrane potential in neurons is about -60 mV. During resting 
conditions, passive inward diffusion of extracellular positive ions (cations; Na+, K+) is 
opposed by an outward diffusion of intracellular negative ions (anions; Cl-, negatively 
charged amino acids and proteins). Transient membrane currents make the neuronal 
membrane either more negative (hyperpolarized) or less negative (depolarized). 
Depolarization of the axon hillock to about -45 mV results in the firing of an action 
potential, caused by the rapid influx of Na+ through volt sensitive Na+ channels. This is 
countered by an efflux of K+, that eventually returns the membrane to its resting state. 
The action potential courses along the axon as the voltage reaches that necessary to open 
voltage-gated Na+ ion channels. The velocity is dependent on the diameter of the axon 
and the amount of myelination. Along the course of myelinated axons are periodic gaps, 
known as Nodes of Ranvier. The low capacitance and concentration of Na+ channels in 
these nodes allows the action potential to jump between nodes (salutatory conduction), 
increasing the speed of conduction over long distances in myelinated neurons. It is 
important to note that larger diameter myelin-insulated axons conduct more quickly than 
smaller myelinated axons. Unmyelinated axons, conduct slowly. Pain is transmitted by 
lightly myelinated Aδ and unmyelinated C-fibers.3 
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Sensory neuronal communication from the periphery, results from the release of 
neurotransmitters in a Ca2+ dependent manner from the axon terminals of presynaptic 
neurons. Thsese neurotransmitters act upon receptors on dendrites or the cell soma of the 
post-synaptic neuron in the spinal cord. If neurotransmitter binding generates 
depolarizing ionic fluxes of the post-synaptic membrane, the net result is an excitatory 
post-synaptic potential (EPSP). However, if the post-synaptic membrane is 
hyperpolarized, an opposite response or inhibitory post-synaptic potential or (IPSP) 
occurs. The intensity of a stimuli is transduced into a frequency code. That is, the more 
intense the sensory stimuli, the more rapid is the firing of axonal action potentials. The 
major consequence of nociceptor firing is the release of excitatory neurotransmitters from 
central terminals onto post-synaptic neurons in the spinal cord. Inhibitory neurons within 
the spinal cord, also respond to increased firing frequency from peripheral sensory 
neurons but release inhibitory neurotransmitters that change the membrane potential in 
the direction of hyperpolarization. In addition to frequency based, temporal summation of 
post-synaptic potentials, there post-synaptic potentials can be summated in a spatial 
manner because one axon terminal can converge on more than one dendrite in the spinal 
cord. Via summation, a painful stimulus transmitted by one primary nociceptive neuron is 
capable of generating high frequency post-synaptic action potentials on many nearby 
central spinal cord neurons. Temporal or spatial summation can lead to an exacerbation 
of the intensity of pain perception despite the fact that the stimulus remains constant.4, 5 
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1.2 Peripheral versus central sensory relay systems 
Grossly, the nervous system in animals is composed of the central nervous system 
(CNS) and the peripheral nervous system the (PNS). The PNS conveys incoming or 
afferent messages and outgoing or efferent messages from the tissues and organs of the 
body and outside environment to and from the CNS (spinal cord and brain). The CNS is 
composed of both myelinated (white matter) and unmyelinated (gray matter) tissue. The 
spinal cord, a relay system of neurons, is housed in the vertebral canal formed anteriorly 
by the vertebral body and posteriorly by boney laminae connecting the tranverse and 
spinous processes. The peripheral nerves enter and exit from openings, or foraminae, 
between two adjacent vertebrae. The spinal cord and brain are protected by the meninges, 
which is composed of three connective tissue membranes. Closest and adhering to the 
spinal cord is a thin layer known as the pia mater. The outside layer is a thicker protective 
layer, the dura mater, while sandwiched between is the arachnoid membrane. Between 
the pia and arachnoid membranes is the subarachnoid space, in which the CSF is 
contained and circulates. This space is also known as the intrathecal (i.t.) space. The 
spinal cord extends from an opening in the skull, known as the foreman magnum, and 
ends inferiorly at level of the L1-2 vertebra in humans, forming a cone-like structure 
known as the conus medullaris. In this area are many nerve rootlets, collectively known 
as the cauda equina or “horses-tail” floating in a pool of CSF, within the lumbar cistern in 
the dural sac.6, 7  
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1.2.1 Sensory relay in the PNS 
There are two major classes of sensory neurons carrying information from the 
periphery to the spinal cord, each classified by letters of the Greek alphabet or Roman 
numerals. The first class are non-nociceptors, possessing Aα (I) and Aβ (II) fibers that 
transmit non-painful stimuli such as light touch, pressure, vibration or proprioception 
(body position). These fibers have large diameters 12-20 and 6-13 µm respectively, and 
are highly myelinated, allowing for rapid conduction of action potentials. Under normal 
conditions, Aα (I) fibers respond to motion and limb position, while Aβ (II) fibers 
respond to vibration and light touch pressure.8 Sensory neurons express many different 
types of receptors. In the skin, mechanoreceptors discriminate tactile, vibratory and body 
position sense (proprioceptive) stimuli. These receptors include Meissner corpuscles 
(tactile, shapes and surfaces), Merkel discs (indentations), hair follicle receptors (tactile), 
Ruffini endings (stretch), Pacinian corpuscles (vibrations). In the muscle, specialized 
muscle spindles respond to  proprioceptive stimuli.9  
The second class are the nociceptive neurons previously discussed. To reiterate, 
nociceptors have receptors that are only activated when mechanical, thermal or chemical 
stimuli reach, noxious harmful (tissue damaging) levels. There are two sub-types of 
nociceptive fibers. Aδ (III) fibers, are small in diameter (1-6 µm) and thinly myelinated, 
and are slow conducting and have a higher activation threshold, perceived as “fast” pain, 
described as a sharp, pricking, well-localized pain. Aδ fibers can be further divided into 
two sub-types. Type I, respond to low mechanical or chemical stimuli, such as pinprick 
but have a high heat threshold (> 50°C). Conversely, Type II fibers have a much lower 
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heat threshold, but a higher mechanical threshold. C (IV) fibers are unmyelinated and 
smallest in diameter, <1.5 µm, thus are very slow conducting, with a very high 
mechanical and thermal activation threshold. Pain perceived via these nociceptors is 
described as “slow”, burning, diffuse and poorly localized. The nociceptors, Aδ and C 
fibers, can be further divided into two broad categories, the peptidergic class, which 
release the neuropeptides, substance P and calcitonin-gene related peptide (CGRP) and 
classical excitatory neurotransmitters such as glutamate. The non-peptinergic fibers 
release only the classical excitatory neurotransmitters. In addition, many non-peptidergic 
neurons express the purinergic ATP-gated ion channel receptor, P2X3. It is important to 
note that PX3 is part of a much larger 2PX receptor family. ATP binding to this receptor 
plays a role in the development of chronic pain.10-12 In summary, nociceptors respond, via 
thermo and mechanoreceptors, to extremes of heat, cold and pressure. 
While mechano and thermo-receptors are critical in nociceptor activation, their 
terminal endings also express chemo- receptors that respond to a host of chemical stimuli. 
One classic example is the chemical in red hot peppers, capsaicin, which activates 
transient receptor potential cation channel (TRPV1). Other TRPV receptors respond to 
natural cooling agents such as menthol and eucalyptol (TRPM8), or acids (ASICs). 
TRPV1 also responds to inflammatory factors generated following tissue damage.11, 15, 16 
The major classical excitatory transmitter released in the dorsal horn of the spinal 
cord by primary sensory afferents, both nociceptive and non-nociceptive, is glutamate. 
Glutamate binds to fast acting ionotropic α-amino-3-hydroxy-5-methyl-4-isooxazole 
proionate (AMPA) receptors, causing an influx of Ca+ that raises baseline membrane 
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potential sufficiently to activate ionotrophic N-methyl-D-aspartate (NMDA) receptors. 
This response will be explained in greater detail below. Metabotropic NMDA, and kainite 
receptors also respond to glutamate. With membrane depolarization, petidergic Aδ and C-
fibers release the small peptides substance P, which binds neurokinin-1 receptors (NK1) 
receptors, and CGRP,15which binds its receptor CGRP1.16-18  
In summary, when nociceptive receptors are activated, an action potential is 
propagated along the course of primary (1o) axons terminating in the dorsal spinal cord 
where they synapse on secondary (2o) projection neurons that carry the message from the 
spinal cord to the brainstem or brain. Others synapse on interneurons that communicate 
with other neurons at the spinal cord level. Whereas nociceptive 1o neurons terminate in 
the dorsal horn (DH), non-nociceptive neurons also synapse locally in the DH, yet have 
major collateral branches that ascend in the dorsal column to the dorsal column nuclei in 
the medulla. Moreover, both nociceptive and non-nociceptive axons send collateral 
branches to other areas of the spinal cord several segments above or below their entry 
into the dorsal spinal cord or to other areas on the same level.19, 20  
1.3 Sensory relay in the CNS 
The DH is the primary spinal cord area for pain modulation. The gray matter of 
spinal cord is divided into ten layers or laminae, analogous to the layers of an onion 
extending from the posterior, Lamina I, to the anterior, Lamina IX. Lamina X is located 
in the center of the spinal cord, surrounding the central canal. The DH includes Lamina I-
VI. Nociceptive sensory afferent axons enter the spinal cord through the dorsal root entry 
zone, collect in the Tract of Lissauer (dorsal lateral fasciculus) and then send axons 
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collaterals into the DH where they synapse on 2o pain projection neurons and 
interneurons in laminae I-VI in the dorsal horn. Nociceptive 2o projection neurons cross 
or decussate to the opposite of the spinal cord (contralateral) where they course rostrally 
toward the brain via the lateral spinothalamic tract, such that painful stimuli received on 
the left side of the body is processed in the right side of the brain. Axons of non-
nociceptors ascend to the medulla, where they synapse in the dorsal column nuclei on the 
same side (ipsilateral). In humans, those non-nociceptive neurons originating below the 
thoracic 6 (T6) vertebral level, ascend in the dorsal column fasiculus gracilis (medial 
dorsal column), while those above T6 ascend in the fasiculus cuneatus (lateral dorsal 
column). At the level of the caudal medulla in the brainstem, axonal fibers from the 
cuneate and gracilis nuclei cross to the contralateral side and ascend via the medial 
lemniscus to the somatosensory cortex. As a result, non-nociceptive stimuli received 
from the left side of the body are also processed by the contralateral somatosensory 
cortex.2, 20  
Important to the development of chronic pain, both myelinated and non-
myelinated, 1o nociceptive and non-nociceptive fibers project to the superficial Lamina I 
and II of the spinal cord. While some nociceptive Aδ project more deeply to Lamina V, 
most synapse in Lamina I, and Lamina II.21 In these lamina, there are inhibitory 
interneurons that release gamma-aminobutyric acid (GABA) or glycine. These inhibitory 
neurotransmittors can act both pre and post-synaptically.12 Type I Aδ fibers have been 
shown to bifurcate upon entry into the dorsal horn and ascend and descend several 
segments. Type II Aδ have main branches that ascend in the dorsal columns giving rise to 
many collaterals that penetrate ventrally to the dorsal horn lamina I, where they arborize, 
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thus communicating with many neurons at several segmental levels.15 Wide dynamic 
range (WDR) neurons that have cell bodies in Lamina V and dendrites in Lamina II-V 
that receive input from Aδ, Aβ and C fibers. WDRs are critical to pain relay and the 
development of pathological pain.21 Peptidergic C fibers mostly terminate in Lamina I 
and II, while non-peptidergic C fibers terminate mostly on Lamina II interneurons.11 Aβ 
fibers enter the dorsal spinal cord with ascending branches and in addition send 
collaterals to Lamina II and V.16 It is possible to propose an anatomical mechanism, 
whereby non-noxious sensory information, such as light touch, is miscoded to noxious 
painful stimuli, based on the contacts that non-noxious Aβ fibers make with Lamina V, 
WDR neurons and the dendrites of Lamina I neurons.  
1.3.1 Ascending pain transmission 
From the spinal cord, 2o nociceptive projection neurons ascend to the brainstem or 
brain. These fibers travel to the medulla, through the pons and further rostrally to the 
mid-brain and on to the thalamus, the major sensory relay system of the brain. There they 
synapse on tertiary 3o (thalamic) sensory neurons that send projections to the post central 
gyrus of the cortex and other cortical areas involved in sensory processing. The post 
central gyrus processes the type, amplitude, location, duration of the noxious stimuli, 
while the hippocampus processes the memory of pain. Other pain processing occurs in 
the limbic system, including the amygdala, anterior cingulate and insular cortex, which 
together process the emotional experience of pain. Noxious stimuli activate the 
hypothalamic-pituitary adrenal axis, which in turn activates the sympathetic nervous 
system and the cardiovascular stress responses associated with pain. While there are 
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several other ascending pathways, two are important for pain transmission. First is the 
spino-reticular tract, composed of ipsilateral axons from laminae VII and VIII, which 
terminate in the reticular formation of the pons and the thalamus. The second, is the 
spinomesencephalic tract composed of neurons from laminae I and V, projecting from the 
anterolateral spinal cord to the mid-brain mesencephalic reticular formation and 
periaqueductal gray matter and from there via the spinoparabrachial tract to the 
parabrachial nuclei in the thalamus. Pain and touch sensations from the head and face 
mostly travel to the brainstem by the cranial nerve V, the trigeminal nerve. Most of these 
1o trigeminal axons enter the mid-pons and descend in the spinal trigeminal tract to 
synapse with the spinal nucleus V which extends from the lower pons along the entire 
length of the medulla. The 2o projections from the trigeminal nucleus then cross to the 
contralateral side before ascending to the thalamus where they synapse on 3o neurons. A 
small portion of trigeminal neurons synapse on 2o projection neurons that remain on the 
ipsilateral side, and ascend directly to the thalamus.19  
1.3.2 Descending modulation of pain 
One of the best characterized systems of descending modulation upon the dorsal 
horn neurons begins in the mid-brain, peri-aquetuctal gray (PAG) and the rostral 
ventromedulla (RVM), including the nucleus raphe magnus and the adjacent reticular 
formations. The system, known as the PAG-RVM, receives ascending information from 
the dorsal horn of the spinal cord and responds to descending information from the higher 
pain processing areas in the forebrain. Conversely, the PAG-RVM sends output fibers, 
mostly serotonergic, back to the dorsal horn of the spinal cord, modulating nociceptive 
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input from peripheral sensory neurons and enkephalin releasing interneurons. The 
neurons of the PAG–RVM have been shown to be the main site in the CNS for the action 
of a number of pain suppressing agents such as endogenous opioids (enkephalins, β-
endorphins, dymorphins, endomorphins and nociceptins) that bind the µ, δ, κ opioid 
receptors. Opioid drugs and endogenous opioids work partially by increasing inward K+ 
conductance, which hyperpolarizes the post-synaptic membrane and indirectly decreases 
Ca+ entry into the presynaptic terminals altering their GABA release.20, 22 Other 
important inhibitors with receptors in this area are cyclooxygenase (COX) inhibitors23 
and cannabinoids.24, 25 In addition, noradrenergic neurons, originating in the locus 
ceruleus of the pons exert descending modulation of dorsal horn interneurons via α2-
adrenergic receptors on these cells, with concurrent release of enkephalins.26  
One role of the neurons of the PAG-RVM is to provide descending inhibitory 
control to the spinal cord. One example of this inhibition of pain responses or 
hypoalgesia (decreased response to painful stimuli) is that which occurs under extreme 
stress and fear. Such is the case when a soldier or athelete continues functioning on the 
battlefield or playing field following injury. The opposite response, hyperalgesia 
(increased responsiveness to painful stimuli), such as that experienced in inflammation or 
nerve injury, can at least in part be attributed to a shift in the balance of descending pain 
modulation from inhibition to facilitation. 
Once thought to be only inhibitory, descending control is now recognized to be 
facilitory as well.24, 27 A seminal study by H.L. Fields et al., using electrical stimulation 
and pharmacological blockade, demonstrated three types of cells in the RVM, ON-cells 
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and OFF-cells and NEUTRAL-cells.28 When ON-cells were active, OFF-cells were silent 
and visa versa. Subsequent experiments confirmed that OFF-cells function to inhibit 
nociceptive neurons in the dorsal horn and as such are anti-nociceptive, while ON-cells 
are facilitory or pro-nociceptive. The role of NEUTRAL-cells in pain modulation has not 
yet been clearly established.28 ON-OFF cells have also been shown to exert similar 
influence from the PAG.29 The equilibrium between these two cell populations in the 
RVM has been associated with the subtle shifts of spinal nociceptive responses leading to 
chronic pain.  
1.4 Pathological Pain 
In some cases, such as after a traumatic injury or wound infection, pain itself can 
become pathological. Some examples are post-surgical pain, phantom pain following an 
amputation, diabetic neuropathy, fibromyalgia and complex regional pain syndrome 
(CRPS).30 Normally, pain serves to protect individuals from harmful stimuli that might 
cause severe tissue damage or injury. Typically, when the harmful stimulus is removed 
the pain goes away.30 Chronic pain, clinically defined as lasting greater than 3 months, is 
no longer adaptive or serving any useful purpose.31 Neuropathic pain is typically 
characterized by hyperalgesia and/or allodynia, a condition in which stimuli not normally 
considered painful, such as a light touch, is perceived as excruciatingly painful.32 Primary 
hyperalgesia occurs at the actual site of the peripheral injury and is very intense, while 
secondary hyperalgesia is in the surrounding, uninjured tissue, and is usually of lesser 
intensity.33 Chronic neuropathic pain is a serious clinical problem that effects millions of 
people annually costing billions of dollars while current treatments are sorely inadequate. 
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31 In a survey conducted by the American Pain Foundation, of 303 pain sufferers 
currently on opioid medications, 50% felt that they had little or no control over their pain 
and 60% experienced break through pain that severely affected their quality of life.34 
There are at least four proposed hypotheses as to how acute pain becomes 
chronic.35 The first is synaptic “plasticity” involving modulation of synaptic efficacy. 
Primary sensory neurons can become sensitized or respond to equal or lesser stimuli with 
greater firing frequency and more release of neurotransmitter. This can happen between 
either two similar (homosynaptic) types of neuronal fibers, or between two different 
(heterosynaptic) fiber types. A second important mechanism involves NMDA receptors, 
producing Ca+ dependent long-term potentiation. The third is loss of inhibition from 
descending pain modulatory pathways and interneurons. Finally, glial cells, activated by 
inflammatory immune responses have been shown to contribute to the onset of 
pathological pain. These mechanisms are explained in detail in the sections that follow.35  
1.4.1 Peripheral Sensitization  
If a 1o nociceptive terminal ending is exposed to sustained stimuli, it fires a 
barrage of action potentials that can lead to temporal and spatial summation accompanied 
by short-term changes at the terminals, known as peripheral sensitization. In now classic 
studies Medall, in 1984,36 showed that a repeated low frequency firing of nociceptive C 
fibers leads to a progressive increase in action potential frequency, with the co-release of 
glutamate, substance P and CGRP from both peripheral and central terminals. The result 
is increased membrane excitability and lowered threshold for receptor activation, 
occurring centrally as well as peripherally. Now while there change in their intensity, 
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subsequent stimuli, even those that are non-noxious, can be perceived as more painful,. 
This form of short-term potentiation of synaptic signaling terminates when the sensory 
stimulus is removed.37-39  
With prolonged firing, endogenous factors are also released from terminal 
endings of nociceptors, including serotonin, cytokines interleukin-1β (IL-1β), substance 
P, protons such as H+, reactive oxygen species (ROS) and other factors that facilitate 
leukocyte migration or extravasation in the tissue injured region. In turn extravasating 
innate immune cells such as mast cells, macrophage and dendritic cells release even more 
factors that compound the excitement of nerve terminals. Together, these molecules are 
known as the “inflammatory soup”.40, 41 As a consequence, peripheral nerve terminals are 
dramatically sensitized, leading to decreased nociceptor-activation thresholds, which if 
sustained, can lead to pathological pain. 37, 39  
1.4.2 Central Sensitization 
In the CNS there are essentially four general mechanisms that contribute to 
“central sensitization”, a form of long term enhancement or facilitation of output from the 
dorsal horn of the spinal cord following injury. These include: 1) increased trafficking of 
AMPA receptor subunits to the synapse, particularly those that are Ca2+ permeable, 2) 
activation of NMDA receptors with sufficient depolarization of the neuronal membrane 
to allow expulsion of a magnesium ion (Mg2+) that under resting conditions normally 
blocks the central channel of the NMDA receptor, 3) activation of kinases, enzymes 
capable of phosphorylating membrane channels and receptors altering their activity, and 
4) activation of downstream intracellular signaling pathways. 38, 39, 41  
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To expand in more detail, with repetitive and prolonged nociceptor firing, there is 
sufficient binding of glutamate to fast acting AMPA receptors, and generation of enough 
post-synaptic depolarization, to activate NMDA receptors. The voltage change results in 
expulsion of a magnesium (Mg2+) ion normally blocking its central channel. The opening 
of this channel allows for a rapid influx of Ca2+ into the neuron and activation of 
Ca2+dependent kinases. Some of these are the Ca2+-calmodulin dependent protein kinase 
(Cam-KII), protein kinase C (PKC) and protein kinase A (PKA). All are capable of 
phosphorylating of tyrosine and serine residues on subunits of the AMPA and NMDA 
receptors with the subsequent activation of intracellular signaling pathways. The 
Ca2+dependent signaling occurring in the development of chronic pain has been 
suggested to be similar to the changes thought to be occurring in long term potentiation 
(LTP) of memory in the hippocampus.42 Elevated Ca2+ levels drive the calmodulin-
induced activation of adenylyl cyclases, increasing cAMP and turning on PKA. Other 
pathways sustaining central sensitization are the phosolipase C/phosphokinase C 
(PLC/PKC) pathways that facilitate release of Ca2+ from the endoplasmic reticulum. 
Another is the mitogen-activated protein kinase (MAPK) pathway activating the kinases 
(ERK 1 and ERK 2), serine threonine kinases that turn on genes under the control of the 
cAMP response element binding protein (CREB), a nuclear transcription factor. Such 
signaling ultimately results in long term changes in gene expression, with transcriptional 
up regulation of pain neurotransmitters, modulators and their receptors with increased 
trafficking of the receptors to the cell surface and expansion of receptor fields. 
Nociceptors are now firing with greater frequency to stimuli of lesser intensity.32, 39  
 16 
1.4.3 Loss of inhibition 
Critical to the enhancement of excitatory pain responses is loss of local DH spinal 
inhibitory influences. Activation of Aδ fibers causes long term NMDA and CA2+ 
depression of DH inhibitory interneuron firing and internalization of AMPA receptors.43 
Peripheral nerve injury can cause the death or apoptosis of GABAergic interneurons in 
the dorsal horn contributing to disinhibition of nociceptive inputs. This cell death may be 
the direct result of glutamate in the synapse. High levels of glutamate are known to be 
toxic in neurons .42, 44, 45  
Loss of descending pain inhibition also exacerbates the chronicity of pain. It has 
been shown that in conditions of chronic inflammation, such as in chronic arthritis that 
ON-cell firing predominates, with elevation of c-fos, a transcription factor up-regulated 
following recent neuronal activity.46 Studies using c-fos labeling to demonstrate dynamic 
neuronal activity, have shown that descending inhibition from the VLM failed to inhibit 
the powerful nociceptive pain signaling from the spinal cord in the early stages of 
inflammation. Thus, the control from the brain and brainstem during inflammation or 
nerve injury can contribute to the positive feedback loops leading to pathologic pain 
states.  
1.4.4 Glial cells 
Research in the last 15+ years has shown that neuropathic pain is at least in part 
the consequence of activated immune cells and immune-like glial cells in the CNS.40, 47 
This activation has been shown to alter and amplify normal nociceptive signaling, leading 
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to alteration of the perception of pain and its chronicity. Both innate and adaptive 
immune cells are also important for pain modulation, not only in acute peripheral 
inflammation and nerve trauma, but also in development of persistent pain. 40, 47 Spinal 
glial cells are widely characterized to be activated by excitatory factors (e.g. substance P, 
ATP) released from the central terminals of Aδ, Aβ and C fibers. In turn these activated 
glia release factors, discussed below, that further stimulate nearby neurons and glia 
creating a positive feed-forward excitatory loop.48, 40 
While there are three glial cell types found in the CNS, the most widely 
characterized to play a role in the development of neuropathic pain signaling are 
microglia, considered the resident immune cell of the CNS and astroglia, known for their 
role in glutamate uptake and neuronal homeostasis (neuronal nutritional support and 
participation in the blood brain barrier). 47, 49, 50 Recently, the oligodendrocyte, the third 
glial cell, responsible for myelination of axons, has been suggested to respond to pro-
inflammatory signaling by IL1-β, in a white matter injury in mouse brain resulting in 
increased secretion of metalloprotease-9 (MMP-9) with the promotion of small blood 
vessels and capillaries (angiogenesis) into the injured area. 51 Another study has shown 
IL-1-β to disturb oligodendrogenesis and increase the number of nonmyelinated neurons 
in neonatal mice.52 Under normal conditions quiescent astrocytes and microglia are 
scattered around the spinal parenchyma.38 Once glial cells become activated, they secrete 
pro-inflammatory cytokines (IL-1β, Il-6 TNF-α, INF-γ) as well as prostaglandins, 
diffusible nitric oxide (NO), ROS, complement proteins, histamine and other small 
molecules. Concurrent with this release and glial activation, are phenotypic changes in 
their normal resting morphology to a more spindly, branched appearance when active.  
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Glial activation contributes to the dysfunction of excitatory signaling from 
nociceptors. 40, 47, 48 The result is altered expression of cytokines, cytokine receptors, volt-
gated sodium channels, increased release of glutamate and enhanced glutamate receptor 
functions in both peripheral and central axon terminals. All these changes subsequently 
provoke disinhibiton at the level of spinal cord and from higher pain regulatory pathways 
and activation and migration of peripheral and CNS resident immune cells. To resolve 
inflammation and restore homeostasis to the extracellular environment, the onset of a 
pro-inflammatory state is followed by a delayed release of anti-inflammatory cytokines 
interleukin-4 (IL-4), interleukin-13 (IL-13), IL-10, and transforming growth factor-beta 
(TGF-β). These restore the local environment to its basal state. 40, 47, 48  
1.5 Immunological interactions mediate pathological pain 
1.5.1  Innate and adaptive immunity  
There are essentially two types of immune responses, each with its own 
specialized cells. The cells in the “innate” or early immune response, have genetically 
evolved to recognize specific molecular patterns on invading pathogens or microbes, 
known as pathogen associated molecular patterns (PAMPS). Innate immune cells, such as 
the antigen presenting cells (APCs), macrophage, dendritic cells (DCs), have specialized 
receptors known as patterned recognition receptors (PRRs) which bind PAMPs, 
activating cell signaling pathways. Receptor activation and the release of certain 
cytokines can stimulate a dynamic process known as phagocytosis in which the 
pathogen/receptor complex is engulfed by cytoplasm and carried into the cell in 
specialized cell surface sub-cellular vesicles or phagosomes. There, the foreign matter is 
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broken down in to small molecular pieces known as antigens. Antigens are then presented 
to the cells of the adaptive immune system, namely B and T cells, by protein complexes 
on the cell surface. These complexes are known as major histocompatibility complex 
(MHC). All cells of the innate immune system are capable of the processes involved in 
antigen presentation.53  
When presented with antigen and in the presence of critical co-stimulatory 
molecules, B cells produce and secrete antibodies that are specific to each antigen. The 
antibody/antigen complexes then bind specialized receptors on phagocytic macrophages 
and are destroyed by cellular enzymes. The second response is cell-mediated immunity 
and relies chiefly on T helper 1 (Th1) cells and T helper 2 (Th2) and other T cells. 40, 53  
In the periphery and CNS innate leukocytes, like macrophage and DCs, are 
continually surveying for foreign materials or pathogens and are rapid responders. 
Adaptive immune responses directed by B and T cells are much more delayed as they 
must be presented antigen by APCs before becoming activated. 
1.5.2  Innate Immune Cells Display Two Distinct Activation Profiles  
 Macrophages and DCs, are capable of two polarized states. M1 or “classical” 
activation is created by expression of pro-inflammatory cytokines, such as IL-1β, TNF-α 
and others, important for pathogen clearance following viral or bacterial derived 
recognition of PAMPs. M1 macrophage assume a rounded morphology, express more 
receptors for the pro-inflammatory cytokines and can be characterized by 
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immunohistochemistry using antibody to human CD68 (rat ED1) a 110 kD protein 
primarily expressed on M1 macrophage cells.54-56  
Conversely, the M2 activation profile is distinguished by the presence of anti-
inflammatory cytokines IL-4, IL-13 and IL-10,54-56 and mostly associated with 
phagocytic activity during wound healing and clearance of dying cells or cells 
undergoing apoptosis. M2 polarized cells can be characterized by the markers, human 
CD163 (rat ED2), a 130 kD macrophage associated antigen, which is a member of the 
scavenger receptor family, exclusively expressed by monocytes and macrophages and 
mannose receptor (MR; human CD206), a classic marker of alternative macrophage 
activation.47, 49, 50, 54-56 
 In the past, the CNS was considered “immune privileged” such that under normal 
conditions, the neurons of the brain and spinal cord parenchyma were protected from 
immune cell invasion by the endothelial blood brain barrier (BBB). It was thought that 
only in the event of an infection or inflammatory process, did these barriers open and 
allow the passage of immune cells. The more recent perspective is that immune traffic is 
normal and necessary for protection from infection and cancer.57, 58 In actuality, the CNS 
contains many cells that when activated can release and express receptors capable of 
responding to cytokines, inflammatory and pain mediators and contribute to pathological 
pain signaling. Antigen presenting macrophage, DCs and other leukocytes capable of 
mounting immune responses and cytokine release, reside in the meninges and around 
small spinal capillaries and blood vessels and in peri-vascular spaces around the central 
spinal canal. 47, 59  
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1.6 Interleukin-10 a powerful anti-inflammatory cytokine 
One of the most powerful anti-inflammatory cytokine, is interleukin-10 (IL-10). IL-
10 dramatically inhibits the exacerbation of the pro-inflammatory responses preventing 
potential cellular and organismal damage.60-62 In the CNS, IL-10 is endogenously produced 
by innate immune cells, such as microglia,63-65 macrophages,66, 67 and DCs.60-62 Astrocytes 
also express receptors for this cytokine.  
The binding of IL-10 to its receptor initiates a number of phosphorylation events that 
activate the Janus kinase (JAK)/ signaling transducer and activator of transcription (STAT) 
signaling pathway and leads to long-term transcriptional alterations. The receptor is 
composed of two subunits, IL-10R1 and IL-10R2 subunits. Two IL-10 molecules form a 
homo-dimer that bind the receptor and constitutively activate two tyrosine kinases, Jak1 and 
Tyk2, associated with the IL-10R1 and IL-10R2 cytoplasmic tails respectively.62 Activation 
of these residues is followed by the recruitment of STAT3 to the receptor and 
phosphorylation of its Tyr705 residue.60 Phosphorylated STAT3, then translocates to the 
nucleus, and binds a STAT3 recognition sequence in the transcriptional promoter for the 
interleukin 1 receptor antagonist (IL-1Ra). Subsequent chromatin remodeling and histone 
acetylation at this promoter exposes other transcription sites to transcription factors such as 
the p65/p50NFκ-B and upregulates expression of IL-1Ra. IL-1Ra is a cytokine capable of 
profound reduction in proinflammatory signaling by the IL-1β cytokine and others. A 
delayed expression of more IL-10 and IL-10 receptor contributes to a robust anti-
inflammatory response.60, 62  
 22 
1.6.1 IL-10 as a Therapeutic for Chronic Neuropathic Pain  
Capitalizing on it natural anti-inflammatory effect, prior work has shown that peri-
spinal intrathecal injection of IL-10 protein can reverse neuropathic pain. However, the 
reversal was only transient, lasting less than 24 hours, an observation explained as being due 
to the short, ~ 2 hour, half-life of the protein. Next, a similar injection strategy was attempted 
using a naked plasmid, containing the gene for IL-10. The hypothesis was that over-
expression of IL-10 protein near the area of the dorsal spinal cord, responsible for pain 
modulation would prolong pain relief. Indeed, the hypothesis proved correct. Pain relief was 
prolonged to 3 months, but required two injections and excessive doses of DNA, (125 µg), 
which is of limited clinical usefulness when translated to humans.68 
1.6.2 Period of Sensitization and Cell Enrichment 
An important discovery was observed during these initial studies. There was a 
discrete interval or “sensitization period” between the two i.t. injections, between 5 hours 
and 3 days, during which the first injection served to sensitize the sub-arachnoid 
compartment to the second injection.69 If the second injection was given outside this time 
window, the length of pain reversal was dramatically shortened, from 3 months to 10 
days.69 
Examination of CSF during the sensitization period showed that it was enriched 
with cells that were found to be mostly macrophage expressing an activated phenotype 
(possible proinflammatory), identified by the a cell surface glycoprotein, ED1(CD68).69 
By six hours, the number of ED1 positive cells had dramatically declined. Six days later, 
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the majority of cells expressed the anti-inflammatory phenotype, identified by ED2 
(CD163), another cell surface glycoprotein. More importantly, increased expression of 
ED2 positive cells paralleled the increase of endogenous IL-10 production in the sub-
arachnoid space, following injection of pDNA.69 
Cell enrichment and sensitization by immune cells can be stimulated by factors 
that act as PAMPs but without the presence of actual bacteria or virus. 70, 71 An example 
are cytosine-phosphate-guanine (CpG) DNA sequences that occur with high frequency in 
bacterial DNA. Naked DNA used in these studies, contains many of these stimulatory 
sequences which may have been responsible for activation of immune cells following the 
first injection of pDNA-IL10 in these early experiments.72 By the time of the second 
injection, three days later, M2 polarized macrophage were poised and ready for 
phagocytosis and efficient uptake of the IL-10 transgene.72, 73 Facilitating a switch from 
M1 activation to M2 activation of the subarachnoid immune and spinal glial cell milieu 
was hypothesized to be one approach to harness innate immune responses for optimal 
transgene uptake and expression. 
In an effort to improve transgene uptake by inducing M2 polarization of peri-
spinal macrophage, Sloane et al. explored the use of a discrete CpG containing 
oligodeoxynucleotide sequence, ODN2006, as candidate gene transfer adjuvant.72 This 
ODN sequence is a natural ligand for toll-like receptor 9 (TLR9), an endosomal receptor 
in macrophages, and part of a large family of Toll-like receptors (TLRs).71 CpG 
sequences are taken up by macrophages and transported by clathrin-coated vesicles to the 
endosome where they fuse and bind to TLR9. This can induce the expression of 
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endogenous IL-10, leading to a phenotypic switch from a pro-inflammatory to an anti-
inflammatory profile shown to facilitate phagocytosis.71,74 A priming injection of 
ODN2006 (2 µg), administered 3 days prior to a low dose of naked pDNA-IL-10 (25 µg), 
causes pain reversal to baseline levels but only for approximately one month. This data 
can be interpreted that ODNs may act as adjuvants. 
In Chapter 3 of this dissertation, two alternative transgene adjuvants, Dexamethasone 
(Dex) and D-mannose, are used with pDNA-IL-10 to achieve enduring pain reversal. Both 
Dex and D-mannose are known to bind their cognate receptors, glucocorticosteroid receptor 
(GR) and mannose receptor (MR), respectively. This binding triggers anti-inflammatory 
signaling cascades in leukocytes (macrophage and dendritic cells) and results in the release 
of IL-4, IL-10 with a concurrent reduction in pro-inflammatory cytokine levels, such as IL1-
β and TNF-α, leading to a switch from an M1 to an M2 phenotype. M2 polarization is 
accompanied by enhanced phagocytic ability.75-77 We hypothesized that a priming injection 
of Dex or D-mannose as an adjuvant might facilitate a switch from M1 to M2 polarization of 
leukocytes near the injection site in the spinal cord. The consequence would be the 
enhancement of IL-10 transgene uptake with subsequent IL-10 expression, thereby achieving 
allodynic reversal with lower doses and number of injections. Such expression of the anti-
inflammatory IL-10 protein by meningeal cells, microglia, dendritic cells and astroglia near 
the injection site would allow for diffusion of the IL-10 cytokine directly near the source of 
the pathologic pain response.78, 79  
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1.6.3  Strategies for intrathecal delivery of pDNA-IL-10 for long term expression of IL-
10  
1.6.3.1  Naked Plasmid 
One of the key barriers for transgene delivery of a naked plasmid DNA (pDNA) is 
translocation across the cell membrane. Moreover, the exact mechanisms by which the non-
viral pDNA reaches the cell nucleus are not well characterized. One potential route is by 
pinocytosis, a process that all cells are capable of performing. The cell membrane surrounds 
the DNA engulfing it in a small vesicle which then travels through the cytoplasm and fuses to 
a larger vesicle known as an endosome (pH 5.0-5.5). The DNA must escape the endosome or 
it can be carried to a lysosome (pH 4.0-4.5) where DNA degradation occurs. If the DNA 
successfully escapes the endosome, it must travel across the cytoplasm to the cell nucleus 
where it must cross the nuclear membrane by fusion or passage through nuclear pores to 
reach the cellular transcription machinery. Other than pinocytic endocytosis, potential 
mechanisms for pDNA entry are 1) phagocytosis or engulfment by specialized cells such as 
macrophage, 2) receptor mediated endocytosis, or 3) entry during mitotic breakdown of the 
outer cell and nuclear membranes during cell division.80  
As noted previously, in order to be transcribed pDNA must cross the nuclear 
membrane or envelope. In replicating mitoic cells, the membrane breaks down and the 
DNA easily crosses, but in cells that are post-mitotic, this process is more difficult. The 
nuclear envelope is a double membrane crossed by many large protein complexes known 
as nuclear pore complexes (NPCS) which regulate transport. NPCs have a pore size of ~9 
nm, which allow free diffusion of small and medium ions and molecules up to 40-60 kD 
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or nucleic acids up to 300 bp. Non-dividing transport of larger molecules such as pDNA, 
requires a sequence specific nuclear localization signal (NSL), which is recognized by 
specialized proteins called importins. Protein-NLS/importin complexes dock at the NPC 
allowing DNA entry.81 The nuclear entry of transfected DNA is accomplished indirectly 
by its association with NLS on transcription factors.82  
1.6.3.2 Synthetic carriers for gene delivery 
It is thought that synthetic delivery platforms can assist in enhancing transgene 
expression by protecting DNA from acidic degradation and promoting endosomal escape.83 
Certain synthetic formulations lower energy barriers and promote membrane fusion or attract 
protons (H+) creating an osmotic sponge attracting water molecules, which burst the 
endosomal membrane.84, 85  
The studies presented in Chapter 1 of this dissertation investigate the potential of 
using a novel silica particle supporting a lipid bilayer known as a “protocell” as a possible 
platform to deliver the 5.9 kilobase pair (kb) pDNA-IL-10 to the CNS by intrathecal 
injection. At the time these studies began, protocells had never been taken in vivo in the 
CNS, so the initial goal was to simply see if they would be tolerated by the animals and to 
determine their anatomical biodistribution following intrathecal injection. In addition we 
wanted to know what spinal cells were interacting with them. Another question was whether 
the IL-10 transgene loaded on protocells could successfully transfect cells, and if the 
transgene generate functional IL-10 protein following transfection. Finally, as proof of 
concept, we wanted to know if IL-10 loaded on protocells could be utilized as therapeutic IL-
10 gene vector that would reverse allodynic behavior in neuropathic rats. We set out to 
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determine these goals in vivo using 62 Sprague-Dawley rats and in vitro with cell culture 
studies. The protocells used in these experiments were “first generation” protocells similar to 
those used by Liu, et al.100,101,215 The mesoporous silica core had a diameter from ~150-200 
nm and a range of pore diameters of ~1-10 nm. The majority of pores were ~3 nm in 
diameter. The core supported either a positively charged, DOTAP:CHOL 1:1 lipid or a 
zwiterionic, neutrally charged DOPC lipid. Silica at pH7 is negatively charged95 and would 
repel the negatively charged pDNA-IL10, so 10% aminoproyltriethoxysilane APTES was 
included to reverse the charge of the silica to positive. (Please refer to Chapter 1 (Methods) 
for more detail.) It is important to note that at the time of these experiments, these were the 
only protocells documented.100,101,215 By the time the “next” generation of protocells was 
developed,94 animals and materials had been utilized and the goals outlined above had been 
completed. It was imperative in these initial studies that we establish a fundamental 
understanding of protocell distribution in the CNS and any potential for toxicity in our 
animal model of neuropathic pain, before further modifying the delivery vector, protocells. 
In total, 3 different protocell cargos were used in the experiments in Chapter 1. The 
first, was a red fluorphore Dextran tetramethyl rhodamine (DexRHO). The second was a 
FAM-tagged 18 base pair single stranded DNA oligomer. FAM is a green fluorophore used 
as a reporter in our microscopic examination of protocell distribution in the CNS and body 
following intrathecal injection of the particles. The third cargo was a 5.9 kilo base (kb) 
plasmid, encoding the gene for IL-10. While determining exactly how these cargos load on 
the protocell was not a goal of the studies in Chapter 1, we have speculated how these 
molecules would load on the protocell in the schematic below (Scheme 1 A-C). 
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Scheme 1- Schematic showing theoretical loading of 3 protocell cargos- A) This cargo is a negatively 
charged, 18 bp DNA oligomer with an approximate length of 6.12 nm and a diameter of ~2. It is tagged 
with a negatively charged fluorophore, FAM, which has a MW of 473.4 and an approximate planar length 
of .139 nm and height of .722 nm, as calculated by bond lengths. FAM-tagged DNA may load directly into 
the silica pores (~3 nm diameter). B) Negatively charged dextran tetramethyl-rhodamine (DEXRHO) is 
composed of a dextran polymer with a MW of 10,000 conjugated tetra-methyl rhodamine groups. The 
tetramethyl-rhodamine group has an approximate planar length of .983 nm and height of .576 nm as 
calculated by bond lengths. This very large molecule is thought to load onto the protocell by adsorption 
with the positively charged DOTAP:CHOL 1:1 lipid bilayer and positively charged 10% aminated 
mesoporous silica core. C) Negatively charged plasmid encoding the gene for IL-10 most likely assumes a 
supercoiled structure and is thought to load by adsorption in a manner similar to DEXRHO. During the 
synthesis process each cargo was mixed with the silica and rinsed 3xs with PBS before the liposomes were 
added.  
 
A more in depth discussion regarding the loading of these cargos and the advantages 
and disadvantages of using protocells and other synthetic platforms for gene delivery will 
presented in Chapter 4, the discussion section of this dissertation. 
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1.7 Global Hypothesis Synthetic delivery platforms and small molecule adjuvants 
will improve the efficacy of spinal interleukin-10 gene therapy for chronic 
neuropathic pain. 
1.8 Research objectives and aims: original and revised 
As experiments progressed, the sequence and content of the original research aims 
was revised to better correlate with the data being observed. The original aims and 
revised aims are outlined below for the reader’s convenience. 
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1.8.1 Original Aims 
Specific Aim I: Encapsulating pDNA-IL-10 in PLGA microparticles (pDNA-IL10-
PLGA) will safely reduce the dose and number of injections required to provide 
pain relief of 3 months or greater 
Specific Aim IA: In vitro characterization of PLGA: 
1) To determine if cultured mammalian cells will remain viable following 
application of pDNA IL-10-PLGA. 
2) To determine if cultured mammalian cells transfected with pDNA-IL-
10-PLGA will express higher levels of IL-10 protein than when 
transfected with naked pDNA-IL-10.  
Specific Aim IB: In vivo characterization of PLGA : 
1) To determine if pDNA-IL10-PLGA will produce pain relief for 3 
months with only one i.t. injection 
2) To determine if pDNA-IL-10 must be encapsulated to produce pain 
relief for 3 months or greater 
3) To determine if there is an optimal dose of pDNA-IL-10-PLGA that 
will provide enduring pain relief lower both the doses of pDNA-
IL-10 and PLGA while a ratio of 1:100 is maintained (1 ug pDNA-
IL-10/100 ug PLGA; ratio = 1/100) 
a) Lower the dose of pDNA-IL-10 while the PLGA dose is 
constant (1 ug pDNA-IL-10/ 1 mg PLGA; ratio = 1/1000)  
Specific Aim II: Protocells can be safely used to deliver small molecules or pDNA-IL10 
(pDNA-IL-10-PCs) to the CNS for enduring pain relief of 3 months or greater 
Specific Aim IIA: In vitro studies: to determine the dissolution and 
biocompatibility characteristics of protocells 
1) To determine the dissolution rate of protocells over time at different 
physiological pH (temperature held at 37ºC) 
2) To determine if cultured mammalian cells will remain viable following 
application of pDNA-IL-10GFP-PCs 
3) To determine if cultured mammalian cells can be transfected with 
pDNA-IL-10GFP-PCs to produce measurable levels of IL-10 
protein 
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Specific Aim IIB: In vivo studies: characterization of protocells and assessment 
of functional transgene delivery 
1) Biocompatibility following spinal delivery in rats 
2) Biodistribution in the CNS and body  
3) Characterization of cellular interactions 
Specific Aim IIB1: Protocell delivery of pDNA-IL-10 will cause pain reversal in 
neuropathic rats  
Specific Aim III: Protocells loaded with known adjuvants and co-administered with 
pDNA-IL10-PLGA will lower the transgene dose required to reverse pain for 3 
months or greater 
Specific Aim IIIA: In vitro studies-characterization of the cellular influence of 
adjuvants (Dex and ODNs) 
1) To determine if mammalian cell cultures are viable in the presence of 
adjuvant loaded protocells  
2) To determine if IL-10 protein levels are improved if adjuvant molecules 
are co-administered with pDNA-IL-10-PLGA 
3) Characterization of the pro or anti-inflammatory cellular profile of 
macrophage cells interacting with adjuvant loaded protocells 
Specific Aim IIIB: In vivo studies- behavioral characterization 
1) To determine if protocells loaded with adjuvants co-injected with 
pDNA-IL-10-PLGA extend pain reversal  
2) To determine if IL-10 gene expression and pain relief will be blocked 
or altered by an anti-IL-10 neutralizing antibody  
1.8.2 Revised Aims 
Specific Aim I: Protocells can be safely used for spinal delivery of pDNA encoding the 
IL-10 gene.  
Specific Aim IA: In vitro characterization: to determine the release and 
biocompatibility characteristics of protocells 
1) To determine the release rate of protocell cargo over time at different 
physiological pH (temperature held at 37ºC) 
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2) To determine if cultured mammalian cells will remain viable following 
application of pDNA-IL-10GFP-PCs 
3) To determine if cultured mammalian cells can be transfected with 
pDNA-IL-10GFP-PCs to produce measurable levels of IL-10 
protein 
Specific Aim IB: In vivo characterization and assessment of functional transgene 
delivery 
1) Biocompatibility following spinal delivery in rats 
2) Biodistribution in the CNS and body  
3) Characterization of cellular interactions 
4) Protocell delivery of pDNA-IL-10 will cause pain reversal in 
neuropathic rats  
Specific Aim II: Immune adjuvants will lower the transgene dose required to reverse 
chronic neuropathic pain  
Specific Aim IIA: Characterization of immune adjuvants to initiate the 
sensitization period for improved pain reversal with low dose IL-10 gene  
1) To determine if a priming injection of DEX will lower the required IL-
10 gene dose for prolonged pain reversal 
Specific Aim IIB: Characterization of D-mannose as an M2 polarizing agent  
1) In vitro: To determine if D-mannose induces an M2 polarized profile in 
macrophage 
2) In vivo: To determine if D-mannose alone leads to pain reversal 
Specific Aim IIC: To identify an M2 polarized profile following the sensitization 
period in pain-reversed rats 
1) In vivo: To determine if IL-10 or IL-1β protein levels are altered in the 
spinal cord if the best candidate adjuvant is delivered prior to 
naked pDNA-IL-10 
Specific Aim IID: To determine if a single co-injection of D-mannose with low 
dose pDNA-IL-10 will generate enduring pain reversal 
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1.9 Brief Summary of Each Chapter 
Chapter 2 describes experiments that characterize the release rates of protocell 
cargo, formulated with either DOPC or DOTAP:Cholesterol lipids. Different pH and time 
values were examined in an effort to understand cargo release under specific conditions. 
These two protocell formulations were tested in vivo by injecting them into the peri-
spinal, i.t., space in Sprague-Dawley rats and found to be biocompatible and non-toxic 
over an 8 week time course. Interestingly, protocells supporting the two different lipids 
revealed not only slightly different release kinetics in vitro, but a clear difference in 
distribution patterns in vivo and transfection efficiency. These studies are the first 
demonstration that protocell vectors can be used as a non-viral platform for spinal 
delivery of a therapeutic gene to reverse allodynia in neuropathic rats, albeit for a short 
duration. 
Chapter 3 explores the use of the two small molecules, Dex and D-Mannose, 
referred to as gene therapy M2 polarizing adjuvants. I observed that compared to Dex, D-
Mannose was superior in priming prolonged and dose dependent suppression of pain in 
neuropathic rats at low transgene IL-10 doses. Macrophage cell culture studies 
demonstrated that D-Mannose was capable of reducing levels of proinflammatory 
modulators, the cytokines IL-1β and tumor necrosis factor TNFα and nitric oxide (NO) 
while increasing endogenous and transgene derived IL-10 protein levels of IL-10, 
supporting notion that the adjuvant, D-mannose altering spinal immune cells in the 
direction of an M2 phenotype and improved efficiency of transgene uptake. 
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Abstract 
Amorphous mesoporous silica nanoparticles (‘protocells’) that support surface 
lipid bilayers recently characterized in vitro as carrier constructs for small drug and DNA 
delivery are reported here as highly biocompatible both in vitro and in vivo, involving the 
brain and spinal cord following spinal delivery into the lumbosacral subarachnoid space 
(intrathecal; i.t.). Specifically, positively charged, 1, 2-Dioleoyl-3-Trimethylammonium-
Propane (DOTAP)-cholesterol (DOTAP:Chol) liposome-formulated protocells revealed 
stable in vitro cargo release kinetics and cellular interleukin-10 (IL-10) transgene 
transfection. Recent approaches using synthetic non-viral vector platforms to deliver the 
pain-suppressive therapeutic transgene, IL-10, to the spinal subarachnoid space has 
yielded promising results in animal models of peripheral neuropathy, a condition 
involving aberrant neuronal communication within sensory pathways in the nervous 
system. However, these non-viral platforms are limited in terms of tuning cargo release-
rates and surface chemistries, thereby minimizing flexibility in lowering dosage 
formulations. We report here that i.t. delivery of protocells, with modified chemistry 
supporting a surface coating of DOTAP:Chol liposomes and containing the IL-10 
transgene, results in functional suppression of pain-related behavior in rats for extended 
periods. This study is the first demonstration that protocell vectors offer amenable and 
enduring in vivo biological characteristics that can be applied to spinal gene delivery. 
2.1 Introduction 
The development of synthetic non-viral vectors for gene therapeutic purposes has 
steadily increased during the past 10 years, an effort that is reflected by increased non-
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viral gene therapeutic clinical trials worldwide.86, 87 While viral vectors are superior in 
gene transfection efficiency, non-viral gene transfer systems are associated with less 
safety concerns. The application of central nervous system (CNS) non-viral gene transfer 
to express therapeutic proteins is significantly underexplored in light of the broad-ranging 
therapeutic potential in controlling a host of neurological diseases. The arsenal of 
potential clinical gene delivery platforms includes cationic lipids and peptides, co-
polymers, polymeric micelles, and modified silica nanoparticles.88-90 Indeed, a significant 
amount of progress toward our understanding and utilizing mesoporous silica 
nanoparticles (MSN) for controlled drug and gene release, while optimizing 
biocompatibility, has occurred in recent years.91 Silicas are present in crystalline and non-
crystalline (amorphous) forms, with amorphous silica occurring either naturally or are 
synthesized. While crystalline silica is widely associated with adverse health effects 
including silicosis that involves proinflammatory cytokine-mediated pathogenesis, 
virtually no toxicity has been identified with synthetic amorphous silicas at moderate 
doses.92, 93 Therefore, synthetic amorphous silicas have been explored in biomedical 
applications including targeted drug delivery for cancer chemotherapeutics and DNA 
delivery for gene therapy.94, 95 The major advantage of using synthesized MSNs is that 
their surface can be chemically modified, resulting in improvements in their drug cargo 
capacity, as well as facilitation of tunable release rates which further enhances their 
biocompatibility and functional capabilities.96 
Mesoporous silicas contain a porous structure with hundreds of channels referred 
to as mesopores, which are able to adsorb bioactive molecules.96 The properties of MSNs 
include a large surface area (> 900m2/g), large pore volumes (> 0.9 cm3/g), a tunable 
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pore size (~1-30 nm), and good chemical and thermal stability; all of which contribute to 
their suitability for controlled drug release applications. Additionally important, efficient 
cellular uptake of mesoporous silica particles is size-dependent, with optimal uptake 
occurring at the sub-micron scale with potential for controlled DNA release.90  
Non-viral spinal gene therapy to suppress neuropathic pain is a relatively new 
approach that has resulted in successful therapeutic outcomes in a variety of animal 
models of pathological pain produced by peripheral nerve inflammation and/or trauma 
from systemic cancer chemotherapeutic administration, peri-sciatic immune activators, or 
chronic constriction injury.73, 79, 97-99 However, high transgene doses and limited cargo 
loading efficiency of polymer platforms were observed, which may minimize the clinical 
utility of this delivery method. One approach to circumvent these limitations is to deliver 
therapeutic genes utilizing MSNs for transgene delivery due to their flexibility in cargo 
loading and release.  
In the present work, in vitro and in vivo long-duration biocompatibility, 
biodistribution, and functional gene expression following delivery to the spinal cord was 
conducted using cationic amine-chemically-modified (functionalized) mesoporous silica 
cores with ~2 nm diameter pores prepared by aerosol-assisted self-assembly, with 
phospholipid bilayers fused to the core surface. The term ‘protocell’ will be used to 
reference MSN-supported lipid bilayers to maintain consistency of nomenclature with the 
initial published description of their manufacture and characterization.94, 100,101 The 
principle attractiveness of utilizing these protocells as drug and gene delivery platforms is 
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in their potential for increased drug containment properties, and the tenability of surface 
chemistry modifications tailored to specific cargos.  
2.2 Materials And Methods 
Animals. A total of 62 adult, male Sprague-Dawley rats (Harlan Labs, Houston, 
TX); 300 +/- 5 g were double housed at 21 +/- 4°C in light controlled rooms (12:12 light: 
dark) and fed standard rodent chow and water available ad libitum. All procedures were 
approved by the Institutional Care and Use Committee (IACUC) of the University of 
New Mexico, and conducted in accordance to the guidelines recommended by the 
International Association for the Study of Pain for the handling and use of laboratory 
animals. 
Behavioral assessment for sensory changes. Baseline spinal cord activity is 
evaluated using the well-characterized protocol for assessing threshold responses to light 
touch applied to the hindpaws with a series of calibrated monofilaments (0.4-15 g). The 
monofilaments generate a touch stimulus when applied to the hindpaw that induces a paw 
withdrawal response within 8 seconds.102,103 Paw withdrawal sensory thresholds are 
highly sensitive to subtle inflammatory perturbations in the spinal cord, as normal 
hindpaw response thresholds (5-10 g) are present during healthy, non-pathological 
conditions, 103, 104 while response thresholds dramatically decrease (< 1 g) in the presence 
of inflammatory signaling.103,104 This behavioral response phenotype is used as an 
indicator of spinal cord health. Prior to behavioral thresholds, rats were habituated to the 
testing conditions for 4 consecutive days, 1 hr/day, in a quiet dimly lit and temperature 
controlled room (26.0-27.0° C), where rats were placed on top of an open grid of bars 
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with 2 mm thickness, spaced 8 mm apart to allow access to the entire plantar surface of 
the hindpaw for tactile stimulation. Response thresholds were determined by a 
logarithmic series of calibrated Semmes-Weinstein monofilaments (von Frey hairs; 
Stoeling, Wood Dale, IL). Testing of behavioral thresholds were conducted identically to 
that described previously.103,104 Briefly, baseline (BL) responses to light mechanical 
touch stimuli were assessed using 10 monofilaments, each with a log-stiffness value, 
defined as log10 (milligrams X 10), values in grams follow in parentheses: 3.61(.407), 
3.84(.692), 4.08(1.202), 4.17(1.48), 4.31(2.04), 4.56(3.63), 4.74(5.49), 4.93(8.51), 
5.07(11.75) and 5.18(15.14). BL values derived from three threshold assessments, at 20 
min intervals, were averaged for the right and left hindpaws separately. After injection of 
protocells, threshold responses were re-assessed at .5, 1, 2, 3, 24 and 72 hrs. In those rats 
that underwent unilateral sciatic nerve injury, thresholds were reassessed at 3 and 10 days 
post surgery and every 2 days, up to 32 days post peri-spinal (intrathecal; i.t.) protocell 
injection. To assess normal food consumption as an indication of general health, body 
weights were measured following 2, 4, 8, 12, 14, 21, 28, and 56 days following i.t. 
administration of protocells. 
Chronic constriction injury (CCI). The surgical procedure for chronic 
constriction injury (CCI) was performed identically as previously described 105, 106. 
Briefly, under isofluorane anesthesia (1.5-2.0% vol. in oxygen), the mid to lower back 
and dorsal thigh were shaved and cleaned with diluted Bactri-Stat AE (EcoLab 
HealthCare Division, Mississauga, Ontario, Canada). Using aseptic procedures, the 
sciatic nerve was carefully isolated and four chromic gut sutures (Ethicon, Somerville, 
NJ) were loosely tied around one sciatic nerve. The overlying muscle was sutured closed 
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with two, sterile, silk sutures (Ethicon, Somerville, NJ), and the overlying skin was 
closed with wound clips. The sciatic nerve of sham-operated rats were identically 
exposed but not ligated. Animal body weight was recorded and recovery from anesthesia 
was observed within 10 minutes. 
Intrathecal (i.t.) injections. Injections were acutely administered and conducted 
as described previously.99,107 Briefly, rats were anesthetized with isofluorane (5.0% 
volume in oxygen) and an 18-gauge cannula constructed from an 18-gauge sterile 
hypodermic needle (Beckton Dickinson & Co., Franklin Lakes, NJ), removed from its 
hub, was inserted percutaneously between lumbar vertebra 5 and 6 (L5-6). During this 
time, a small amount of cerebral spinal fluid (CSF) efflux from the 18-gauge cannula and 
a tail flick were observed, indicating subarachnoid catheter placement. A 1 ml Hamilton 
syringe connected to a 30-gauge, 0.5 inch needle inserted into a catheter composed of a 
30 cm-length polyethylene tubing (PE-10; cat# 427401; Becton Dickinson, Sparks, MD) 
was then used to draw up DOTAP:Chol or DOPC protocells (1.0, 0.1 or 0.01 mg) in a 
total volume of 20 µl sterile, isotonic saline. The drug-filled PE-10 catheter was then 
inserted into the open end of the 18-gauge guide cannula, and advanced 7.7 mm rostrally, 
placing the internal portion of the PE-10 catheter at the lumbosacral enlargement of the 
spinal cord where axon terminals of sciatic afferent nerve fibers synapse onto pain-
relevant spinal cord neurons. Injections were given over a 0.5-1 minute interval. 
Following drug injection, the PE-10 catheter was removed followed by removal of the 
18-gauge cannula, and both were discarded. The total time required for these i.t. 
injections was 2-3 minutes. All animals displayed full motor activity following recovery 
from anesthesia. 
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Preparation of plasmid DNA. The plasmid vector used in these studies was 
identical to that previously described.107 This plasmid’s transcriptional cassette consists 
of a cytomegalovirus enhancer/chicken beta-actin (CB) promoter driving expression of 
the rat IL-10 gene containing a point mutation (F129S) and the SV40 polyadenylation 
signal. The identical plasmid lacking the IL-10 gene was used as a control. Both plasmids 
were amplified in SURE II competent E. coli (Stratagene, Cedar Creek, TX.) and isolated 
using an endotoxin free Giga plasmid purification kit (Qiagen, Valencia, CA).  
 Preparation of mesoporous cationic silica “core” protocells. The mesoporous 
silica particles were prepared by the surfactant self-assembly method described 
previously.100, 108 Briefly, a homogeneous solution of the soluble silica precursor, 
tetraethylorthosilicate (TEOS; Sigma-Aldrich Corp., St. Louis, MO), and hydrochloric 
acid was mixed in ethanol and water. A surfactant, cetyl trimethylammonium bromide 
(CTAB; Sigma-Aldrich Corp., St. Louis, MO), with an initial concentration much less 
than the critical micelle concentration was added to lower the surface tension of the liquid 
mixture and act as the mesoporous structure-directing template. Aerosol solutions of 
soluble silica plus surfactant were then generated with nitrogen as a carrier atomizing gas 
using a commercially available atomizer (Model 9392A, TSI, Inc., St. Paul, MN). The 
aerosol droplets were solidified in a tube furnace at 400 °C until dry. Once dried, a 
durapore membrane filter, kept at 80 °C, was used to collect the particles. As a final step, 
the surfactant was removed at 400 °C for 5 hrs via calcination. The surface of the 
mesoporous silica core in these studies was chemically modified with 10% by wt. 
aminopropyltriethoxysilane (APTES; Sigma-Aldrich Corp., St. Louis, MO) to create a 
positive surface charge to increase loading efficiency of negatively charged cargo.  
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Preparation of liposomes for protocells. The lipids used in this study were 
either positively charged, 1, 2-Dioleoyl-3-Trimethylammonium-Propane (DOTAP; cat. # 
890890C; Avanti Polar Lipids Inc. Alabaster, AL) or zwitterionic and neutrally charged, 
1, 2- dioleoyl-sn-glycero-3-phosphocholine (DOPC; cat. # 850375; Avanti Polar Lipids 
Inc., Alabaster, AL). Cholesterol was added to DOTAP in a 1:1 ratio, as it has been 
reported to improve transfection efficiency when included in cationic liposomes.109 
Phospholipids were dissolved in chloroform at concentrations of 10-25 mg/ml. Lipid 
aliquots of 2.5 mg were placed in scintillation vials. Alexa Fluor 647, a red fluorescent 
dye (absorption 650 nm and emission 658 nm; Invitrogen, Carlsbad, CA), was added at 
2% for labeling studies. Chloroform was then evaporated under nitrogen flow. The vials 
were then stored overnight in a vacuum oven to remove remaining chloroform. Samples 
were stored at -20oC until used. 
To prepare liposomes, vials were brought to room temperature and samples 
rehydrated with 1 ml buffer (10 mM MOPS, pH 7.0, 60 mM NaCl) and shaken for 1 hr, 
which resulted in a cloudy suspension. The suspension was extruded through a 100 µm 
pore diameter membrane with in a mini-extruder (Avanti Polar Lipids), and repeated for a 
minimum of 21 times. The resulting liquid was placed in a fresh vial and stored at 4 °C 
until used in the preparation of DNA loaded protocells. 
Preparation of DNA loaded “protocells”. An 18 bp-DNA oligomer (5ʹ′-
CTTGAGAAAGGGCTGCCA-3ʹ′) tagged with 6-carboxylfluorocein (FAM; absorption 
492 nm emission 520 nm; Invitrogen, Carlsbad, CA) was used to identify the safety 
profile and anatomical location of protocell cargo following i.t. injection. To load the 
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silica core with DNA, 35 µl of 200 µM DNA was added to 3.5 mg of cationic silica 
nanoparticles, gently mixed in sterile 0.5X PBS (25 mg/ml; 140 µl per 3.5 mg particles) 
and allowed to incubate for 5 min. In a sterile microcentrifuge tube, 300 µl of 2.5 mg/ml 
of liposome mixture was added and mixed with the nanoparticle/ DNA mixture by 
pipetting until homogeneous. The resulting mixture was allowed to sit at room 
temperature for 1 hr with occasional agitation by pipetting and then centrifuged for 2 
min. at 6000 RPM to remove excess lipids. The supernatant was discarded, and the pellet 
was washed in sterile PBS followed by centrifugation at 6000 RPM. Pellets 
(protocell/18mer-DNA-FAM/ lipid mixture) were washed 3X and resuspended in sterile 
PBS at 50, 5 or 0.5 mg/ml. Identical steps were followed when loading pDNA-IL-10 and 
resuspended in 50 mg/ml.  
Characterization of silica. Transmission electron microscopy (TEM) images 
were acquired with a JEOL 2010 200kV high-resolution transmission electron 
microscope. The pore diameter was calculated by the Barrett-Joyner-Halenda (BJH) 
method.110 The total surface area was calculated by the Brunauer, Emmett & Teller 
(BET) method,111 from the N2 sorption isotherm shown in Supplemental Figure 1. 
Characterization of cargo release-rate from protocells. Mesoporous silica 
nanoparticles (25 mg) modified with 10% APTES were dispersed in 1 ml PBS to give a 
concentration of 25 mg/ml, 12.5 µl of 20 mM dextran-tetramethylrhodamine 
(DexRho;Molecular Probes, Invitrogen, Carlsbad, CA) was added to yield ~250 µM. The 
solution was agitated at room temperature for 45 min, and 50 µl aliquots of each protocell 
formulation for each time point were centrifuged for 2 min, washed 3X with 200 µl of 
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0.25X PBS to remove unincorporated dye. The dye-loaded cores were then mixed with 
DOTAP:Chol 1:1 (DOTAP:Chol) or DOPC liposomes as outlined above. A total of 200 
µl of pH appropriate buffer was added to each sample to give a final concentration of 
6.25 µg/µl. The particles and buffers were kept at 37°C. At designated time points, 1, 3, 
6, 24, 48, 72, 96 and 168 hours (1 week), samples were removed, centrifuged at 14000 
RPM for 2 minutes to precipitate the silica. A 100 µl sample of supernatant was then 
transferred into a borosilicate microcuvette to measure absorbance at 555 nm on a 
Beckman DU 530 UV/vis spectrophotometer (Beckman-Coulter, Inc., Fulterton, CA). In 
order to determine the quantity of dye released, absorbance readings from the supernatant 
samples were compared against a serial dilution curve based on known concentrations of 
dextran-tetramethylrhodamine. (100% loading was determined as 200 ng/ul). The 
following buffers were brought to a 1L volume in dH20 to generate the corresponding pH 
values: 0.1 M Acetic acid (pH 2), 0.1 M Citrate with 0.03% H2O2 (pH 4), 10.0 mM PBS 
(pH 7.4), 10.0 mM PBS with 0.1% BSA (pH 8.0), and 0.1 M Amino-Methyl-Propanediol 
(pH 10). 
Microscopy. For tissue collection, rats were euthanized by overdosing with 
sodium pentobarbital (Abbott Laboratories, North Chicago IL) at 72 hr, and 2, 4 and 8 
wks (N=3 rats for each time point and each protocell formulation (DOTAP:Chol or 
DOPC). Blood samples were taken and mixed with 0.1 ml heparin (APP Parmaceuticals, 
LLC., Schaumour, IL) to prevent clotting. Transcardial PBS (warmed to ~45°C; 3-5 min) 
perfusion, followed by room temperature .01M PBS; (3-5 min), and then ice cold 4% 
paraformaldehyde (pH 7.24; 6-8 min) perfusion. Spinal cord, brain, cervical nodes, 
thymus, spleen, kidney and liver were harvested and post fixed in 4% paraformaldehyde 
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overnight and transferred to PBS and stored at 4°C. Bone encased spinal cords were 
placed in 10% ethylenediaminetetraacetic acid (EDTA) solution (~3-4 weeks) to chelate 
calcium and soften bone for sectioning spinal cord encased in the spinal column to 
maintain anatomical integrity of the perispinal meninges. The entire spinal cord was cut 
and cross-sectioned into five, 5 mm, segments starting at the i.t. injection site (pt 0) and 
proceeding both rostrally and caudally. Brain and organ tissues were cryoprotected in 
30% sucrose in (0.1M PBS + 50 µl 10% sodium azide) for 24 hrs, embedded in O.C.T. 
compound in cryomolds (cat# 4565-Sakura Finetek, Torrence, CA), flash frozen in 45°C 
isopentane on dry ice and finally stored at -80°C until the time of sectioning. For 
cryosectioning, 10 µm tissue slices were cut on a cryotome, Microm HM505E (Zeiss, 
Thornwood, NY), and placed on Vectabond (Vector Laboratories, Burlingame, CA) 
coated slides. 
Quantitative spectral imaging. For FAM-tagged DNA, multi-spectral tissue 
imaging and quantification was conducted as previously described.106 Briefly, images 
were obtained using an Axioscope microscope connected to a Nuance Camera 2.8 (FX) 
Multispectral Imaging System, (Cambridge Research and Instrumentation Inc., (CRI) 
Wolburn, MA).112 This camera contains a liquid crystal tunable filter (LCTF) capable of 
filtering light from 400-720 nm, and can capture a series of images of a particular tissue 
region at 10 nm wavelength increments. Every pixel of every image (series collected at 
specific 10 nm wavelength increment) was then analyzed by CRI software to determine 
its peak spectral intensities from 400-720 nm. For each tissue type examined, the 
software subtracts background fluorescence, defined as any spectral emission falling 
below that of specific fluorescence. True FAM signal (excitation 494 nm; emission 522 
 46 
nm) was determined from a control cover-slipped slide on which a small drop of 100X 
diluted FAM-tagged DNA 18-oligomer was placed. The autofluorescence was 
determined by imaging naïve tissue. The intensity of FAM fluorescence across the full 
wavelength range (400-720 nm) was calculated using the computer software. A minimum 
threshold intensity was set automatically by the software and FAM spectral emissions 
below this point were not included in the calculation. The FAM intensity signal “counts” 
were then averaged per exposure time (sec) per mm2 area for each image collected (signal 
counts/sec/ mm2). An image was acquired for each of 4 slices (n=4) per tissue region (e.g. 
spinal cord) per rat, and then averaged to generate a mean value for a tissue region per rat 
(N=3 rats/treatment group). An overall mean value is calculated for each treatment group, 
and the data are reported as signal counts/sec / mm2. Detailed information regarding the 
computer software can be found on the Caliper Life Science website, a subsidiary of 
Perkin-Elmer(URL:http://www.caliperls.com/products/microscopy-imaging-
analysis/microscopy-imaging/nuance-fx.htm). 
Immunohistochemistry. Tissues were collected and sliced identically as 
described above (n=3 rats with 12 slices per anatomical area). Next they were 
permeabilized and blocked against non-specific antibody binding in PBS + 5% BSA + 
0.5%Triton-X for 1 hr at RT. Primary antibodies were diluted in a solution of PBS with 
0.1% BSA, 0.3% Triton-X with 0.1% sodium azide and incubated overnight at RT in a 
humidity chamber with slight rotation. Primary antibodies were diluted as follows: ED1 
(a.k.a CD68, a classic marker of pro-inflammatory macrophage activation) 1:300; ED2 
(a.k.a. CD162, a marker of alternative activation, anti-inflammatory) 1:300 (ED1- Cat# 
SC-7084 and ED2- Cat # SC-18796; Santa Cruz Biotechnology, Santa Cruz, CA); GFAP 
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(astroglia) (Cat#AB5804,Millipore,Temecula, CA) 1:300; OX42 (microglia/macrophage) 
monoclonal (Cat# MCA 275EL, AbD Serotec, Raleigh, NC) 1:300; and Cleaved-Caspase 
3 (Asp175) (apoptotic cells) (Cat#9664 Cell Signaling Technology, Beverly, MA) 1:200. 
Slices were washed 3Xs with 0.1M PBS and then incubated for 2 hrs at room temperature 
in a dimly lit room at a 1:200 dilution of a Rhodamine Red-labeled secondary antibody 
(Jackson Immunoresearch Laboratories, West Grove, PA) in the same solution as that 
used for primary antibodies. Unbound secondary antibody was removed with three, 5 min 
washes in 0.1M PBS. Slices were then covered with a fluoro-protectant, Vectashield, 
containing the nuclear stain DAPI (4, 6-diamidino-2-phenylindole) (Vector Laboratories, 
Burlingame, CA), cover slipped, and stored at 4°C. Three slides, with 3 tissue sections on 
each slide (n=9), were examined for each primary antibody. As a negative control, no 
primary antibody was added to an additional slide. A positive control for the Caspase-3 
antibody was also included in this experiment. Cultures of Raw 264.7 mouse macrophage 
cells, representative of CNS meningeal macrophage, were treated with bacterial 
lippopolysaccharide (LPS; 1 µg/ml) for 2 hours to initiate apoptosis, and then were 
subjected to the activated Caspase-3 antibody. Red Apoptotic cells stained positively and 
confirmed the integrity of the Caspase-3 antibody (data not shown). Tissues or cells were 
examined using an Olympus BX- 60 fluorescent microscope, Olympus D71 camera and 
software (Olympus America, Inc., Center Valley, PA). 
Confocal imaging. To determine subcellular location of FAM-tagged protocells, 
40X confocal image z-stacks of ED-1 + Raw 264.7 macrophage were obtained with a 
Zeiss Axiovert 100 inverted microsope (Carl Zeiss Laser Optics, Oberkochen, Germany) 
using LSM510 Image Acquisition software. The microscope excited the fluorophore of 
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interest DAPI, FAM, and rhodamine with one of three lasers: argon-405 nm; NeHe1-543 
nm; HeNe2-633nm respectively.  
Cellular transfection. For HEK 293 cell culture procedures, human embryonic 
kidney cells (HEK 293) cells were purchased from American Type Culture Collection 
(ATCC; Manassas, VA-cat# CRL-1573) and maintained in Minimum Essential Medium, 
containing Earle’s Salts and L-glutamine (Invitrogen- cat# 11095) to which was added 
10% heat inactivated fetal calf serum (FCS) (Gibco-Cat#10438) and 100 U/ml penicillin 
and 100 µg/ml Streptomycin (Gibco-Cat#15140). Cells were allowed to grow to 80% 
confluence and were then trypsinized with 0.05% Trypsin-EDTA (Gibco-Cat# 15400) to 
loosen cells. The cell suspension was centrifuged in a sterile 50 ml conical tube at 1500 
RPM for 5 mins at 4o C. After adding 20 ml of fresh media, the cells were counted by 
standard technique on a hemocytometer and passed to a new sterile T-75 flask, plated at 
10.0–15 X 106 at each pass. Cells were incubated at 37°C with an atmosphere of air, 
95% and CO2, 5%.  
For transfection with protocells, HEK 293 cells were plated at 1.0 X106 cells/mL 
on 24 well, sterile, poly-D lysine coated, culture plates (Becton Dickinson, Twin Oak 
Park, Bedford, MA) in 1 ml sterile MEM or DMEM respectively, both supplemented 
with 10% heat inactivated FCS and 100 U/mL penicillin and 100 µg/ml streptomycin and 
allowed to grow 24 hrs to 80% confluency. Media was exchanged with 1 ml fresh media 
containing 500, 50, 25, 10, and .5 µg/ml DOTAP or DOPC protocells loaded with 
pDNA-IL-10-GFP or pDNA-IL-10. Blank protocells without pDNA served as a control. 
The protocell containing media was removed after 5 hrs and replaced with fresh media. 
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Media was collected 24 hrs later and analyzed for GFP transfection (green fluorescence) 
and/or IL-10 using IL-10 ELISA (R&D Systems, Minneapolis, MN) according to 
manufacturer’s instructions or immunostaining with IL-10 primary antibody (R&D 
Systems, Minneapolis, MN) with rhodamine 2° antibody in a procedure identical to that 
used for the immunohistochemical staining outlined above.  
Cell viability assay. HEK 293 cells were plated at 5-6 X106 cells/mL on 24-well 
sterile poly-D lysine coated culture plates (Becton Dickinson, Twin Oak Park, Bedford, 
MA) in 1 ml sterile MEM supplemented with 10% heat inactivated FCS, 100 U/ml 
penicillin and 100 µg/ml streptomycin, and allowed to grow to 80% confluency. Media 
was removed and 1 ml of fresh media was added containing 500, 50, 25, 10, and .5 µg/ml 
DOTAP or DOPC protocells loaded with pDNA-IL-10-GFP, or blank protocells. The 
media was removed after 5 hrs and replaced with fresh media and the cells allowed to 
incubate for an additional 21 hrs. Cells were removed with a standard sterile cell scraper 
and 500 µl of cell suspensions placed in a flow cytometry tube on ice (Falcon Cat# 
352008- Becton Dickinson Labware, Franklin Lakes, NJ). Three minutes before 
examination by flow cytometry (Facscan4, Becton Dickinson), 50 µl of 10 µM ethidium-
homodimer D-1 was added to label dead cells.  
Mouse macrophage (RAW 264.7) cells. RAW264.7 cells were obtained from 
American Type Culture Collection (ATCC, Manassas VA, USA-cat # TIB-71) and 
cultured as adherent cells in Dulbecco’s Modified Eagle’s Medium (Sigma-Aldrich, cat# 
D6429) supplemented with 10% heat-inactivated fetal bovine serum (Gibco, cat # 10082-
147) and 100 U/ml penicillin and 100 µg/ml streptomycin (Gibco- cat#-15140122) and 
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maintained at 37°C under humidified 5% CO2 atmosphere. Cells were grown to 85% 
confluency, collected by scraping, and sub-cultured for 3 passages. For these 
experiments, dead cells were counted by hemocytometer using trypan blue exclusion.  
Measurement of nitric oxide production 
RAW 264.7 cells were seeded at a density of 2.75 x 105 cells/ml in 24 well plates 
24 hours prior to experimentation and maintained at 37°C under humidified 5% CO2 
atmosphere. At 85% confluency, the supernatant was exchanged with DMEM containing 
different formulations of DMEM and protocells or protocell constituents and followed by 
a 2 hour incubation then washed twice in PBS (pH 7.4, Gibco-cat # 10010). Wells treated 
with 10 ng/ml lipopolysaccharides from Escherichia coli (LPS, Sigma-Aldrich, cat 
#L6529) were exposed to DMEM containing LPS for 10 minutes followed by removal 
and washed twice in PBS. Nitric oxide production was measured using the commercially 
available Griess Reagent System (Promega, USA, cat #-G2930) according to the 
manufacturer’s instructions. Absorbance was measured at 550 nm using a Tecan 
Infinite® plate reader (Tecan Systems, Inc., San Jose, CA). All experiments were run in 
triplicate.  
Data analysis. Psychometric behavioral analysis was performed as previously 
described103 to compute the absolute threshold that resulted in the 50% hindpaw 
withdrawal response. As described previously103, 104, 113 withdrawal thresholds were 
determined by using the software program, PsychoFit. The software for PsychoFit may 
be downloaded from L.O. Harvey’s website (http://psych.colorado.edu/~lharvey). This 
program fits the pattern of hindpaw responses for each timepoint to a Gaussian integral 
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psychometric function and generates a 50% threshold value for that time point. As such, 
parametric statistical analyses (repeated measures ANOVA) are applied to determine the 
statistical significance between treatment groups at multiple timepoints using the 
computer software, GraphPad Prism, version 4.03 (GraphPad Software Inc., San Diego, 
CA). All other statistical analyses were performed using the computer software, 
GraphPad Prism, version 4.03 (GraphPad Software Inc., San Diego, CA). All data is 
expressed as mean +/- SEM. Post hoc analysis was completed using Bonferroni’s test. 
2.3 Results  
2.3.1 Characterization of protocells 
Mesoporous silica particle cores were prepared by the surfactant templated 
aerosol-assisted self-assembly method previously developed and communicated.114 The 
resulting hydrophilic nanoparticles were further modified with APTES and characterized 
by a uniform, ordered and connected mesoporosity (Figure 2.1, A), with a specific 
surface area or 935 m2/g and pore diameter of 2-5 nm (Figure 2.1, B, C). Each 50 µl 
aliquot containing 1.25 mg protocells was examined for loading capacity using the 
negatively charged molecule, dextran tetramethylrhodamine (DexRho) (Figure A.13 B). 
Protocells formulated with DOPC lipids resulted in a cargo loading capacity of ~ 13.49 
µg Dex Rho, and protocells formulated with DOTAP:Chol lipids exhibited a cargo 
loading capacity of ~ 16.12 µg DexRho. 
Protocells with either DOPC or DOTAP:Chol formulations were characterized 
separately for their release of DexRho cargo. Separate aliquots were individually 
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incubated in pH solutions ranging from 2-10, for durations of 1 to 168 hours. While both 
DOTAP:Chol and DOPC formulated protocells revealed pH-dependent increases in cargo 
release with increased duration (Figure 2.1, D, E), a statistically insignificant trend 
toward greater cargo release at pH 4 compared to pH 7.4 was observed with 
DOTAP:Chol protocells. These cargo release profiles are relevant to physiological 
conditions of cellular organelles, such as lysosomes, that have acidic compartments 
typically near pH 4. Additionally, physiologically relevant pH 7.4 occurs in extracellular 
regions, suggesting that protocell cargo may remain associated with protocells until 
cellular uptake and trafficking into the more acidic late endosomes and lysosomes where 
the cargo is released.  
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Figure 2.1 Characterizations of protocells. 
(A) TEM image of mesoporous silica nanoparticles; scale bar = 50 nm. (B) Nitrogen sorption isotherm of 
10% aminated silica nanoparticles. (C) Determination of pore size of 10% aminated silica nanoparticles by 
the Barrett-Joyner–Halenda (BJH) method.110 (D) DOTAP:Chol protocells and (E) DOPC protocells 
examined from 1 – 168 hours in specific pH solutions. The negatively charged fluorophore, dextran 
tetramethylrhodamine (DexRho) loaded into the protocells served as cargo. Dashed line indicates 20% 
release for ease of comparison between groups and conditions. For both DOTAP:Chol and DOPC 
protocells cargo release increased as time and pH increased. A significant interaction between time and pH 
was revealed (DOTAP:Chol: F(35, 84) = 2.16, p = 0021; DOPC: F(35, 84) = 2.35; p = 0.0008). A trend for 
increased cargo release at pH 4 compared to pH 7.4 from DOTAP:Chol protocells was observed. 
DOTAP:Chol protocells at pH 6 revealed the greatest degree of cargo retention at 3 and 72 hours (p < 
0.05). The pattern of greater cargo retention (~15%) at pH 7.4 and 6.0 in DOTAP:Chol protocells suggests 
that cargo will remain associated with protocells until taken up within the cell and released within the late 
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lysosome for optimal cargo delivery. (A, B, C – Data provided by the Brinker Group; D, E- Experiment 
performed by Audra Kerwin; statistical analysis and graphic by Ellen Dengler) 
2.3.2 In vitro cellular viability 
Cells remain viable following application of protocells formulated with 
DOTAP:Chol or DOPC. HEK cells were incubated with 10-500 µg/ml protocells 
formulated with DOTAP:Chol or DOPC containing plasmid DNA encoding the anti-
inflammatory cytokine, interleukin-10, and the reporter gene, green fluorescent protein 
(pDNA-IL-10/GFP; 10 µg/mg protocells) for 24 hrs. Protocells without cargo served as 
controls. To examine the effects of DOTAP:Chol or DOPC protocells containing pDNA-
IL-10/GFP cargo on cellular viability, flow cytometry was used by applying Ethidium-
Homodimer-1 (EH-1) to stain the cells. EH-1 enters the cell nucleus and intercolates with 
DNA only in dead or dying cells in which the membrane is breaking down. Thus, EH-1 
does not interact with DNA of live cells with intact membranes. Excitation of EH-1 at 
528 nm leads to 617 nm emission (red fluorescence), which is detected by the flow 
cytometer, and each dead cell is counted. The percentage of dead cells is quantified per 
10,000 cells. The percent of live cells was determined (Figure 2.2). Cells left untreated 
served as an index of basal cell viability, which was observed to be > 98%. To ensure 
dead cell quantification, a separate group of cells were treated with 0.1% saponin, and 
only ~3% remained viable. Protocells formulated with either DOTAP:Chol or DOPC 
resulted in < 5% dose-related decrease in cell viability compared to live controls and 
remained stable even at the highest dose of 500 µg/ml. Thus, cells exposed to 
DOTAP:Chol or DOPC protocells remained healthy, suggesting that DOTAP:Chol or 
DOPC protocells lack overt toxicity in vivo. 
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Figure 2.2 Cells remain highly viable following application of DOTAP:Chol and DOPC protocells 
containing pDNA-IL-10-GFP. 
Cells were incubated for 24 hours with DOTAP:Chol or DOPC protocells loaded with pDNA-IL-10-GFP 
or blank control protocells (no pDNA) at varying concentrations across a 50-fold dose range, 500, 50, 25 
and 10 ug/ml. Dead cells were identified by flow cytometry after staining with ethidium-homodimer-1. 
Results are representative of the percentage of gated cells (average of 4 experiments) compared to untreated 
control cells, **p < 0.01; ***p < 0.0001. (Experiment, statistical analysis and graphics by Ellen Dengler) 
2.3.3 Protocells are well tolerated in an animal model.  
Light touch sensory threshold assessment is highly sensitive to subtle 
perturbations in spinal cord homeostasis. Increases in local spinal immune signaling 
molecules lead to spinal sensitization of pain-related projection neurons resulting in a 
hypersensitivity to light touch stimuli applied to the body area innervated by axons whose 
central terminals also project to the affected spinal segment.102, 103 Thus, assessing 
alterations in light touch thresholds from basal values following central nervous system 
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protocell application can be a timely, robust and reliable in vivo examination of protocell 
early-phase toxicity within the local spinal cord compartment. Baseline (BL) sensory 
threshold values for both hindpaws were recorded prior to an i.t. injection of 
DOTAP:Chol or DOPC formulated protocells loaded with a FAM-18 bp single stranded 
DNA oligomer. Thresholds close to 10 grams of stimulus intensity were observed in all 
rats prior to treatment (Figure 2.3). Following an i.t. injection of 0.01 or 1 mg 
DOTAP:Chol formulated protocells, a small increase in light touch sensitivity of the left 
paw was observed at 30 min and rapidly recovered to basal levels and remained stable 
during a 72 hr observation period (Figure 2.3, A, B). Normal insignificant basal 
variations in paw thresholds were observed in 0.01 mg protocell and control, vehicle 
injected rats. Conversely, both 0.01 and 1 mg DOPC formulated protocells induced a 
small increase in light touch sensitivity (values dropped to <1.0 g stimulus intensity) in 
both the left and right hindpaws at 2 hrs, that mostly recovered to BL values during the 
remaining 72 hr observation period (Figure 2.3, C, D). The transient 2-hr increase in 
light touch sensitivity following DOPC formulated protocells was unexpected given 
reports show that in vitro, DOPC toxicity is virtually absent. However, in vivo subtle 
changes in the local spinal milieu may occur to a greater extent that alters early-phase 
toxicity and corresponding neuronal processing of normal sensory stimuli. Nevertheless, 
normal body weight gain was observed in all rats throughout an 8 week observation 
period during which time, animals remained active and well-groomed (Figure 2.3, E). 
Taken together, these data support that i.t. administration of DOTAP:Chol, lack 
alterations from normal sensory processing and both DOTAP:Chol and DOPC 
formulated protocells are well-tolerated in the peri-spinal region of rats. 
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Figure 2.3 In vivo subtle differences in biocompatibility are revealed between DOTAP:Chol and 
DOPC protocells. 
Baseline threshold responses of both hindpaws (left and right) between animal groups were similar; at 10 g 
(right y-axis) (F(4, 14)= 0.3721; p > 0.05). (A, B) Following i.t. injection with either 1 or 0.01 mg of 
DOTAP:Chol or (C, D) DOPC protocells, threshold responses remained unchanged throughout the 
timecourse (0.5, 1, 2, 3, 24, 48 and 72 hrs) suggesting no spinal inflammation. (C, D) For DOPC - treated 
animals, while a decrease in thresholds was not observed across the majority of the timecourse left- F(24, 60)= 
1.88, p > 0.05; right- F(24, 60)= 1.01 p > 0.05), there was a small but significant decrease at 2 hours in both 
hindpaws (p < 0.05 left and right), indicating a subtle and transient spinal cord inflammation resulting in 
decreased sensory thresholds . All animals exhibited normal feeding, grooming and exploratory behavior 
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throughout the 8-week observation. (E) Body weight gain remains normal following i.t. injection with 
DOTAP:Chol or DOPC protocells. At BL, there was no significant difference in body weight between 
untreated (open triangles) and treated animals that received i.t. DOTAP:Chol (2 wks, solid circles; 4 wks, 
solid diamonds; 8 wks, solid squares) or DOPC protocells (2 wks, open circles; 4 wks, open diamonds; 8 
wks, open squares)(F(6, 14)= 2.837, p = 0.0506), followed by a normal gain in body weight. This normal gain 
in body weight between control animals and those receiving protocells by i.t. injection remained consistent 
over time in all groups of animals (n = 3 per group). (Behavioral testing, statistical analysis and graphics by 
Ellen Dengler) 
2.3.4 Intrathecal (.i.t) DNA delivered by DOTAP:Chol or DOPC protocells remains 
closely associated with meninges.  
Non-coding 18 bp oligonucleotide DNA labeled with the fluorophore, FAM 
(Ex/Em 492/517 nm; green) delivered by either DOTAP:Chol (Figure A.13 A) or DOPC 
formulated protocells remained closely associated with the cells of the meningeal layer in 
the spinal cord, but did not penetrate tissue parenchyma. A representative spinal tissue 
section near the i.t. injection site, revealed DOTAP:Chol protocells containing FAM-
tagged DNA (green) in/adjacent to the meningeal layer (Figure 2.4, A, B, D), with 
cellular nuclei counter-stained with the nuclear specific flurophore, DAPI. Glial cell 
astrocyte processes and endfeet (astocytes stained for glial fibrillary acidic protein, 
GFAP; red) are typically present at the neural-pial meningeal interface, which are capable 
of taking up extracellular material. Yet, no co-localization of FAM-tagged DNA protocell 
cargo within astrocytes was observed (Figure 2.4, A, white arrow). However, immune-
relevant macrophage and microglia that normally reside in meninges and at the neural-
pial interface are highly efficient phagocytic cells. Indeed, FAM-tagged DNA containing 
protocells robustly co-localized with macrophages/microglia (stained for CD11b marker; 
red) in the meningeal peri-spinal region. Co-localization appears yellow (Figure 2.4, B, 
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white arrow). While microglia are present (red) in the deeper spinal parenchyma, FAM-
tagged DNA is absent (Figure 2.4, B). 
 Caspase-3 is a well-characterized enzyme that plays a critical role in the late 
stages of programmed cell death (apoptosis). Immunohistochemical detection of Caspase-
3 (red) was entirely absent in the spinal cords and brains of rats where DOTAP:Chol 
formulated protocells were present. A representative image of protocells containing 
FAM-tagged DNA (green) in the meninges reveals no positive Caspase-3 
immunoreactivity at 8 wks following i.t. injection (Figure 2.4, C). Confocal examination 
of meningeal macrophage/microglial cells immunostained for expression of ED1, a 
marker for activated immune cells with a proinflammatory phenotype, revealed 
DOTAP:Chol protocells containing FAM-tagged DNA were closely associated with the 
DAPI-stained peri-nuclear area of ED1 expressing cells (Figure 2.4, D, white arrow). 
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Figure 2.4 Histological examination of DOTAP:Chol protocells with DNA cargo. 
 Fluorescent histological examination of spinal cord sections near the lumbar spinal cord injection site 
(segments L3-4) 8 weeks after i.t. injection of DOTAP:Chol protocells loaded with FAM-tagged 18 base 
pair (18bp) DNA oligomer. (A) Protocells containing DNA cargo (green; white arrow) are not colocalized 
with astroglia stained for glial fibrillary acidic protein, GFAP (red). (B) However, protocells are 
colocalized in the pial meninges with activated microglia/macrophage stained for OX2 (red). 
Colocalization of microglia with DNA cargo (green) results is indicated (white arrow). (C) There is no 
evidence of cellular death in the meninges or spinal cord, as indicated by the absence of positive staining 
for the apoptotic marker, activated Caspase 3 (red) while protocell-containing DNA cargo (green; white 
arrow) is clearly present. (D) Confocal image identifying DOTAP:Chol protocell cargo of FAM-tagged 18 
bp DNA (green) in the peri-nuclear area (cell nuclei stained with DAPI; blue) of meningeal macrophage 
cells stained for the classic activation marker, EDI (red; white arrow) in the dorsal spinal cord. Overlap 
reveals yellow cytoplasmic and peri-nuclear staining. All images are at 20X; scale bar = 40 µm. (A-D- IHC 
and fluorescent imaging by Ellen Dengler; D- confocal imaging by Tamara Roitbach) 
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2.3.5 In vivo biodistribution of protocells.  
Eight weeks following i.t. injection, protocells remain in the CNS and are not 
found in peripheral tissue. As the animals appeared to experience no adverse effects from 
DOTAP:Chol or DOPC formulated protocells, even at the highest dose, the 
biodistribution of protocells within and outside of the central nervous system (CNS) was 
quantified. In these experiments, rats received an i.t. injection of DOTAP:Chol or DOPC 
protocells loaded with FAM (1 µg FAM 18bp DNA oligomer/1 mg protocells), and 
tissues were harvested 2, 4, and 8 weeks later. Blood, the immune organs (cervical lymph 
nodes, thymus and spleen), the filtering organs (kidney and liver), as well as sections 
from the brain, cervical, thoracic and lumbar spinal cord were examined to quantify 
protocells by spectral microscopy analysis that allows computerized de-convolution and 
quantification of the true FAM-signal from background autofluorescence (Figure 2.5, 
and Table 1).  
The blood was negative for FAM detection (data not shown). The highest amount 
of FAM levels at 72 hr post DOPTAP:Chol or DOPC protocell injection were observed at 
the i.t. injection site in the lumbar spinal cord, which significantly decreased by 8 wks 
(Figure 2.5, B). Only DOPC formulated protocells containing FAM-tagged DNA 
accumulated in the brain by 8 weeks (Figure 2.5, A). Thus, differences in the 
biodistribution between the two protocell lipid formulations were observed. Also at 8 
weeks, the DOTAP:Chol protocell FAM signal had diminished and was only significant 
locally, near the injection site, suggesting that DOTAP:Chol formulated protocells may 
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be optimal to maintain localized drug effects, while leaving the brain and the body 
primarily undisturbed.  
Outside the central nervous system, FAM signal was negligible including in the 
liver and kidney. At 72 hours, a minor but significant amount of FAM was detected in the 
thymus following treatment of both DOTAP:Chol and DOPC formulated protocells. The 
data represented in Figure 2.5, A and B are included in Table 1 to provide relative 
comparisons in FAM detection levels with respect to FAM levels observed in other tissue 
regions that in most cases, appear negligible.  
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Figure 2.5 The spread to brain following i.t. protocell injection is determined by the lipid bilayer 
formulation. 
 Graphs are representative of the key data in the corresponding Table I. Fluorescent spectral signal from 
FAM-tagged 18bp DNA cargo in cryo-sliced tissue sections (n = 4) of DOTAP:Chol or DOPC protocell i.t. 
treated animals is compared to the spectra of background autofluorescence from naïve animals. (A) In the 
brain, after 72 hours, there was no significant signal from FAM-tagged DNA delivered by either 
DOTAP:Chol or DOPC protocells. By 8 weeks, background signal in DOTAP:Chol protocell treated tissue 
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was comparable to that of auto-fluorescence (p > 0.05), while the signal from FAM-tagged DNA delivered 
by DOPC protocells had significantly increased compared to autofluorescence (F(2, 6) = 8.60; p = 0.0173. 
(B) At the lumbar spinal cord protocell delivery site, FAM-tagged DNA delivered by both DOPC and 
DOTAP:Chol prototocells was clearly present at both 72 hours and 8 weeks when levels of FAM signal 
analysis was compared to levels from autofluorescence (F(2, 6) = 6.18; p = 0.0348), with the signal at 72 
hours significantly higher than that at 8 weeks (F(1, 6 )= 10.71; p = 0.0170). (Table 1) Values (1 X E-04) of 
each anatomical region are an average of computer-generated spectral analyses taken from 4 separate 
images of four 10 µm sliced tissue sections. Yellow boxes indicate those areas in which the signal from 
FAM-tagged DNA cargo reached levels that were significantly higher than control autofluorescence for 
that tissue. Asterisks indicate the amount of significance. Very low levels of DOTAP:Chol protocells were 
detected in the lymph organs, such as thymus and spleen, while DOPC remained in the CNS. *p < 0.05; 
**p < 0.01; ***p < 0.0001. (Tissue slicing by Ellen Dengler with assistance from Leisha Armijo; Spectral 
microscopy and computerized analysis by Ellen Dengler with assistance from Kate Gentry)  
2.3.6 Protocell IL-10 gene delivery leads to robust transgene expression.  
Following a 24 hr incubation with DOTAP:Chol formulated protocells containing 
pDNA-IL-10/GFP, robust GFP protein was observed in ~40% of HEK cells (Figure 2.6, 
A). Transfection of HEK cells with a bicistronic plasmid containing the gene for IL-10 
and GFP successfully resulted in expression of both proteins, GFP and IL-10, indicating 
functional IL-10 transgene expression in GFP expressing HEK cells (Figure 2.6, A; 
insert). Protocells formulated with either DOTAP:Chol or DOPC and loaded with 
plasmid DNA encoding the IL-10 gene alone (pDNA-IL-10) or in combination with the 
reporter gene, pDNA-IL-10/GFP, were incubated with HEK cells to examine transgene 
IL-10 protein expression. It is important to note that HEK cells do not produce IL-10 
protein thus providing a reliable assay to quantify transgene-specific IL-10 gene 
activation. The cell culture supernatants were examined for IL-10 protein using ELISA 
assay procedures (Figure 2.6, B,C). Surprisingly, only those protocells formulated with 
DOTAP:Chol containing pDNA-IL-10 or pDNA-IL-10/GFP resulted in a robust dose-
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dependent increase in protein IL-10 levels compared to untreated controls, with the 
greatest amount of protein (~900 pg/ml) produced following incubation with 500 µg/ml 
DOTAP:Chol formulated protocells. In contrast, IL-10 protein from transgene IL-10 
delivered by DOPC protocells containing either pDNA-IL-10 or pDNA-IL-10-GFP was 
significantly lower and reached maximal values of no greater than 100 pg/ml. 
 
Figure 2.6 DOTAP:Chol protocells improve cellular transfection of pDNA-IL10 transgene.  
In vitro transfection of HEK cells with a bicistronic plasmid containing the genes for both IL-10 and GFP 
employing an internal ribosomal entry site results in expression of GFP (A; green). Staining with antibody 
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for IL-10 (red) shows colocalization (yellow) in a GFP-positive HEK cell (green), indicating functional 
bicistronic transgene expression (A; insert). pDNA IL-10-GFP (B) or pDNA-IL-10 (C) delivered by 
DOTAP:Chol protocells results in functional transgene expression as measured by IL-10 protein release in 
culture supernatants following a 24 hour incubation. Results are the average of 4 representative 
experiments (F(1, 4) = 24.85; ***p < 0.0001, **p < 0.01). Scale bar = 10 µm in both Figure 6A and insert. 
(A- Transfection experiment and IHC by Ellen Dengler; B-ELISA by Ellen Dengler with assistance from 
Brandi Bowman) 
2.3.7 Protocells are functionally effective as gene delivery platforms.  
Given that IL-10 transgene delivered by DOTAP:Chol formulated protocells 
yielded robust transgene-derived IL-10 protein levels in cell culture (Figure 2.6) and 
DOTAP:Chol protocells appeared to show minimal toxicity in vivo (Figure 2.3), we next 
asked whether DOTAP:Chol formulated protocells containing pDNA-IL-10 (Figure 
A.13 C) could act therapeutically by delivering sufficient amounts of the IL-10 transgene 
to suppress light touch hypersensitivity (allodynia), a neuropathic condition mediated by 
sensitization of spinal neurons that communicate to brain areas about pain-related stimuli. 
Allodynia occurs when non-painful stimuli are coded as painful. Following BL 
assessment of withdrawal behavior to light touch tactile stimuli, rats underwent either 
sham surgery or CCI of the sciatic nerve. Clear development of allodynia was observed 3 
and 10 days later (Figure 2.7, A, B). On Day 10, rats received an i.t. injection of 
DOTAP:Chol formulated protocells containing pDNA-IL-10, pDNA-control (non-coding 
DNA), or equivolume vehicle (20 µl). While sham rats remained stably non-allodynic, a 
rapid and complete reversal from neuropathic allodynia was observed in IL-10 treated 
rats. Neuropathic rats injected with i.t. control pDNA or vehicle remained stably 
allodynic throughout a 26-day timecourse. It is important to note that a prior report 
demonstrated an equivalent dose of i.t. naked pDNA-IL-10 lacks efficacy to reverse 
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allodynia.14 Taken together, these data show that pDNA-IL-10 delivered to the peri-
spinal regions by DOTAP:Chol protocells was able to reverse allodynia to BL levels for 
almost 2 wks. These data support that the production of IL-10 protein from pDNA-IL-10 
transgene loaded on protocells is functionally and physiologically effective.in reversing 
pain thresholds. 
Materials composing protocells do not lead to nitric oxide (NO) production. In 
order to assess subtle and transient cell-stress responses to the identical DOTAP:Chol 
protocell formulation examined for in vivo spinal gene therapy, cultured macrophage 
cells (Raw 264.7) were examined, given the observed in vivo spinal co-localization of 
DOTAP:Chol protocells with macrophages/microglial cells, as described above in figure 
4. Macrophages were assayed for NO following a 2-hour incubation with whole 
protocells or the component silica core and lipid (DOTAP:Chol) (Figure 2.7). 
Lipspolysaccharide (LPS) was included, as it is known to produce robust enhancement of 
NO in this cell line.115-118 As expected, cells incubated with LPS for 10 minutes produced 
increased levels of NO compared to untreated controls. However, similar basal NO levels 
were observed between untreated controls, whole protocells, silica cores and 
DOTAP:Chol lipid, suggesting that these materials do not generate transient or even 
subtle cell stress events. 
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Figure 2.7 Intrathecal delivery of protocells loaded with pDNA-IL-10 causes therapeutic reversal of 
allodynia. 
(A and B) At pre-treatment baseline (BL) values, no significant differences were observed (ipsilateral and 
contralateral; p > 0.05). Following BL assessment, animals underwent CCI of the left sciatic nerve, and 
threshold values were reassessed 3 and 10 days later. Robust allodynia was observed compared to sham-
treated controls (ipsilateral- F(8, 36) = 4.94; p < 0.0004; contralateral- F(8, 36) = 19.89; p < 0.0001). On day 10 
after CCI, rats then received an i.t. injection with DOTAP:Chol/ pDNA-IL-10 protocells or control 
DOTAP:Chol protocells without DNA. A significant bilateral reversal of allodynia beginning on day 12 
after CCI (day 2 after i.t. injection), and continuing through day 22 was observed (overall treatment effect, 
ipsilateral- F(4, 108) = 44.91; p < 0.0001; contralateral- F(4, 108) = 85.09; p < 0.0001). Each CCI operated group 
(closed symbols) received an i.t injection of DOTAP:Chol protocells loaded with pDNA-IL-10 (squares; n 
= 7) or a non-coding DNA (triangles; n = 5) (10 µg pDNA in 1mg protocells in 20 µl PBS) or PBS vehicle 
(circles; n = 3) (20 µl). Each sham-operated group (open symbols) received an i.t. injection of non- coding 
DNA (triangles; n = 5) (10 µg pDNA in 1 mg protocells in 20 µl PBS) or PBS vehicle (circles; n = 3) 
(20ul). Black arrow indicates i.t. injection; *p < 0.05; **p < 0.01; ***p < 0.0001. Nitric oxide 
concentration was measured in cultured Raw 264.7 cells (C) in LPS (black bar) and non LPS-stimulated 
cells (white bar) and those treated with whole protocells or constituents of protocells; silica core (500 µg) 
or Dotap:Chol lipid (20 µl)(hatched bars); All three treatments resulted in significantly less NO production 
than the LPS stimulated positive control (F4,14 = 321.8; p < 0.0001). (A, B – Behavioral testing by Ellen 
statistical analysis by and graphics by Ellen Dengler; C- Experiment run by Audra Kerwin; statistical 
analysis and graphics by Ellen Dengler) 
2.4 Discussion 
Our results demonstrate that mesoporous silica nanoparticle (MSN) cores with 
their surface fused to either DOTAP:Chol or DOPC formulated liposomes (protocells) 
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differentially release cargo (Dextran Rhodamine; a negatively charged fluorophore) when 
exposed to a wide range of pH values, with both formulations resulting in high cellular-
viability values (>90%) following a 50-fold dose range exposure (Figure 2.1, Figure 
2.2). Additionally, peri-spinal application (subarachnoid, intrathecal; i.t.) of either 
DOTAP:Chol protocells or DOPC protocells in separate groups of rats resulted in 
different toxicity and biodistribution profiles. Subtle but significant differences in 
hindpaw sensory threshold values were generally lower in DOPC protocell-treated rats at 
3 hrs compared to thresholds of DOTAP:Chol protocell treated rats (Figure 2.3, A-D). 
Importantly, assessment for threshold changes in light mechanical touch from baseline is 
a surrogate indicator for physiological perturbations involving early-phase toxicity or 
spinal cord inflammation104 that can go undetected by overt observations for general 
health measures such as ambulatory function and body weight gain. Indeed, an 8-wk 
observation period for body weight gain revealed no differences between i.t. 
DOTAP:Chol protocell and DOPC protocell-treated animals (Figure 2.3, E). Spinal 
immunohistochemical examination of DOTAP:Chol protocells containing DNA revealed 
clear co-localization with macrophage/microglial cells at the spinal-meningeal interface 
(Figure 2.4, A, B, D), with a complete lack of cell death, as indicated by the absence of 
immunoreactivity for the late phase necessary apoptotic enzyme, caspase-3 (Figure 2.4, 
C). These finding support that DOTAP:Chol protocells offer a significant degree of 
biocompatibility. However, clear differences were observed between the in vivo 
biodistribution of DOTAP:Chol protocells and DOPC protocells. While both 
DOTAP:Chol and DOPC formulated protocells surrounding the spinal cord injection site 
were identified for as long as 8 wks following administration, only DOPC protocells 
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revealed an increased spread to brain observed at 8 wks (Figure 2.5, A and Table 1). 
Furthermore, IL-10 transgene expression in vitro was significantly greater following 
cellular incubation with DOTAP:Chol-protocells containing plasmid DNA encoding IL-
10 (pDNA-IL-10) than cells incubated with DOPC-protocells-pDNA-IL-10 (Figure 2.6). 
Based on the overall profile of DOTAP:Chol protocells in their biocompatibility, 
localized biodistribution and greater transgene expression, DOTAP:Chol protocells were 
loaded with pDNA-IL-10 to examine their therapeutic potential as a novel non-viral gene 
transfer vector delivered to the spinal cord to treat peripheral neuropathic pain. Compared 
to various control-treated rats, i.t. injections of DOTAP:Chol pDNA-IL-10 protocells 
resulted in robust bilateral reversal of allodynia for as long as 12 days (Figure 2.7, A, B). 
Importantly, inflammatory nitric oxide, used as a sensitive and specific factor indicative 
of cell stress, was virtually absent in macrophages exposed to the composite 
DOTAP:Chol protocell formulation or its constitutive components (Figure 2.7, C). 
Our data show that protocells are capable of prolonged drug delivery, as 
DOTAP:Chol-protocells bilayers retain ~60% of negatively charged cargo at pH 7.4, 
which mimics CSF as well as extracellular pH, during a 1 week timeframe. Importantly, 
protocells at lower pH values release 25-50% of cargo within a 72 hr window. 
Importantly, a substantial amount of protocell cargo content remains by 1 week (Figure 
2.1, D, E), supporting the possibility that enduring cargo release for many weeks can be 
achieved resulting in long-duration therapeutic transgene efficacy. Future studies will 
determine whether trafficking to late lysosomes containing ~3-4 pH values results in a 
significant amount of cargo release as well as enduring efficacy. While the mechanism of 
protocell escape from lysosomes remains unknown, the general pattern of pH-dependent 
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cargo release may support an approach that optimizes cargo delivery to the intracellular 
compartment. Of further note is the stability of cargo-associated protocells formulated 
with either DOTAP:Chol or DOPC at pH 6, suggesting that early endosomal organelles 
(typically near pH 6) stabilize protocell cargo until subsequent trafficking to lysosomes. 
Confocal microscopy shown in the current report demonstrates that protocell cargo is 
indeed present within and adjacent to cellular nuclei of macrophages in the spinal 
meninges surrounding the injection site. These observations suggest that while protocells 
do not necessarily need to enter the nucleus for transgene host cell gene activation, 
nuclear localization is possible.  
While MSNs have been widely studied and are known for in vitro 
biocompatibility, high cargo capacity, tunable pore diameters and surface chemistries 114, 
119-124, this report is the first in vivo demonstration of protocell constructs as being non-
toxic and functionally capable as non-viral spinal gene therapy vectors. The therapeutic 
application of protocells is highly beneficial for several critical reasons. First, a low in 
vitro toxicological effect by the components of protocells is observed (Figure 2.7, C), as 
our data show unaltered levels of inducible nitric oxide, a factor that is rapidly produced 
following cell stress and inflammation known to mediate the induction of reactive oxygen 
species further contributing to cell stress.125, 126 The current data also reveal a lack of in 
vivo toxicological effects following spinal protocell application (Figure 2.3, A-D), as 
spinally-mediated sensory hindpaw response-thresholds remained unchanged from 
baseline, a physiological ‘read-out’ of healthy conditions. Further, we demonstrate that 
spinal tissue immunohistochemical examination indicated the complete absence of 
activated Caspase-3 (Figure 2.4 C), a critical enzyme that mediates programmed cell 
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death.127 Second, these protocells offer simpler manufacturing methods aimed at 
controlling cargo displacement compared to more sophisticated methods that employ 
additional organic molecules used for ‘gating’ silica pores.128 Third, a high degree of 
flexibility to modify silica surface chemistry and pore size to tailor adsorption of specific 
cargo129 is available. Collectively, these properties of protocells make them attractive 
platforms for non-viral drug or gene delivery using a wide range of formulations. In the 
current study, this first-generation protocell supporting a DOTAP:Chol lipid bilayer 
appears to be functionally effective as spinal gene delivery vehicles for pain-related 
therapeutic purposes. 
The majority of worldwide clinical trials using non-viral gene delivery techniques 
currently represents ~27% of the total gene therapy clinical trials,130 with these trials 
mostly applying naked plasmid DNA, and none aimed at neuropathic pain control. 
However, the examination of gene therapy applications for neuropathic pain in animal 
models has significantly increased during the past dozen years, with candidate gene 
products intended to disrupt pain-associated biochemical changes, or themselves, act as 
analgesics.131 These trends point to the extraordinary need for new approaches toward 
developing novel pain therapeutics, as currently available drugs are minimally effective 
for pathological pain. Thus, the emerging area of CNS gene therapeutics for pain control 
is rapidly growing.  
Neuropathic pain results from pathology in the nervous system and arises from 
aberrant signals in sensitized injured axons in the peripheral and/or central nervous 
system.132 The anti-inflammatory cytokine, IL-10, leads to exceptionally robust 
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suppression of several pain-related conditions including allodynia in various animal 
models.133 Allodynia, as assessed in this study, is a pathological sensory condition 
whereby non-noxious stimuli such as mechanical light touch to the skin are processed as 
painful.134 and spinal IL-10 gene therapy results in prolonged suppression of chronic 
allodynia.97 Indeed, non-viral naked plasmid DNA or polymer-encapsulated gene therapy 
to control neuropathic pain has been successfully demonstrated in animal models of 
neuropathic pain.73,79,135 Interestingly, these non-viral approaches are thought to harness 
phagocytic innate immune cells that are present at low levels in the peri-spinal meninges 
and subarachnoid space,97 as an increase in phagocytic macrophages accumulate 
surrounding the intrathecal lumbar spinal injection site. However, the transgene dose, 
release rate and cellular targets are constrained by the method of gene delivery used in 
these prior studies. Conversely, increased transgene dose (cargo retention) and greater 
flexibility in DNA release rate and cellular targeting can be achieved via protocells as 
delivery platforms. 
The prior established efficacy of IL-10 for pain control allows comparisons with 
novel gene delivery approaches, like protocells, that result in therapeutic pain-
suppression, and enables one to identify new and improved gene and drug carrier 
platforms with promising clinical applications. Our data demonstrate that this first-
generation DOTAP:Chol protocell formulation is a highly feasible carrier platform for 
spinal gene therapy. It is important to note that developing next-generation protocell 
platforms are aimed at delivering cargo that act to stimulate transgene uptake; a multi-
therapy approach, and may be superior to existing approaches. 
 74 
2.5 Conclusions 
This work characterizes the in vitro and in vivo toxicological profile of liposomes 
fused on MSNs, and examines their use as gene therapeutic vectors delivered to the 
spinal cord. These liposome-supported MSN constructs are referred to as protocells, 
which act to retain and protect DNA cargo used in these studies. The advantage of 
applying protocells as cargo delivery systems (drug and genes) lies not only in their 
potential for exceptional cargo capacity, cell-specific targeting and tunable release rates, 
but also, as demonstrated in this report, in their high and enduring biocompatibility 
within the CNS. As non-viral vectors, protocells allow transgenes of interest to remain 
physiologically functional. Most intriguing is the potential application of this approach to 
other CNS diseases.136, 137 The data in this report demonstrate that protocells loaded with 
the IL-10 transgene and delivered peri-spinally produce robust pain suppression 
supporting prior reports that spinal IL-10 gene therapy leads to a reduction of pain.68,72,73, 
98,138 Thus, protocells offer a potentially new drug delivery vessel to the CNS with 
intrinsic flexibility to tailor drug therapy. 
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Abstract 
Non-viral naked plasmid DNA gene therapy encoding the anti-inflammatory 
cytokine, interleukin-10 (pDNA-IL-10), results in therapeutic efficacy when delivered to 
the peri-spinal subarachnoid region (intrathecal; i.t.) to suppress chronic neuropathic pain 
in animal models. However, two sequential i.t. naked pDNA injections must occur within 
a discrete 5-72 hr period, defining a time of local immune cell sensitization for improved 
transgene uptake and prolonged pain suppression assessed by decreases in light touch 
sensitivity known as allodynia. Utilizing the anti-inflammatory M2-polarizing properties 
of the synthetic glucocorticoid, dexamethasone, or the hexose sugar, D-mannose, to 
prime local peri-spinal immune cells, we examined improvement of transgene efficacy 
with reduced naked pDNA-IL-10 doses previously determined ineffective when delivered 
without a priming pre-treatment. Compared to dexamethasone, i.t. mannose priming 
significantly and dose-dependently prolonged pDNA-IL-10 pain suppressive effects, 
reduced spinal IL-1β and enhanced spinal and dorsal root ganglia IL-10 
immunoreactivity. Macrophages exposed to D-mannose revealed reduced 
proinflammatory tumor necrosis factor-α, IL-1β, and nitric oxide, and increased 
endogenous and transgene-derived IL-10 protein production. A single co-injection of 
mannose with a 25-fold lower pDNA-IL-10 dose produced prolonged pain suppression in 
neuropathic rats, supporting this novel approach of tuning spinal immune cells toward an 
activated M2 phenotype for improved non-viral gene therapy. 
Key Words: M2 polarized, cytokine, sciatic nerve, gene therapy, intrathecal injection, 
spinal, allodynia, rat 
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3.1 Introduction 
Existing drugs, which primarily target neurons, partially reduce pain (~25-40%) 
in less than half of the 7-8% of patients suffering from chronic neuropathic pain in the 
US,139, 140 which underscores the need to develop new therapeutic approaches to treat 
pathological pain. Modern views of pain processing are emerging which include critical 
roles of factors released from non-neuronal cells in the central nervous system (CNS), 
like glial cells,141, 142 and glia in the dorsal root ganglia (DRG) that house pain-related 
neurons.143, 144 Glial proinflammatory cytokines like interleukin-1β (IL-1β ) and tumor 
necrosis factor-alpha (TNF-α), and inducible factors such as calcium-independent nitric 
oxide (NO) are characterized to mediate the initiation and maintenance of experimental 
neuropathic pain. Leukocytes (e.g. macrophages, dendritic cells, T cells), responding to 
glial cytokines and NO, accumulate in DRG sites as well as peri-spinal subarachnoid 
regions immediately adjacent to spinal pain transmission neurons during pain 
neuropathies produced by remote, localized peripheral nerve lesions,145, 48, 146-150 
suggesting that leukocytes may further contribute to neuropathic pain. Leukocyte-derived 
IL-1β, TNF-α and other immune-related signaling factors in peri-spinal subarachnoid 
regions can create continuous feed-forward cytokine production and activity. Notably, 
accumulation of leukocytes into these sites concomitant with neuropathic pain is 
generated in the absence of infection. Together, the actions of spinal and DRG glia, as 
well as local leukocytes, enhance signaling processes that mediate neuropathic pain in 
animal models.  
 79 
Because IL-1β, TNF-α and NO are so powerful, leukocytes and glial cells have 
evolved the means to create negative feedback suppression of their activity. This is 
achieved by mechanisms that include the production of anti-inflammatory cytokines, of 
which interleukin-10 (IL-10) is one of the most potent. IL-10 can inhibit a variety of 
cytokines including IL-1β and TNF-α by preventing intracellular kinase activation 
pathways, and preventing IL-1β and TNF-α transcription, translation, post-translational 
processing and protein release.151, 152 Additionally, IL-10 is both a natural product of glia 
(astrocytes and microglia)153 and leukocytes, such as macrophages and dendritic cells, 
which express IL-10 receptors.62 Importantly, adult spinal cord neurons do not produce 
IL-10 and do not express IL-10 receptors, even under neuropathic conditions.154, 155 Prior 
reports demonstrate that IL-10 administration is an effective strategy to produce pain 
relief by blunting glial mediators of neuropathic pain signaling.156, 97, 98,157,158 Thus, the 
application of IL-10 is a therapeutic intervention of pathological cytokine and NO-
mediated pain signaling, without exerting direct actions on neurons. 
Gene therapy has received some recognition as a tool to target glia for pain 
control.131, 159, 160 While gene transfer using non-viral naked plasmid DNA (pDNA) is the 
least effective method to transform host cells with therapeutic genes of interest,161 our 
prior work demonstrates that utilizing pDNA encoding the IL-10 transgene (pDNA-IL-
10) delivered to the peri-spinal subarachnoid (intrathecal; i.t.) region produces robust and 
enduring pain reversal in animal models.68, 97 While a clearly defined mechanism by 
which spinal cord non-viral pDNA gains access to host cell machinery for transgene 
expression is poorly understood, one strong possibility is that gene transfection can result 
from non-specific phagocytosis by macrophages/dendritic cells.80 Although virtually 
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every cell type is capable of phagocytosis, macrophages and dendritic cells are 
specialized immune phagocytic cells that reside within healthy and intact peri-spinal 
meninges.78 Additionally, spinal cord microglia and astrocytes are ascribed as highly 
efficient phagocytic cells of the CNS.162, 163 Indeed, microglia are “the macrophages of 
the CNS”, and astrocytes maintain a healthy microenvironment by routinely 
clearing/digesting dying cells. Naked pDNA can stimulate macrophages, dendritic, and 
glial cells,71, 164, 165 leading to the rapid production of cytokines that trigger leukocyte 
extravasation from circulation into peri-spinal meninges and the i.t. space.72 The cell-
enriched peri-spinal subarachnoid region may be a key component for augmented 
transgene uptake and expression.  
Different phenotypic profiles of immune and glial cell activation in the meninges 
may be particularly permissive for non-viral, DNA-based gene transfer, which can be a 
unique target for therapeutic long-duration pain control. Activation of phagocytic 
leukocytes (particularly macrophages and dendritic cells) leads to the production and 
release of a family of proinflammatory cytokines including IL-1β and TNF-α that are 
characterized as possessing an M1 polarized/classical activation phenotype (pro-
inflammatory state). More recently, these same cell types have been described with an 
M2 polarized/alternative activation phenotype that is characterized by a distinct set of 
anti-inflammatory cytokines55 including IL-4 and IL-10.54,166-169 One hallmark of 
alternative activation is increased expression the mannose receptor (MR)167 in the 
presence of increased IL-4 and IL-10 protein production with decreased IL-1β, TNF-α 
 and NO production.54, 166-169 Moreover, the synthetic glucocorticoid, dexamethasone, is 
characterized to induce MR expression and induces an M2 polarized/alternative 
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activation phenotype.167 M2 polarized/alternatively activated leukocytes (e.g. 
macrophage/dendritic cells) and glial cells express low levels of pro-inflammatory IL-1β, 
TNF-α, cytokines, and higher levels of IL-10, and reveal enhanced IL-10-mediated 
phagocytic capacity.170 Thus, spinal transgene uptake may be substantially improved by 
targeting M2 polarized/alternatively activated leukocytes, including macrophages present 
in the peri-spinal subarachnoid region, to phagocytose naked pDNA encoding IL-10. 
We recently reported the discovery of a sensitization period between two 
sequential peri-spinal i.t. injections of naked pDNA that exploits immune phagocytes 
(e.g., macrophages) for improved IL-10 transgene uptake (Scheme 1).72,107 The 
components of the naked pDNA used in the first injection does not require the presence 
of the IL-10 transgene. However, the IL-10 transgene must be present in the pDNA used 
for the second injection to result in long-duration pain relief. Thus, the pDNA used for 
the first injection may simply act to stimulate the surrounding local leukocytes and is 
thought to initiate a local cellular response that leads to enhanced uptake of the IL-10 
transgene used for the second injection.72 The sensitization period is discrete within the 
spinal subarachnoid microenvironment, with a 5-72 hour inter-injection interval, as inter-
injection intervals outside of this period fail to produce transgene-derived IL-10 mRNA 
expression, increased IL-10 protein or long-duration pain relief. 68, 72, 73, 171  
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Scheme 1 Illustration depicting the “sensitization period”. 
This scheme describes a discrete window of time or sensitization period, from 5-72 hours following the 
first i.t. injection of pDNA-IL-10 (100 µg), during which the second injection of pDNA-IL-10 (25 µg) must 
be given to generate stable and enduring pain relief. If the second injection is given outside of this time 
interval, pain reversal is dramatically shortened. During the sensitization period, an accumulation of 
leukocytes was found surrounding the i.t. injection site, a large number identified as macrophages.135 A 
possible mechanism underlying improved transgene therapeutic efficacy during this period may be a 
change in the macrophage cytokine profile with a switch from proinflammatory M1/classical activation to 
anti-inflammatory M2/alternative activation resulting in improved phagocytosis of transgene. 
 The goal of the present studies is to sensitize and shift peri-spinal immune 
phagocytes to an M2 polarized/alternative activation phenotype for enhanced pDNA-IL-
10 uptake within the sensitization interval that leads to enduring pain relief. 
Dexamethasone and D-mannose, both previously characterized to strongly induce the 
expression of the M2 polarized/alternative activation phenotype, will be examined as 
factors capable of priming peri-spinal macrophages for improved pDNA-IL-10 transgene 
uptake, as assessed by the efficacy of low-dose transgene i.t. delivery (duration of 
therapeutic pain suppression) and increased IL-10 protein expression in discrete spinal 
and DRG regions critical for pain processing.  
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3.2 Results 
3.2.1 Dexamethasone primes subsequent i.t. pDNA-IL-10 to produce transient and 
minimal behavioral reversal of allodynia 
The synthetic glucocorticoid steroid, dexamethasone (DEX), given as an initial i.t. 
priming injection and followed by an i.t. pDNA-IL-10 (25 µg) injection results in a 
delayed and transient reversal of allodynia produced by chronic constriction injury (CCI) 
of one sciatic nerve. This is a well-characterized and widely used animal model of 
chronic peripheral neuropathic pain that results in clinically relevant neuropathic 
behavioral changes such as allodynia and is assessed by sensitivity to light touch using 
the von Frey test (Figure 3.1). Following establishment of baseline (BL) responses to 
von Frey filaments, animals are treated with either CCI or sham surgery. Compared to 
sham-operated controls that reveal stable threshold responses near BL values, clear 
development of allodynia occurs in CCI-operated rats, as measured 3 and 10 days later. 
Rat hindpaw responses now occur at <1.0 grams of touch stimuli. On day 10, sham and 
CCI animals received 2 sequential i.t. saline injections 3 days apart. Shams remained 
stably non-allodynic hindpaw throughout the 27-day timecourse while neuropathic CCI-
operated rats given similar injections had clear and chronic hindpaw allodynia throughout 
the same period. Those CCI animals given a priming i.t. injection of 62.4 ng DEX, but 
not 6.2 ng, followed 3 days later by an i.t. injection of pDNA-IL-10 (25 µg) experienced 
a delayed onset of partial but short-term reversal of allodynia, lasting only 2 weeks. 
Similar behavioral hindpaw responses were observed contralateral to CCI (Figure 3.1).  
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Figure 3.1 Dexamethasone for improved pDNA-IL-10 uptake does not create robust pain reversal. 
(a and b ) Baseline (BL) hindpaw sensory threshold responses to light mechanical touch were measured by 
the von Frey test with calibrated monofilaments). There were no significant differences observed between 
groups (Ipsilateral, F(3,24) =0.2154; p=0.8846; Contralateral, F(3,24)=0.6930; p=0.5665). Following either 
CCI or sham surgery, behavioral testing continued at the time points indicated on the x-axis. Animals 
receiving CCI surgery developed stable allodynia from day 3 to day 10 compared sham-operated animals 
(day 10: Ipsilateral, F(3, 24) =53.54; p<0.0001; Contralateral, F(3, 24)=71.70; p<0.0001). On day 10 following 
CCI surgery, animals received an i.t. injection of DEX (62.4 ng, n=6 or 6.2 ng, n=6), or equivolume i.t. 
saline (n=7) and sham-operated animals received i.t. equivolume saline (n=6). Three days later, an i.t. 
injection of pDNA-IL-10 (25 µg) or equivolume saline was given. Sham-control animals remained non-
allodynic, while CCI animals given i.t. saline remained allodynic. I.t. pDNA-IL-10 following a priming 
injection of DEX (62.4 ng) revealed a delayed and partial bilateral pain reversal (Ipsilateral, F(3,140) =33.83; 
p<0.0001; Contralateral, F(3,140)=19.7; p<0.0001). Black arrows indicate i.t. injections. (A, B- Behavioral 
testing by Ellen Dengler with assistance from Lauren Alberti and Brandi Bowman) 
3.2.2 D-Mannose primes subsequent i.t. pDNA-IL-10 to produce long-term behavioral 
reversal of allodynia 
An i.t. priming injection of D-mannose dose-dependently and dramatically 
increased the therapeutic efficacy of 25 µg i.t. pDNA-IL-10 given within a 3-day inter-
injection interval (Figure 3.2). Non-neuropathic sham-operated saline injected control-
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treated rats revealed stable, bilateral non-allodynic responses, while CCI-treated rats 
given i.t. saline control injections revealed ongoing bilateral chronic allodynia throughout 
a 91-day timecourse. Strikingly, an i.t. priming injection of D-mannose (50 µg) followed 
three days later by i.t. pDNA-IL-10 (25 µg) produced a complete reversal of allodynia 
similar to BL thresholds that stably persisted for 3 months. Allodynia never returned. 
Also provocative was the observation that a 10-fold lower i.t. priming dose of D-mannose 
(5 µg) followed by i.t. pDNA-IL-10 produced a partial and enduring relief from bilateral 
allodynia. However, when a priming injection of D-mannose (50 µg) was followed by a 
25 fold lower dose of i.t. pDNA-IL-10 (1 µg) there was complete but only transient 
reversal from allodynia of ~11 days (Figure 3.2).  
 
Figure 3.2 The D-Mannose used to prime M2 polarization for improved pDNA-IL-10 uptake reverses 
allodynia greater than 90 days. 
(a and b) No significant differences in BL responses between groups prior to CCI or sham surgery were 
observed (Ipsilateral, F(4,32)=1.009; p=0.4197; Contralateral, F(4,32)=1.147; p=0.3551). Sham operated 
animals (open triangles; n=6) remained non-allodynic throughout the time course. CCI animals (open 
diamonds; n=7) revealed clear allodynia from day 3 to day 10 compared to shams (day 10: Ipsilateral, 
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F(4,32)=32.87; p<0.0001; Contralateral, F(4,32)=37.01; p<0.0001). On day 10, animals received an i.t. 
injection of either D-mannose (50 µg; 5 µg) , or equivolume saline followed three days later by pDNA-IL-
10 (25 µg or 1 µg) or equivolume saline. Following the first priming injection of D-mannose (50 µg; closed 
squares; n=8), a robust reversal was observed, compared to CCI-saline injection (Ipsilateral, F(3, 70)=15.87; 
p=0.0004; Contralateral, F(3, 70)=20.40; p=0.001). Full reversal to BL levels continued for a 3 month period 
beyond the 2nd injection of pDNA IL-10 (25 µg) in those animals given D-mannose (Ipsilateral, F(3, 384) 
=57.46; p<0.0001; Contralateral, F(3, 384) =59.20; p<0.0001). A 2nd injection of a lower dose of pDNA-IL-
10 (1ug: closed triangles; n=5) produced a transient 11-day reversal. Animals pretreated with the lower 
dose of D-Mannose (5 µg) followed by a second injection of pDNA-IL-10 (25 µg) (closed circles, n=7) 
showed partial bilateral reversal for the 3 month time course that was not significant (Ipsilateral, F(3,17)= 
12.71; p=0.0270; Contralateral, F(3, 17)= 14.64; p= 0.002). (A, B- Behavioral testing by Ellen Dengler with 
assistance from Lauren Alberti, Brandi Bowman, Vanessa Garcia and Daniel Moezzi) 
3.2.3 Characterization of D-mannose: short-term reversal of allodynia, M2-polarization, 
and increased IL-10 transgene expression. 
Results illustrated in Figure 3.2 raise the possibility that D-mannose may exert 
enduring pain-suppressive effects in the absence of transgene IL-10. To examine this 
question, we investigated whether a single i.t. injection of D-mannose could sustain 
prolonged pain relief. Following BL threshold assessment, all animals underwent CCI 
surgery, and threshold responses revealed clear bilateral allodynia 3 and 10 days later. On 
day 10, a single i.t. injection of 50, 5, or 0.5 µg D-mannose or saline was delivered. 
Behavioral thresholds revealed robust bilateral reversal from allodynia following the 
highest dose of i.t. D-mannose compared to lower doses or saline (Figure 3.3, a and b).  
To examine whether D-mannose could directly induce an anti-inflammatory 
phenotype, mouse macrophage RAW264.7 cell cultures were used as a cell type 
comparable to macrophages that occur in high populations in high numbers in the peri-
spinal subarachnoid region. A classic proinflammatory response was initiated by 
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Lipopolysaccharide (LPS), which is cell-wall particles from gram-negative bacteria, to 
mimic the local peri-spinal signaling milieu present during chronic peripheral neuropathic 
conditions, namely increased TNF-α, IL-1β and nitric oxide production. These data 
confirm that cells pre-incubated with D-mannose followed by challenge with LPS 
resulted in increased IL-10 protein levels (Figure 3.3, c) with simultaneous ablation of 
IL-1β protein (Figure 3.3, d), and a robust reduction of protein TNF-α (Figure 3.3, e), 
and NO production (Figure 3.3, f). Interleukin-4, an anti-inflammatory cytokine strongly 
associated with an M2 phenotype, was also tested. However, D-mannose at the doses 
tested yielded no reliable IL-4 protein increases (data not shown). Thus, in cultured 
macrophage cells, D-mannose creates a robust reduction in pro-inflammatory markers 
while significantly elevating IL-10 during stimulatory conditions that activate 
inflammatory pathways.  
A possible mechanism for increased pDNA-IL-10 efficacy on pain reversal 
observed in Figure 2 is that D-mannose could increase transgene uptake. To directly 
examine D-mannose’s effects on pDNA-IL-10 uptake, cultured RAW264.7 cells (mouse 
cell line) were incubated with either D-mannose, pDNA-IL-10 (encoding rat IL-10 
protein; 0.5 µg or 5.0 µg), or D-mannose + pDNA-IL-10 (0.5 µg or 5.0 µg). A significant 
increase in rat IL-10 protein levels were measured from supernatants of cells treated with 
D-mannose in combination with pDNA-1L-10 at either 0.5 µg or 5.0 µg (Figure 3.3, g). 
IL-10 protein levels increased with increased dosages of the pDNA-IL-10 transgene only 
in the presence of D-mannose. It is important to note that the ELISA for rat IL-10 does 
not cross-react with mouse IL-10 protein levels, demonstrating that plasmid-derived IL-
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10 protein is robustly expressed when the IL-10 transgene is delivered to RAW264.7 
cells in combination with D-mannose.  
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Figure 3.3 D-Mannose generates short-term reversal of allodynia without pDNA-IL-10. 
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(a and b) No significant BL response differences between groups prior to CCI was observed (Ipsilateral, 
F(3,13) =0.4995; p=0.6910; Contralateral, F(3,13)=0.1761; p=0.9099). All animals underwent CCI surgery and 
revealed clear allodynia by day 10 with no significant differences between groups (F(3,13)=0.1897; 
p=0.9010; Contralateral, F(3,13)=0.2234; p=0.8780). On day 10, animals were given a single i.t. injection of 
D-mannose (50, 5, or .5 µg; closed squares, closed circles, or closed diamonds respectively) or an 
equivolume saline only (n=3-4/group). Saline-treated animals (open diamonds) remained bilaterally 
allodynic throughout the time course. Treatment with D-mannose (50 µg, n=3) resulted in bilateral partial 
reversal from allodynia that gradually returned by day 20 following injection (Ipsilateral, F(3,70)=15.87; 
p<0.0005; Contralateral F(3,70)= 20.40; p=0.0001). Black arrows indicate i.t. injection. (c-f) Cultured Raw 
264.7 mouse macrophage cells were pretreated with D-Mannose (100 mM) followed by a 2 hour incubation 
with a combination of D-Mannose (100 mM) and LPS (10 ng). (c) Compared to control treatment (No 
Tx=no treatment; Mann=D-mannose), LPS-stimulated cells given D-mannose treatment resulted in 
significantly increased IL-10 protein production, (d) almost complete ablation of IL-1β levels (e) 
significantly reduced TNF-α protein levels, and (f) reduced NO production. (g) Cultured Raw 264.7 mouse 
macrophage cells were pretreated with D-Mannose (500 mM) for 5 hours followed by a 24 hour incubation 
with D-mannose with or without pDNA-IL-10, or D-Mannose and pDNA-IL-10 alone. Those cells 
incubated with D-mannose and pDNA-IL-10 showed robust and significantly increased exogenous rat IL-
10 production over controls (F(5,17)=69.3; p<0.001)*p<0.05; **p<0.01; ***p<0.0001 (A, B- Behavioral 
testing by Ellen Dengler with assistance from Lauren Alberti, Vanessa Garcia and Daniel Moezzi; C-G- 
Experiment run by Audra Kerwin with statistical analysis and graphics by Ellen Dengler) 
3.2.4 Intrathecal D-mannose priming followed by i.t pDNA-IL-10 results in increased IL-
10 and decreased IL1β expression in spinal cord and DRG 
The data described above show that D-Mannose (50 µg) followed by pDNA-IL-
10 (25 µg) results in enduring pain reversal. We next examined whether cytokine changes 
critical for neuronal pain processing occurred in regions where active glial and immune 
cells are found. We examined by immunohistochemical detection, IL-10 and IL1 β in 
lumbar and DRG tissue regions from behaviorally verified rats. Following BL 
assessment, behavioral thresholds were reassessed on day 3 and 10 to ensure the presence 
of chronic allodynia in CCI-treated rats. As before, animals received an i.t. injection of 
saline, or D-mannose (50 µg) followed three days later by saline or pDNA-IL-10 (25 µg). 
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Duplicating the results of our prior experiment above, i.t. D-mannose followed 3 days 
later by i.t. pDNA-IL-10 produced full and sustained reversal from allodynia compared to 
non-mannose controls receiving either i.t. saline followed by pDNA-IL-10, or 2 i.t. saline 
injections in CCI-treated rats (Figure 3.4, a and b). Animals were deeply anesthetized on 
Day 29 and spinal cord and DRG tissues were collected to examine potential spinal and 
DRG cytokine changes corresponding to the observed behavioral profile. The anatomical 
regions of the spinal cord analyzed correspond to the terminals of sciatic nerve fibers 
entering the L4-L6 spinal cord from the corresponding DRG. Primary antibodies 
immunoreactive (IR) for IL-10 and IL-1β, were detected using immunoreactive 
Rhodamine-Red fluorophore-conjugated secondary antibodies. Immunofluorescence was 
quantified using computer-assisted spectral analysis software as described in the 
methods, below. 
Analysis of ipsilateral spinal cord IL-10 (Figure 3.4, c), revealed significant 
increases in IL-10 IR in D-mannose-pDNA-IL-10 treated rats compared to non-mannose 
treated controls. Contralateral spinal cord IL-10 IR revealed similarly increased levels 
(data not shown). Representative photomicrographs of the quantified data are shown 
(Figure 3.4, d-f), revealing IL-10 IR occurs primarily in gray matter in the deeper spinal 
laminae. Conversely, fluorescent quantification demonstrates that spinal IL-1β IR is 
significantly reduced in D-mannose primed pDNA-IL-10 injected rats compared non-
mannose treated controls (Figure 3.4, g). As with IL-10, representative 
photomicrographs are shown (Figure 3.4, h-j) that are part of the analyzed data of the 
different treatment groups, and depict a punctate pattern primarily in the white matter of 
the spinal cord. Contralateral IL-1β IR appears similar (data not shown) to that observed 
 92 
in the ipsilateral spinal cord, but failed to reach significance. Unexpectedly, IL-10 IR was 
significantly increased in DRG following D-mannose-pDNA-IL-10 treatment compared 
to non-mannose treated controls (Figure 3.4, k). Representative photomicrographs 
(Figure 3.4, l-n) are shown. Notably, the pattern of IL-10 IR is peri-neuronal. 
Given high variance was observed only in the saline-pDNA-IL-10 group, a 
Grubb’s Z-test172 (as described in Methods) was applied to identify an outlier from the 
group mean, and one rat was omitted from the lumbar and DRG analyses, resulting in 
saline-pDNA-IL-10 data that is representative of 8, and not 12, tissue slices.  
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Figure 3.4 Spinal and DRG pro-and anti-inflammatory markers expression. 
(a and b) Verification of animal behavior prior to tissue collection is represented. There were no differences 
between groups at BL prior to CCI or sham surgery (Ipsilateral, F(5,18) =0.2597; p=0.8999; Contralateral, 
F(5,18)=0.4947; p=0.9398). As before, CCI treated animals revealed clear bilateral allodynia to day 10 
compared to sham controls (Ipsilateral, F(5, 18) = 35.54; p<0.0001; Contralateral, F(5, 18)=35.96; p<0.0001). 
On day 10 following sham or CCI surgery, animals were given an i.t. pretreatment with D-mannose (50, 
µg) or equivolume saline injection followed three days later by i.t. pDNA-IL-10 (25 µg; closed squares; 
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n=7) or equivolume saline (closed circles; n=4). Saline-CCI treated animals (open diamonds; n=3) 
remained bilaterally allodynic throughout the time course compared to sham-D-mannose (open squares; 
n=3) or sham-saline (open circles; n=6) treated animals (Ipsilateral, F(3,9)=28.79; p=0.0001; Contralateral, 
F(3,9)=19.7; p=0.0007). These data replicated our earlier results above, and reveal that i.t. pretreatment with 
D-Mannose (50 µg) followed by pDNA-IL-10 (25 µg) causes a full bilateral reversal of allodynia compared 
to CCI-control groups (Ipsilateral F(4,126)= 30.27; p < 0.0001; Contralateral F(4,126)= 35.75; P< 0.0001). At 
day 29 while rats remained fully reversed from allodynia, spinal cord and associated DRG tissues were 
collected and stained for the anti-inflammatory cytokine, IL-10 or the pro-inflammatory cytokine, IL-1β. 
(c) Animals that received D-mannose (50 µg) on day 1 and pDNA-IL-10 on day 3, revealed significantly 
greater IL-10 immunoreactivity (IR) in the lumbar spinal cord compared to those animals injected with 
saline only or saline followed by pDNA-IL-10 (Ipsilateral F(3, 5)=34.23; p<0.01; Contralateral F(3, 5)=2.714; 
p>0.05). (d,e,f). Representative images used for the data analysis are presented (red=IL-10 IR, blue=cell 
nuclei). (g) Adjacent tissue sections revealed significantly less IL-1β IR in the ipsilateral lumbar spinal cord 
compared to non-mannose treated control groups (Ipsilateral F(3,5)=10.67; p<0.05; Contralateral F(3,5)=3.73; 
p> 0.05). (h, i, j). Corresponding fluorescent images of the analyzed data are presented (red =IL-1β IR, 
blue=cell nuclei). (k) In addition, significantly greater IL-10 IR in the DRG is observed in the D-mannose 
primed treatment group compared to both non-mannose treated control groups (Ipsilateral F(3, 5) =10.35; 
p<0.05; Contralateral F(3, 5) =5.73; p>0.05). (l, m, n). Corresponding fluorescent images of the analyzed 
data are presented (red =IL-10 IR, blue=cell nuclei). Data for the contralateral DRG data are not shown. 
*p< 0.05; **p< 0.01; ***p<0.0001; all images were taken at 10X; scale bar =100µm (A, B- Behavioral 
testing by Ellen Dengler with assistance from Lauren Alberti, Vanessa Garcia and Daniel Moezzi; C-N- 
Tissue slicing by Ellen Dengler with assistance from Pamela Palermo; IHC and spectral microscopy by 
Ellen Dengler with assistance from Jenny Wilkerson; computerized analysis by Ellen Dengler with 
assistance from Jenny Wilkerson and Pamela Palmero) 
3.2.5 A single i.t. co-injection of D-Mannose with a very low dose of pDNA-IL-10 
extends reversal of allodynia 
Robust and fast-acting anti-inflammatory responses of macrophage cells were 
observed following D-mannose exposure in culture suggesting that D-Mannose may 
rapidly act to shift local peri-spinal immune cells to an M2 activated phenotype. Indeed, 
behavioral profiles following i.t. D-mannose treatment described in Figure 2 produced 
reversal from allodynia within 24 hrs. To expand upon these findings, we examined 
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whether the efficacy of a low dose of pDNA-IL-10 (1µg) shown to induce an ~11 day 
pain suppression (Figure 3.2), could be improved with a single co-injection of D-
mannose. As before, von Frey BL responses were assessed, followed by sham or CCI 
treatment and a reassessment of allodynia through day 10. Compared to non-neuropathic 
sham controls, CCI produced clear bilateral allodynia by day 10, which persisted 
following an i.t. saline injection, while non-neuropathic sham control animals given i.t. 
saline remained non-allodynic through a 26 day timecourse (Figure 3.5, a and b). 
However, animals that received a single i.t. co-injection of D-mannose (50 µg) with 
pDNA-IL-10 (1 µg) resulted in a clear bilateral reversal of allodynia that was sustained 
for 26+days (Figure 3.5, a and b), while control saline or DNA-injected rats remained 
fully allodynic. These data demonstrate for the first time that a single injection of D-
Mannose (50 µg) co-injected with pDNA-IL-10 (1µg) reverses allodynia for ~26 days.  
 
Figure 3.5 A single co-injection of D-mannose with low dose pDNA-IL-10 produces enduring reversal 
of allodynia. 
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 (a and b) No significant BL response differences were observed between groups prior to CCI or sham 
surgery (Ipsilateral, F(3, 32) =0.8932; p=0.4973; Contralateral, F(36, 32) =1.393; p=0.231. As before, CCI 
treated animals revealed clear bilateral allodynia through day 10 compared to sham controls (Ipsilateral, 
F(3,32) =32.07; p<0.0001; Contralateral, F(3, 32)=38.78; p<0.0001). On day 10 after testing, sham rats received 
a single i.t. saline injection (open triangles; n=8) or D-Mannose (50 µg; closed triangles; n=4), and CCI rats 
received a single i.t. co-injection of D-Mannose (50 µg) with pDNA-IL-10 (1 µg; closed squares; n=10), 
pDNA lacking the IL-10 gene (control pDNA; open circles; n=7), or equivolume saline (open diamonds; 
n=6). Sham-saline and CCI-saline or CCI-control pDNA resulted in no change from bilateral allodynia 
throughout the time course, D-mannose co-injected with a low-dose of pDNA-IL-10 (1 µg) (closed squares, 
n=5) resulted in a significant and full reversal of allodynia throughout the 3 week time course (Ipsilateral 
F(3, 238)= 60.23; p<0.001; Contralateral =F(3, 224)=22.18; p< 0.001). (A, B- Behavioral testing by Ellen 
Dengler with assistance from Lauren Alberti and Daniel Moezzi) 
3.3 Discussion 
The studies in the current report describe the timing and dose refinement of a non-
viral peri-spinal naked plasmid DNA (pDNA) therapy by which long-term suppression of 
neuropathic pain is achieved. Long-term efficacy of this naked DNA therapy requires 
initial priming of peri-spinal intrathecal (i.t. subarachnoid) meningeal immune cells 
followed by i.t. injection of pDNA encoding the anti-inflammatory cytokine, interleukin-
10 (IL-10), which is in line with the previous observation that i.t. stimulatory 
oligodeoxynucleotide (ODN) injection facilitated therapeutic pain reversal upon i.t. 
pDNA-IL-10 injection.72 While i.t. ODN injection served to prime local innate immune 
cells for improved uptake of pDNA-IL-10, these ODN adjuvants are characterized to 
stimulate the immune cell receptor, Toll-like receptor 9 (TLR9) that leads to 
proinflammatory cytokine production,173 suggesting that ODNs may not be the ideal 
adjuvant for transgene therapy. However, corticosteroids provide robust anti-
inflammatory effects by suppressing the activation of multiple proinflammatory genes,75 
and thereby, may act to facilitate transgene uptake by controlling pDNA-derived 
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proinflammatory cytokine production. A recent report demonstrated that dexamethasone, 
a potent synthetic glucocorticoid widely used to control clinical inflammatory conditions, 
co-delivered with pDNA yielded greater pDNA uptake and lower proinflammatory 
cytokine levels.174 Surprisingly, results in the current report demonstrate that a priming 
i.t. dexamethasone injection followed by i.t. pDNA-IL-10 failed to significantly improve 
the efficacy of pDNA-IL-10 treatment, and in fact, failed to alter behavioral sensitivity to 
light touch (Figure 3.1), a pain-related condition referred to as allodynia. Conversely, i.t. 
D-mannose, characterized to exert anti-inflammatory effects,175,176 primed subarachnoid 
immune cells in a dose-dependent manner, such that a subsequent i.t. pDNA-IL-10 
injection produced complete and enduring suppression of allodynia induced by CCI 
(Figure 3.2). These results suggest that D-mannose may dramatically alter the peri-spinal 
microenvironment in strong favor of transgene uptake. These data are the first 
demonstration of enduring neuropathic pain suppression by a 5-fold lower dose of i.t. 
naked pDNA-IL-10 (25 µg), than the 125 µg previously documented.135 These 
experiments support the notion that D-mannose may alter an active and ongoing process 
in the subarachnoid compartment prior to transgene administration such that lower doses 
of i.t. pDNA-IL-10 are transformed into efficacious treatments for pain suppression. 
While the combination of i.t. D-mannose followed 3 days later by i.t. pDNA-IL-
10 significantly improved pDNA-IL-10 efficacy, the possibility that D-mannose could 
exert enduring pain reversal in the absence of IL-10 transgene treatment remained a 
possibility and was addressed in the current study. Intriguingly, i.t. D-mannose alone 
produced a dose-dependent but transient reversal of allodynia (Figure 3.3, a and b), 
demonstrating that mannose alters spinal proinflammatory cytokine actions characterized 
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as crucial mediators of neuropathic pain in animal models.59 The transient reversal of 
allodynia additionally suggests that the enduring pain reversal is not due to the effects of 
mannose only, but to the effects following pDNA-IL-10 treatment.  
In further of support of prior studies documenting the anti-inflammatory role of 
D-mannose, the current data show that D-mannose not only blunts the protein release of 
the proinflammatory cytokine, TNF-α, and the inflammatory signaling molecule, nitric 
oxide (NO) generated by calcium-independent inducible NO synthase, but also fully 
suppresses IL-1β protein levels with simultaneous increases in IL-10 protein levels in 
lipopolysaccharide (LPS) stimulated macrophage cell cultures (Figure 3.3, c-f). Thus, 
these data suggest two important and related mechanisms could be altered by spinal 
application of D-mannose. First, a single injection of D-mannose creates complete but 
transient reversal of allodynia in an animal model of peripheral neuropathy that is 
mediated by spinal proinflammatory TNF-α, IL-1β and NO actions. Thus, D-mannose 
could exert broad spinal anti-inflammatory actions relevant to pathological pain 
processing. Second, the spinal anti-inflammatory effects of D-mannose may be critical 
for inducing a local immune cell switch to an M2 activated phenotype, thereby 
optimizing naked pDNA-IL-10 uptake.  
Given D-mannose pretreatment profoundly improved pDNA-IL-10 efficacy as 
demonstrated by a >90-day pain-reversal profile at transgene doses previously shown as 
transiently effective,23 we examined whether D-mannose improved transgene IL-10 
uptake in cell culture. The data are striking and demonstrate that in the presence of D-
mannose, transgene-derived IL-10 protein levels increase as the IL-10 transgene dose 
 99 
increases. Thus, D-mannose may be acting as a transgene adjuvant in vivo, to enhance 
IL-10 transgene uptake that ultimately produces enduring pain reversal. 
Spinal cords from rats showing enduring behavioral reversal from allodynia 
produced following an i.t. D-mannose injection followed 3 days later with i.t. pDNA-IL-
10 (Figure 3.4, a and b), revealed significant increases in IL-10 protein 
immunoreactivity (IR). These data suggest that pretreatment with D-mannose improves 
transgene uptake for sustained pain suppression by priming peri-spinal immune cells to 
respond to transgene material by a process of enhanced phagocytosis. 
Simultaneous decreases in IL-1β IR are observed (Figure 3.4, c-n) in spinal white 
matter and in corresponding DRG. While speculative, this pattern of staining observed in 
white matter appears similar to that observed following oligodendrocyte staining, as 
previously described.177, 178 DRG is home to sensory neurons that process pain, and an i.t. 
injection of D-mannose followed by pDNA-IL-10 three days later, within the 
sensitization period, plays a role in altering DRG cellular IL-10 IR expression levels. 
Notably, the pattern of IL-10 IR is peri-neuronal, likely expressed by satellite glial cells 
and/or infiltrating macrophage that are capable of modifying sensory neuron activity and 
subsequent allodynia. Bilateral allodynia with bilateral spinal decreases in IL-10 IR and 
unilateral increases in spinal and DRG IL-1β induced by unilateral CCI observed in the 
present report supports recent publications.106, 112 Bilateral IL-10 IR levels were similar to 
control levels in IL-10 following gene therapy treatment. IL-10 gene therapy additionally 
reduced ipsilateral IL-1β spinal and DRG levels. These data additionally suggests that IL-
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1β in contralateral spinal cord and DRG do not play a significant role in contralateral 
allodynia. 
The sensitization period of the peri-spinal region can be examined to understand 
the potential mechanism that leads to immune-mediated transgene uptake. This interval 
can also be exploited to achieve single-injection combination small-molecule adjuvant-
pDNA co-therapy. Indeed, the data reported here show for the first time, that a previously 
demonstrated ineffective low dose of pDNA-IL-10 (1 µg) is now efficacious for 3+ 
weeks when delivered with mannose upon a single i.t. injection (Figure 3.5). These 
observations suggest that inducing an M2 phenotypic switch to optimize transgene uptake 
is a viable approach for non-viral gene therapy. 
Prior work demonstrates that relief from allodynia, produced chronic CCI-induced 
neuropathy of the rat sciatic nerve, is observed at increasingly longer intervals (reversal 
from allodynia) with each subsequent i.t. pDNA-IL-10 injection, but not with control 
pDNA. That is, allodynia is reversed 3, 7, and 26 days following an initial, second and 
third i.t. injection, respectively,107 which supports that the IL-10 receptor is not 
desensitized following prolonged exposure, and an ongoing active cellular process is 
present. Adjustment of the time interval between the initial and second pDNA-IL-10 
injection, such that the second injection occurs during reversal from allodynia (e.g. 3 day 
inter-injection interval), results in a ~2-month pain relief profile.107 An examination of 
the i.t. inter-injection interval revealed the magnitude and the duration of allodynia 
reversal is significantly diminished and shortened if the inter-injection interval occurs 
outside sensitization period (5 – 72 hour),72 suggesting time-sensitive cell-mediated 
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mechanism in the lumbar meninges surrounding the i.t. injection site may be important 
for therapeutic transgene actions. 
Macrophages and dendritic cells are the predominant immune cells found in the 
meninges, including the pia mater which is in direct contact with underlying spinal cord 
pain-projection neurons.147, 179 Increases in these cell types in meninges after chronic 
neuropathic pain produced by partial sciatic nerve ligation have been identified,147 
suggesting that these cell types may make up a population of sensitized cells upon initial 
priming and subsequent pDNA uptake within the sensitization interval. Notably, 
additional local macrophage cell enrichment measured in CSF from hours to days after an 
i.t. pDNA-IL-10 injection corresponds to the sensitization interval.97, 135 The pro-and-
anti-inflammatory phenotype of these cells in lumbar CSF shifts during the sensitization 
interval and beyond to 6-days, as measured by the expression the pro-inflammatory 
marker, ED1, and the anti-inflammatory expression of the scavenger receptor, CD163 
(also known as ED2), supporting the potential importance of the M1 polarized/classical 
activation phenotype (pro-inflammatory state) and the M2 polarized/alternative activation 
phenotype180, 54, 166-169 in mediating transgene uptake. Cells characterized as M2 polarized 
are strongly associated with an anti-inflammatory cytokine profile that includes 
interlukin-4 (IL-4) and IL-10, with low levels of TNF-α, IL-1β,54, 55, 181 reveal enhanced 
phagocytic capacity.170 Indeed, cell culture protein data from the current report 
demonstrate that while IL-4 protein levels remained unaltered in mannose-stimulated 
macrophages, significant IL-10 protein increases were measured from cell culture 
supernatant with simultaneous decreases in NO, TNF-α and IL-1β, supported the 
possibility that i.t. D-mannose induces an M2 polarized phenotype. Thus, M2 polarized 
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macrophages and other immune cells may be critically important for enhanced peri-spinal 
transgene uptake.  
Interestingly, i.t. pDNA-IL10 in healthy, non-neuropathic control groups results 
in only small increases in IL-10 transgene expression in the meninges and DRG.171 This 
observation is critical because it suggests that conditions in non-pathological spinal cord 
are not sufficient for substantial pDNA-based IL-10 transgene expression. Indeed, pain is 
only minimally alleviated when i.t. pDNA-IL-10 is injected prior to full allodynia.171 We 
speculate that pre-emptive i.t pDNA-IL10 is ineffective because the local environment 
may not be permissive for non-viral transgene uptake and subsequent expression. 
Clinically, gene delivery-based therapeutics will be applicable to people who have 
persistent pain, and not for prophylactic pain treatment. Together, these data suggest that 
active and ongoing cellular processes during the sensitization period may impact 
continuous transgene expression and efficacy, and that anti-inflammatory signaling is 
necessary for enduring duration pain relief.182  
D-Mannose is a simple hexose sugar with a molecular weight of 180.2 which 
decreases inflammatory processes during wound healing,175 reduces oxidative bursts 
required in inflammatory processes,183 suppresses adjuvant-induced arthritis in a rat 
model,184 and inhibits LPS-induced IL-1β, TNF-α, and decreased NF-kB/p65 critical for 
pro-inflammatory cytokine expression, and immune cell influx following intratracheal 
instillation of LPS in rats, a model of sepsis-associated acute lung injury and respiratory 
distress syndrome.176, 185 The macrophage mannose receptor (MR) is a glycoprotein 
pattern recognition receptor involved in host defense innate immunity by recognizing 
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mannosylated ligands (e.g. lysosomal hydrolases) and phagocytosis of a variety of 
bacteria, yeasts and parasites that express mannosylated molecules at their surface.186-189 
Cells identified to express the MR include brain astrocytes, microglia, in meninges and 
perivascular macrophages as well as some neuronal populations (hippocampus, pons 
cerebellum and cortex).190, 191 Mannose-mediated MR activation leads to secretion of IL-
10 and other cytokines that contribute to a down-regulation of M1 polarized immune 
responses including decreased IL-1β and TNF-α protein production.192 The presently 
reported data are in support of these prior reports and extend these findings by 
demonstrating that mannose stimulates an anti-inflammatory profile both in vitro and in 
vivo. Indeed, macrophage cell cultures pretreated with mannose blunt or abolish NO, 
TNF-α and IL-1β levels while increasing IL-10 expression following LPS stimulation. 
Moreover, in vivo i.t. injection of mannose transiently reverses allodynia associated with 
spinal proinflammatory cytokines and significantly enhances therapeutic efficacy of IL-
10 spinal gene therapy increases spinal protein IL-10 IR.  
We speculate that mannose acts to ‘prime’ cells in the meninges to augment 
macrophage and dendritic cell phagocytosis of pDNA-IL-10. Importantly, the current 
data show the enduring effects of mannose to stimulate M2 polarized peri-spinal immune 
response eliminates the necessity of a second injection, as a single co-injection of 
mannose with pDNA-IL-10 produces enduring 3-week suppression of allodynia. Thus 
spinal subarachnoid mannose may be a key component for augmented transgene uptake 
and therapeutic expression. Studies are in progress to further define the role of the MR in 
enhancing spinal transgene uptake, thus further reducing required pDNA-IL-10 doses, 
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with the goal of producing an extended duration of neuropathic pain suppression lasting 
multiple months. 
3.4 Materials and methods 
Animals 
One hundred-twelve total, adult, male Sprague-Dawley rats (Harlan Labs, 
Houston, TX, USA) were used in these experiments. Their weight upon arrival was 300 g 
+/- 5 gm; the animals were housed at 21 +/- 2°C in light controlled rooms (12:12 light: 
dark; lights on at 6:00 AM) and fed standard rodent chow and water available ad libitum. 
Behavioral testing was performed during the first 4 hrs of the light cycle. All procedures 
were approved by the Institutional Care and Use Committee (IACUC) of the University 
of New Mexico, following NIH Guidelines for the Care and Use of Laboratory Animals 
and in accordance with guidelines in the Ethical Issues of the International Association 
for the Study of Pain.  
von Frey test for mechanical allodynia 
The von Frey test was used to quantify rat hindpaw responses to tactile 
stimulation and conducted identically as previously described. 102, 103 Briefly, rats were 
habituated to the testing environment consisting of placing rats on an overhead shelf 
composed of open powder-coated wire grid allowing access to the entire plantar surface 
of the hind paw for tactile stimulation by a logarithmic series of calibrated Semmes-
Weinstein monofilaments (von Frey hairs; Stoeling, Wood Dale, IL, USA). Rats were 
habituated for 4 consecutive days, 20-30 min/day in a quiet area with dim red lighting, at 
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26.0-27.0° C. Following habituation, baseline (BL) light touch sensitivity was assessed 
using monofilaments. The monofilaments were randomly applied, perpendicular to the 
left and right hind paws for 8 sec, to determine the threshold stiffness that would elicit 
paw withdrawal. Ten monofilaments were used, each with a log-stiffness value, defined 
as log10 (milligrams X 10), values in milligrams follow in parentheses: 3.61 (407), 3.84 
(692), 4.08 (1202), 4.17 (1479), 4.31 (2041), 4.56 (3630), 4.74 (5495), 4.93 (8511), 5.07 
(11,749) and 5.18 (15,136). Both the ipsilateral and contralateral withdrawal responses 
were measured and testing was conducted prior to and 3 and 10 days after surgery, and 
again following i.t. injections at designated time points presented in the representative 
figures. Three baseline measures were averaged for the right and left paws separately. 
The log stiffness that resulted in the 50% response threshold values (absolute threshold) 
was computed by fitting into a Gaussian integral psychometric function, PsychoFit, 
allowing parametric statistical analysis.103, 104, 113, 193 The software for PsychoFit may be 
downloaded form L.O. Harvey’s website (http://psych.colorado.edu/~lharvey).  
Chronic constriction injury (CCI) 
The surgical procedure for chronic constriction injury (CCI) was performed 
identically as previously described.99, 105 Briefly, under isofluorane anesthesia (1.5-2.0% 
vol. in oxygen), the mid to lower back and dorsal thigh were shaved and cleaned with 
diluted Bactri-Stat AE (EcoLab Health Care Division, Mississauga, Ontario, Canada).	  
Using aseptic procedures, the sciatic nerve was carefully isolated and four chromic gut 
sutures (Ethicon, Somerville, NJ, USA) were loosely tied around one sciatic nerve. The 
overlying muscle was sutured closed with two, sterile, silk sutures (Ethicon, Somerville, 
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NJ, USA), and the overlying skin was closed with wound clips. The sciatic nerve of 
sham-operated rats were identically exposed but not ligated. Animal body weight was 
recorded and full recovery from anesthesia was observed within 10 minutes. 
Drugs 
Commercially available water soluble dexamethasone (DEX; cat# D2915) and D-
mannose (cat# M6020) were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
Intrathecal (i.t.) injections  
Injections were acutely administered and conducted as described previously. 99, 107 
Briefly, rats were anesthetized with isofluorane (5.0% volume in oxygen) and an 18-
gauge guide cannula constructed from an 18-gauge sterile hypodermic needle (Beckton 
Dickinson & Co., Franklin Lakes, NJ, USA) with the plastic hub removed, was inserted 
percutaneously between lumbar vertebra 5 and 6 (L5-6). During this time, a small amount 
of CSF efflux from the 18-gauge cannula and a tail flick were observed, indicating 
subarachnoid catheter placement.  
Injectors used for i.t. delivery were constructed as follows. A 1 ml sterilized 
Hamilton syringe connected to a 30 cm-length polyethylene tubing (PE-10; cat# 427401; 
Becton Dickinson, Sparks, MD, USA) via a 30-gauge, 0.5-inch needle inserted into a 
catheter. The open end of the PE-10 tubing (catheter) was then used to draw up 
DOTAP:Chol or DOPC protocells (1.0, 0.1 or 0.01 mg) in a total volume of 20 µl sterile, 
isotonic saline. The drug-filled PE-10 catheter was then inserted into the open end of the 
18-gauge guide cannula and advanced 7.7 mm rostrally, placing the internal portion of 
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the PE-10 catheter at the lumbosacral enlargement of the spinal cord where axon 
terminals of sciatic afferent nerve fibers contact pain-relevant spinal cord neurons. 
Injections were given over a 0.5-1 minute interval. Following drug injection, the PE-10 
catheter and the 18-gauge cannula was removed and were discarded. The total time 
required for these i.t. injections was 2-3 minutes. All animals displayed full motor 
activity following recovery from anesthesia. 
Preparation of plasmid DNA 
The plasmid vector used in these studies is described previously.107 It consists of a 
5.9 base pair circular plasmid DNA containing a transcriptional cassette consisting of a 
cytomegalovirus enhancer/chicken beta-actin promoter driving expression of the rat IL-
10 gene including a point mutation (F129S) and a viral SV40 polyadenylation signal. The 
transcription cassette is flanked by a 149 base-pair inverted terminal repeat sequence. An 
identical plasmid lacking the IL-10 gene was used as a pDNA control. Both plasmids 
were amplified in SURE II competent E. coli (Stratagene, Cedar Creek, Tx., USA) and 
isolated using an endotoxin free Giga plasmid purification prep kit (Qiagen, Valencia, 
Ca., USA).  
Tissue sample preparation 
Procedures described for tissue processing followed those previously 
described.106, 112 Briefly, following behavioral assessment at Day 29 after i.t. injection, 
animals were overdosed with 8-1.5 cc of sodium phenobarbital (Sleepaway, Fort Dodge 
Animal Health, Fort Dodge, IA, USA) and perfused transcardially with saline followed 
by 4% paraformaldehyde. Whole vertebral columns with intact spinal cords (cervical 2 
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through sacral 1 spinal column segments) were removed, and underwent overnight 
fixation in 4% paraformaldehyde at 4°C. This procedure ensured that all relevant 
anatomical components, including the spinal cord, DRG, and related meninges, were 
intact within the vertebral column, allowing important spatial relationships to remain 
intact to examine corresponding functional interactions at specific spinal cord levels. All 
specimens underwent ethylenediaminetetraacidic acid (EDTA; cat# EDS; Sigma Aldrich, 
St. Louis, MO, USA) decalcification for 30 days, and spinal cord sections were 
subsequently paraffin processed and embedded in Paraplast Plus Embedding Media 
(McCormick Scientific, St. Louis, MO, USA), as previously described. 194 Adjacent 
tissue sections (7 µm) were mounted on vectabond-treated slides (Vector Labs, 
Burlingame, CA, USA), and allowed to adhere to slides overnight at 40°C, followed by 
deparaffinization, and rehydration via descending alcohols to PBS (1X, pH 7.4). Sections 
were then processed with microwave antigen retrieval procedures (citrate buffer pH 6.0, 
or tris-based buffer, pH 9.0; BioCare Medical, Concord, CA, USA).  
Antibody staining 
Procedures conducted for antibody staining were conducted similar to that 
previously described.106, 112 In brief, slides were incubated with 5% normal donkey serum 
(NDS), in PBS (1X, pH 7.4) for 2 hours, followed by overnight primary antibody 
incubation in a humidity chamber at 3° C. Slides underwent secondary antibody 
incubation for 2 hours in a humidity chamber at room temperature, rinsed in PBS, and 
then coverslipped with Vectashield containing the nuclear stain 4’, 6-diamidino-2-
phenylindole (DAPI) (Vector Labs, Burlingame, CA, USA). For detection of IL-10 and 
IL1-β expression, sections were incubated overnight with primary antibodies (IL-10; R & 
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D Systems, Minneapolis, MN, USA; IL1-β; Santa Cruz Biotechnology, Santa Cruz, CA, 
USA), incubated with biotinylated secondary antibody for 1 hour, and then treated with 
Vectastain ABC Elite kit (Vector Labs, Burlingame, CA, USA) and stained using TSA 
Plus Fluorescein System (PerkinElmer Life Sciences, Waltham, MA, USA) and finally 
cover slipped with Vectashield containing DAPI. Stained section orientation was kept 
consistent throughout for proper identification of ipsilateral and contralateral spinal cord 
and DRGs. For lumbar spinal cord, sections were taken from L4-L6, and the ipsilateral 
spinal cord analyzed. L5 DRG sections were taken with the most proximal portion of the 
DRG analyzed. Low magnification photomicrographs were obtained using a Nikon 
Optiphot fluorescent microscope equipped with a DP2-BSW (Olympus) camera.  
Spectral imaging for immunofluorescent quantification 
Procedures conducted for immunofluorescent quantification of stained section 
were conducted identically to that previously described.106, 112 In summary, multi-spectral 
tissue imaging was obtained using an Axioscope microscope connected to a Nuance 
Camera 2.8 (FX) Multispectral Imaging System, (Perkin-Elmer, MA, USA). This camera 
contains a liquid crystal tunable filter (LCTF) able to filter light over a 420-720 nm 
interval capturing a series of images at every 10 nm increment. Every pixel of every 
image (series collected at specific 10 nm wavelength increment) was then analyzed by 
CRI software (Cambridge Research and Instrumentation Inc., (CRI) Wolburn, MA) to 
determine its peak spectral intensities from 400-720 nm. A different imaging protocol 
was established separately for spinal cord and DRG. A major aspect of the protocol 
requires the software to subtract background fluorescence, defined as any spectral 
emission falling outside that of tissue-specific autofluorescence. The image was then de-
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convoluted into images containing: 1) the spectra of a true Rhodamine Red signal 
(Rhodamine Red emission: 600 nm+/- 5 nm), as determined from a control cover-slipped 
slide on which a small drop of 100 X diluted fluorophore was placed, and 2) the 
autofluorecence wavelength emission-spectra determined for spinal cord and DRG tissue 
not exposed to primary antibody. Two sets of control slides with tissue sections, one with 
only PBS without primary but with secondary antibody treatment, and the other, with 
primary but without secondary antibody treatment, were then used to objectively 
eliminate autofluorescence and very low-intensity fluorescence. Using these control 
slides, the Nuance software allows the user to set an acceptable threshold of very low-
level emission fluorescent intensity (as opposed to the software’s “autothreshold” option) 
within and outside the Rhodamine Red emission peak wavelength range between tissue 
samples. Stained tissue sections with Rhodamine Red are then examined under the 
microscope eyepiece and the very low-level emission intensity is then re-adjusted by the 
user to reflect the actual images observed through the eyepiece. Thus, the experimenter 
determines low-level emission intensity by closely replicating the composite computer 
image with that observed through the microscope eyepiece. The resultant image contains 
Rhodamine Red, but without artifactual very low-level emission intensity and without 
autofluorescent wavelength peaks near to the Rhodamine Red wavelength peak, while 
retaining all the cellular and anatomical features of the actual tissue specimen. Emission 
values that fall below this acceptable threshold of low-level emission or outside the 
Rhodamine Red wavelength peak were eliminated from our immunofluorescent 
quantification.  
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The amount of fluorescent wavelength signal was calculated by the computer 
software for each area of contiguous pixels defined as a region of interest (ROI). A 
minimum threshold intensity was set that excluded autofluorescent and artifactual low-
level background. The Rhodamine Red fluorescent signal intensity for each ROI that falls 
above this threshold was quantified and given a numerical value. These signal “counts” 
were then averaged and divided by the exposure time for each image collected per ROI 
An image was captured for each of 4 slices (n=4 slices per rat and 3 rats per group=12 
total slices analyzed per experimental group) for the spinal cord and separately for the 
DRG tissue region (ipsilateral or contralateral). The positive Rhodamine Red data from 
all 12 slices per experimental group was then averaged to represent a group average and 
reported as “signal counts/sec/mm2”. More detailed information regarding the Nuance 
spectral system can be found at URL: http://www.cri-inc.com/products/nuancew.asp. 
Cell Culture 
Mouse macrophage (RAW 264.7) cells were obtained from American Type 
Culture Collection (cat# TIB-71; ATCC Manassas, VA, USA) and cultured as adherent 
cells in Dulbecco’s Modified Eagle’s Medium (cat#D6429; Sigma-Aldrich, St Louis, 
MO, USA) supplemented with 10% heat-inactivated fetal bovine serum (cat# 10082-147; 
Gibco-Life Technologies, Grand Island, NY, USA) and 100 U/ml penicillin and 100 
µg/ml streptomycin (cat# 15140122; Gibco-Life Technologies, Grand Island, NY, USA), 
and maintained at 37°C under humidified 5% CO2 atmosphere. Cells were grown to 85% 
confluence, collected by scraping, and sub-cultured for 3 passages. For experiments, dead 
cells were counted by hemocytometer and trypan blue exclusion.  
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Nitric Oxide Assay 
RAW 264.7 cells were seeded at a density of 3.0 x 105 cells/ml in 24 well plates 
24 hours prior to experimentation and maintained at 37°C under humidified 5% CO2 
atmosphere. At confluence to 85%, the supernatant was removed and replaced with 
DMEM containing 10 mM mannose or fresh DMEM that was allowed to incubate for 1 
hour. After 1 hour incubation with mannose, media from the wells was removed and 
replaced with fresh DMEM containing either 10 mM D-Mannose, 10 ng/ml 
lipopolysaccharide (LPS) from Escherichia coli (LPS; cat# L6529; Sigma-Aldrich, St 
Louis, MO, USA), 10 mM D-mannose and 10 ng LPS, or DMEM alone. The different 
treatments were allowed to incubate with the cells for 10 minutes, followed by removal 
of supernatant and a 2X wash with 1X Phosphate Buffered Saline (PBS, pH 7.4, cat# 
10010; Gibco-Life Technologies, Grand Island, NY, USA). Supernatant was removed 
from each well and nitric oxide production was measured using commercially available 
Griess Reagent System (cat# G2930; Promega Corp., Madison, WI, USA). Briefly, 50 µl 
of supernatant from each well was removed and mixed with 50 µl of sulfanilamide 
solution and 50 µl of N-1-napthylethylenediamine dihydrochloride. The reaction was 
allowed to incubate protected by light and the absorbance was measured at 550 nm using 
a Tecan Infinite® plate reader (Tecan Systems, Inc., San Jose, CA). Limit of detection for 
the NO assay=1.56 µM. All experiments were run in triplicate.  
Quantification of IL-1β, IL-10, TNFα protein levels 
RAW 264.7 cells were treated exactly as outlined above with the exception that 
100 mM D-Mannose is used and cells were allowed to incubate for 2 hours with LPS. In 
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a second experiment, the same number of cells were incubated with 500 mM D-mannose 
for 5 hours. The media from the wells was then removed and replaced with fresh DMEM 
containing either 500 mM D-mannose with or without pDNA-IL10 (0.5 or 5 µg), pDNA-
IL10 (0.5 or 5 µg) without D-mannose, or DMEM only. After washing, the supernatant 
was removed from each well and assayed by mouse ELISA according to the 
manufacturer’s instructions. (IL-1β, cat# SML800C; IL-4, cat# M4000B; IL-10, cat# 
M100; TNFα, cat# MTA00B, R & D Systems, Inc., Minneapolis, MN, USA) Limit of 
detection for the IL-10 protein assay=15.6 pg/ml; positive IL-10 kit control value= 
117.68 pg/ml; limit of detection for the IL-1β assay= 12.5 pg/ml; positive IL1-β kit 
control value=553.75 pg/ml; limit of detection for the TNFα=10.9 pg/ml; positive kit 
control value=110.17 pg/ml. All experiments were run in triplicate. 
Data analysis 
 Psychometric behavioral analysis for hindpaw threshold responses was 
performed as previously described103 to compute the log stiffness that would have 
resulted in the 50% paw withdrawal rate. Briefly, thresholds were estimated by fitting a 
Gaussian integral psychometric function to the observed withdrawal rates for each of the 
tested von Frey hairs, using a maximum-likelihood fitting method.113, 193 Estimated 
thresholds derived from a Gaussian integral function yield a mathematical continuum and 
thus, are appropriate for parametric statistical analyses.103, 113, 193 The computer program 
PsychoFit may be downloaded from L.O. Harvey’s website 
(http://psych.colorado.edu/~lharvey). Repeated measures two-way analysis of variance 
(ANOVA) procedures were applied to determine statistical significance between 
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experimental treatment groups, with significance determined at p< 0.05. All other data 
analyses were performed using one-way ANOVA on the computer program GraphPad 
Prism version 4.03 (GraphPad Software Inc., San Diego, CA). All data are expressed as 
mean +/- SEM. For post-hoc analysis, the Bonferroni’s test was performed. Given 
unusually high variance was observed in immunofluorescent-quantified tissue only from 
the saline-pDNA-IL-10 group, a Grubb’s Z-test172 was applied to identify a potential 
outlier from the group. 
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4. Discussion 
4.1 Gene delivery to the CNS 
4.1.1  Clinical uses 
Over the past three decades, the development of gene based therapeutics has been 
rapidly growing. While advances for the treatment of genetic-based disorders such 
hemophilia, cystic fibrosis have been made,195 development of gene therapeutics for 
neurological diseases, such as Alzheimer’s, Parkinson’s, Huntington’s disease and 
chronic neuropathic pain is an important and exciting contribution to the field of 
neuroscience. Delivering genes to the CNS poses a particular problem in that the blood 
brain barrier must be crossed. Transport of genes to neurons presents some especially 
difficult challenges. The specialized electrical nature of the neuronal membrane, with the 
fluxing of membrane charge associated with the firing of action potentials, can make 
negatively charged DNA uptake problematic due to repulsive forces. In addition, the 
elongated morphology of the neuron can necessitate the transport of the therapeutic gene 
across long distances.88, 196  
In general, the expression of the therapeutic gene is intended to either improve 
or reduce a specific cellular response. In genetic diseases, the intention is for the gene 
to replace the defective one. In other cases, such as in IL-10 gene therapy for 
neuropathic pain, the intention is to increase gene expression above endogenous levels. 
Conversely, protein levels can be reduced, for example by blocking transcription with 
small anti-sense RNA (siRNA).88, 197 The gene of choice can be delivered in simple 
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“naked form” or loaded onto viral or synthetic vectors, such as the protocells evaluated 
in Chapter 2 of this dissertation. Each of these delivery platforms has its own 
advantages and disadvantages which will be addressed below. 
Brief mention should be made of some of the methods used for gene therapy 
delivery in human clinical trials and animal models. Most common is standard injection 
of gene into the muscle, the abdomen or the vein. Another approach uses a gene gun and 
pressurized gas or liquid to increase permeability of cell membranes by poration. 
Ultrasound or electric current (electroporation) are also used for this purpose. As noted 
above, delivery to the CNS is difficult as the gene must pass the BBB, so gene and/or 
vector is usually placed into the brain by direct injection. One group injected 
fluorescently tagged silica particles directly into lateral ventricles.136 Ours is the first 
evaluation of intrathecally injected of silica based particles.  
4.2  Approaches 
4.2.1 Viral vectors 
Virus-based gene delivery is most often accomplished by using replication-deficient 
viruses containing the gene of interest, but with the disease-causing sequences deleted 
from the viral genome. Both RNA and DNA viruses have been utilized for this 
purpose.198 Viruses are essentially composed of a protein coat or capsid that encases 
either DNA or RNA and are specialized to inject this nucleic acid contents into a cell and 
use the “host” cell transcription machinery to reproduce.199 Consequently, viral vectors 
have high transfection efficiencies, as they are naturally evolved and highly specialized 
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for transfer of DNA across the host cell membrane.198 Most often a virus enters a cell 
through receptor mediated endocytosis following binding of a protein on the capsid to a 
cell surface receptor.199 
 One of the most frequently used viral vector is engineered from the adeno-associated 
virus (AVV).8 This vector was used in our early studies to deliver the IL-10 gene.99 AAV 
vectors retain only about 300 bp of the original viral genome, so there is very little risk of 
recombination events with wild-type virus that might lead to infection. In fact, no viral 
products are actually expressed in the cell, reducing the risk of pathogenicity and 
immunogenicity. Other attributes are heat stability and resistance to solvents, changes in 
pH and temperature.200, 201 Particularly important, AAV vectors are able to transfect not 
only dividing cells, but non-dividing cells which reduces the problem of “gene dilution” 
or loss of the therapeutic transgene in future generations of dividing cells.201 There are 12 
different serotypes of human AAV, each characterized by specific cell surface antigens, 
allowing a particular AAV vector to be designed for tissue specific delivery.200, 201 An 
advantage for the treatment of CNS disease, one AAV serotype, AAV9, is able to cross 
the BBB.202  
Lentiviral vectors (LVs), derived from human immunodeficiency virus-1 (HIV-1), 
have been used for gene transfer as they can transfect both non-dividing cells and 
dividing cells.202 Important to gene therapy for chronic pain and neurodegenerative 
disease, is their ability to transduce most cell types including the cells of the CNS; 
neurons, astrocytes, adult neuronal stem cells, oligodendocytes and glial cells. Of special 
interest, some LVs can undergo retrograde transport from the neuronal axon to cell body, 
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which is critical for potential gene therapy in motor neurons. LVs are not, however, able 
to cross the blood brain barrier, limiting the practicality of their use for gene delivery in 
the CNS. An advantage of LV vectors over AVV, is that they are able to accommodate 
larger transgenes. It is critically important that they be replication deficient to reduce the 
risk of HIV infection. One of the risks of using LV, because it is a single stranded RNA, 
is that reverse transcriptase, the transcription enzyme that converts RNA to DNA is error-
prone and may result in mutations that might possibly cause disease.202 
One of the major drawbacks of all viral vectos is their small size, which limits the 
size of the therapeutic gene insertion. Gene expression is sometimes slow in onset, for 
example when single stranded DNA must be converted to double stranded DNA, before 
the transgene is transcribed.200 Finally, it has been shown that viral vectors can 
preferentially integrate into transcriptionally active areas possibly leading to insertion of 
the therapeutic gene into the genome, “insertional mutagenesis”.201 Incorrect insertion 
might activate or inactivate the “wrong” gene, and can lead to tumorogenesis or 
leukemia.200 In addition, mutagenesis might alter the transgene product encoded by the 
vector, and eliminate or pollute the expressed protein by changing its function. 
One of the key problems in using viral vectors to carry a transgene, such as the gene 
for IL-10, are immune responses to the vector itself or the virally transduced cells. 
Clearly, immunogenicity and oncogenicity are the major risks of using of viral vectors for 
therapeutic gene delivery. In fact in human clinical trials, a gene delivered by an  
adenoviral vector to treat a rare disorder, ornithine transcarbamylase deficieny, caused a 
fatal acute inflammatory reaction in the lung. In another study a gene for treating 
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immunodeficiency disease was delivered by a LV vector and five subjects developed a 
leukemia-like blood disorder attributed to insertional mutagenesis and resulted in another 
fatality.203 These cases heightened public concern and awareness about the potential 
dangers of viral vectors and hastened the development of non-viral, synthetic materials to 
delivery therapeutic genes. Never the less, as of May 2011, 1703 gene therapy clinical 
trials were being conducted across the world, the majority delivered by viral vectors.204 
4.2.2 Non-viral vectors 
Non-viral vectors are either naked DNA or synthetic vectors, composed of materials 
that bind to negatively charged (anionic) DNA or RNA through electrostatic interaction. 
Consequently, positively charged (cationic) materials are used more frequently than 
those with negative or neutral charge. Through these interactions, the genetic material is 
condensed to nano-sized complexes that are able to cross cellular and nuclear 
membranes more efficiently than the naked nucleic acid. The materials used for 
synthetic gene delivery platforms are many, but for the purposes of this discussion 
attention will be focused on cationic lipids, cationic polymers and mesoporous silica 
nanoparticles. 
4.2.2.1  Naked DNA 
The obvious advantage to using naked plasmid DNA are that it can be engineered 
to contain genes of quite a large size such as the IL-10 gene which is ~557 bp and it is 
easily and relatively inexpensively amplified to quantities needed for in vivo use by 
commercially available kits. It is also easily stored short term at -20°C and longer periods 
at -80C°.205, 206 
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One of the key problems in using naked DNA is transport across cell 
membranes.83, 88 Being a hydrophilic negatively charged molecule, it is easily repelled by 
cell membranes, which contain many negatively charged proteins. As already discussed 
in the introduction of this manuscript, DNA must escape endosomal or phagocytic 
transport vesicles intracellularly and reach the nucleus to be transcribed. In addition, it 
can be easily degraded by nuclease enzymes, and/or the acidic environment of lysosomes. 
If DNA is administered directly into the blood stream or intra-muscularly, it can be 
degraded by serum enzymes.14 As with virally delivered transgene, naked plasmid DNA 
can be diluted in subsequent generations of cells. 82 For these reasons, gene delivery by 
injecting naked plasmid intravenously or under the skin has been unsuccessful.207 
Intrathecal delivery, the method used to deliver the IL-10 transgene, offers an 
improvement in that the gene is placed directly near the dorsal spinal cord site of pain 
modulation, thus is poised to alter cytokine profiles of nearby glial and meningeal cells 
known to contribute to neuropathic pain onset. 
One potential problem of naked DNA frequently cited in the literature, is that it 
can trigger adverse innate immune responses, as often it contains CpG base sequences 
that are recognized by toll-like and scavenger receptors on immune cell surfaces.82, 195 
These sequences might be actually working to our advantage in our double injection 
paradigm. The immune responses evoked by the 1st injections are thought to prime 
leukocytes, making them more capable of IL-10 transgene uptake that alters the actions 
of nearby spinal glia and meningeal immune cells.72 
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4.2.2.2  Cationic liposomes  
Cationic liposome-mediated gene transfer, a process known as lipofection, is one 
of the most common method of non-viral delivery.82, 208 LipofectamineTM 2000, marketed 
by Life Technologies, Grand Island, New York, is one commonly used cationic lipid 
transfection agent. The lipids used for lipofection, share a similar structure of positively 
charged, water attracting (hydrophilic) head group, connected by a linker to a water 
repelling (hydrophobic) tail. This linkage, between the head and tail groups, is important 
for biodegradability. The head groups are frequently composed of amine (NH) groups 
containing 1, 2, 3 or 4 hydrogens (H+), known as primary (1o), secondary (2o), tertiary 
(3o) or quaternary amines (4o) respectively.18 Thus, the head group binds with the 
negatively charged phosphate groups in nucleic acids. Also, often included in the head 
groups are cholesterol or steroid rings, the purpose of which will be explained later. The 
hydrophobic tails are usually straight or branched carbon chains.82, 208 
Advantages and disadvantages have been noted with the use of lipoplexes. In their 
favor, lipoplexes are easy and cheap to produce, and are non-toxic, supporting their use in 
cell culture for short-duration gene expression. They can also be engineered for tissue 
specific delivery208 and have been used for intrathecal gene delivery to the CNS.260 
However their use for in vivo gene delivery has been limited as they are prone to generate 
acute cellular toxicity and inflammatory responses at higher doses and durations of 
exposure.82, 195 
The transfection efficiency of cationic lipids can vary dramatically depending on 
their composition. The nature of the linker and number of charged groups, the overall 
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shape and charge of the lipid can alter interaction with DNA and cellular membranes. For 
example, positively charged head groups improve the interaction of the lipoplex with 
negatively charged cell membranes.82 The greater the positive charge the more intimate 
the contact with the membrane, and the logical result is that the lipoplex will have a 
greater chance of entry into the cell.208 Conversely, if the charge becomes overly positive, 
the amount of compaction or condensation of DNA increases, reducing the probability of 
release and eventual transcription in the nucleus.195  
  One frequent complication in using lipoplexes for gene delivery is that they can 
aggregate forming a larger complex.82, 195 When mixed with DNA, lipids immediately 
form compacted micellar structures due to the hydrodynamics of the lipids. The 
hydrophyllic heads are exposed to the surrounding extra or intra cellular fluid, while the 
hydrophobic tails are directed toward the interior of the micelle. While protecting DNA 
from degradative enzymes, the exposed positive charges of the exterior head groups can 
interact with negatively charged platelets, erythrocytes and serum proteins in the blood 
causing aggregation and the formation of small clots.15 Moreover, a larged sized 
aggregate reduces interactions with the cell membrane and lowers transfection efficiency. 
Surface charge can be shielded by the inclusion of polyethylene glycol or (PEG), a 
hydrophilic, neutrally charged polymer, which can prolong the circulation half-life of 
lipoplexes, while at the same time reducing the charge interaction between the lipoplex 
and cell membrane, reducing transfection efficiency.82, 195 
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4.2.2.3  Cationic polymers  
When DNA is mixed with cationic polymers, the net result is the formation of 
condensed nano-sized polyplexes, a complex of DNA and polymer, similar to lipoplexes. 
According to Kundu and Shamara,197 ideal polymers should be non-toxic, non-
immunogenic and biodegradable and package large amounts of DNA. Some of the many 
other polymers that are being used for gene transfer are polyethylenimine (PEI), 
Polyamidoamine (PAMAM), acrylate, poly(amino-ester) based polymer vectors, and the 
FDA approved, biodegradable formulation, poly-lactic co-glycolic (PLGA) used in our 
laboratory.197 Biodegradability ensures that there is no cellular accumulation over time.  
As with lipids, the interaction of the polymer with DNA and the formation of a 
polymer-DNA complex, is dependent on factors “intrinsic” to the polymer itself such as 
the number of its charge groups, the structure of charge groups (1o, 2 o, 3 o, 4o), and their 
spacing within the polymer, polymeric branching and hydrophobicity.82 Also important to 
DNA loading are “extrinsic” factors, such the ionic strength of the solution in which the 
polyplex is formed, the charge ratios of DNA/polymer and the kinetics and 
thermodynamics involved with polyplex formation.82 Polyethylenime (PEI) serves as a 
good example of how intrinsic and extrinsic factors effect gene delivery. Intrinsically, the 
structure of branched PEI has been shown to be more toxic resulting in lower DNA 
transfection efficiency than linear PEI.82 The extrinsic environment surrounding the 
polymer-DNA complex is hypothesized to play a role in increasing transfection by 
improving endosomal escape. PEI contains many amine groups that are mostly 
unprotonated at physiological pH. In the acidic environment of the endosome, there are 
many protons (H+) that are readily absorbed by the amine groups on PEI. One hypothesis 
 125 
is that this condition lowering the acidity in the endosome, leading to an influx of 
negative ions, resulting in a build up of H20 and osmolytic pressure that ruptures the 
endosomal membrane allowing the polyplex/DNA complex to escape and travels to the 
nucleus. This process has been termed the proton sponge effect.84, 209  
 Several benefits of synthetic vectors are that they can be designed to release cargo 
in a time or pH dependent manner and their surface is easily modified.195, 197 By attaching 
cell targeting molecules such as cell receptor-specific ligands, antibodies or small 
stimulatory molecules, they can be designed to directly target one cell type and avoid 
damage to others.91, 210, 211 
Toxicity to cells is the major limitation to the use of polymeric gene delivery 
platforms. In vivo, their longevity and biodistribution remain relatively unexplored.195 
Like liposomes, some polyplexes can tend to aggregate forming larger complexes in the 
blood and have been found in lung and liver following intravenous administration. But, 
because of easy modification, inclusion of an anionic or neutrally charged polymer, such 
as water soluble PEG or cholesterol, can reduce aggregation and increase circulation 
times.195 Like lipoplexes, polyplexes can be immunogenic, either from the polymer itself 
or the DNA, although one group has shown less proinflammatory cytokine induction by 
the use of polyplexes over lipoplexes.212 Despite toxicity problems, their potential as 
therapeutic delivery agents remains high due to their flexibility of design, easy 
modification with targeting molecules, potential to cross the blood brain barrier.  
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4.2.2.4  Mesoporous silica nanoparticles 
MSNs, such as those used to form the core of protocells, have many properties that 
make them desirable for drug and DNA delivery. Slowing et al. summarizes these factors 
eloquently.96 First, their diameter and pore size are adjustable from 50-300 nm and 2-6 
nm respectively. They have a rigid structure that is resistant to degradation by heat, pH, 
mechanical stress and hydrolysis. Their high pore volume (> 0.9 cm3) and surface area (> 
900 m2/g) allows efficient loading of drug on two functional surfaces, the internal surface 
of the pore and the external surface. Finally, because of the regular nature of the pores, 
they are easily sealed to prevent premature “leaking” of cargo.96, 123, 129, 213 More 
advanced modifications for loading small molecules or drugs into MSNs involve “gating” 
strategies to seal cargo in the pores, such as the use of quantum dots or small 
nanoparticles to cap the pore.96 In addition, they are easily customized for specific 
targeting. MSNs can be engineered for controlled release of cargo with changes in 
temperature, pH, enzymatic cleavage or exposure to light.95, 96 
As with most nanomaterials, modulation of particle size, shape, and surface charge 
can greatly influence cellular uptake, cellular and bodily responses, and biodistribution.96, 
123, 129, 213 Because their ultra small size, nanoparticles do not physically behave as larger 
particles and the physics of their actions with each other and other molecules may be 
unpredictable in different tissues, cells, blood and bodily fluids. Thus it is important that 
their biotoxicity be evaluated with each modification.214 Studies such as those in Chapter 
2, which evaluate cell stress as a function of surface charge, are important contributions 
to our current understanding of these materials.  
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4.2.2.5  Protocells 
The protocell, essentially a MSN with a lipid bilayer on its surface, offers 
additional advantages. According to Liu et al.,101 the lipid bilayer on the MSN core of a 
protocell actually provides a “synergistic system” for simultaneously loading and sealing 
cargo. For example, while a negatively charged fluorescent dye was unable to load a 
negatively charged mesoporous core, the dye was easily loaded when a positively 
charged lipid was used as a bilayer. In fact, the lipid-sealed protocell was able to load a 
concentration of dye that was 100X that of the surrounding solution.101 The lipid layer is 
easily conjugated to PEG to improve circulation time and both are easily conjugated to 
specific cell targeting molecules such as receptor ligands or antibodies.95 In vitro, 
protocells have been shown to successfully deliver hydrophobic cancer therapeutics94 and 
plasmid DNA.215  
The synthesis of MSN used for the silica core of the protocell involves the 
hydolysis of a silica precursor such as tetraethylortosilicate (TEOS) dissolved in ethanol 
and water to form a homogenous solution or “gel-sol”. Hydrochloric acid is used as a 
catalyst to begin the growth and nucleation process, while a surfactant, 
cetyltrimethylammonium bromide (CTAB), an alkyl ammonium salt, serves as a liquid 
crystalline template for the mesoporous structure. If the reactions are kept at 
concentrations above the critical concentration for micelle formation, regular crystalline 
mesoporous nanostructures are formed.95 It has been proposed that the silica material 
forms “inorganic walls” between ordered surfactant micelles forming pores in a process 
of self assembly.216 Further engineering lead to the development of an Evaporation 
Induced Self Assembly (EISA) method. This method uses a dip-coating process to form a 
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thin film of silica/surfactant micelles that organize into liquid-crystalline mesophases as 
the concentration of soluble silica increases, with the evaporation of solvent. Brinker and 
colleagues,217 improved upon this procedure by forcing the silica/surfactant solution 
through an atomizer to form aerosol droplets. The droplets direct the process of self 
assembly to form spherical MSNs.217 In the last phase of synthesis, the particles are dried 
in a furnace by evaporation or calcination to drive off excess solvent. There are two other 
approaches for forming MSNs, a growth-quench approach, which uses a dilution and pH 
change to “quench” or slow the silica condensation reaction and another that separates 
the nucleation and growth stages into two processes.213 Important for drug or DNA 
delivery, regardless of which synthesis process is used, the fine tuning of the reaction 
temperature and relative amounts of reactants can control the orientation and diameter of 
pores and particle size.  
Another key advantage of the MSN is that silanol groups inside the pores and on 
the outside surface can be altered by changing the electrostatic, hydrostatic and colloidal 
properties improving their biocompatibility.95, 213 These functional groups can then be 
used to covalently attach other molecules for cell specific targeting or adsorb other 
coatings, to change the charge and hydrophobicity of the MSN. The positively charged 
polymer, polyethylene glycol (PEG), is one such coating, used to reduce aggregation with 
serum proteins and increase circulation times. On the protocell, the surface coating is the 
lipid bilayer. By using lipids with different charge, fluidity and melting/transition 
temperatures, the interaction of the protocell with biological membranes can be 
controlled. Such was the case in the transfection studies in Chapter 2, in which pDNA-IL-
10-GFP delivered via DOTAP:Cholesterol covered protocells to HEK cells, caused 
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significantly more IL-10 expression than when delivered on DOPC protocells. Co-lipids 
or “helper” lipids such as cholesterol or dioleoylphosphatidylethanolamine (DOPE) are 
added to the bilayer to help increase the fluidity and favor “mixing” or fusion of the 
protocell with cell membranes and facilitate transfection efficiency by improving the 
transfer of nucleic material to the cell interior. 
Intracellular endosomal vesicles are composed of a single, mostly anionic 
membrane on the surface exposed to the cytoplasm. Once inside the endosome, 
cholesterol is thought to alter membrane electrical potentials by absorbing charge via its 
cyclic ring structure and displace anionically charged lipids from the outside membrane 
to the inside, promoting transfer and escape of lipid coated particle/DNA complex from 
the inside to the outside, by a “flip-flop” mechanism.85, 218 Therefore, inclusion of 
cholesterol with positively charged DOTAP in the protocell bilayer, might improve 
transfection efficiency by enhancing DNA escape from the endosome so that more was 
available for transcription in the nucleus. 
In total, 3 different protocell cargos were used in the experiments in Chapter 1. The 
first was a FAM-tagged 18 bp single stranded DNA (ssDNA). FAM is a green fluorophore 
used as a reporter in these studies. FAM or 6-carboxyfluoroscein is a molecule composed of 
a number of benzene rings and other carbon ring structures (Figure A.13 A). It has a MW of 
537.5. While the 3-dimensional structure of a molecule can vary depending upon pH and 
salinity and other physical characteristics of the solution surrounding it, a rough estimate of 
its size can be determined by its bond lengths.258 Using this method the dimensions of FAM 
were determined to be ~.139 nm in width and ~0.722 nm in height. The length of the 18 bp 
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DNA at .34 nm/bp253 is ~6.12 and diameter of the ssDNA is ~2 nm253. It nucleotide 
composition is 5’-CTTGAGAAAGGGCTGCCA-3’ and as no self-complimentarity254 so it 
will not form the hair-pin loops common to other single stranded sequences. For these 
reasons it is most likely that the FAM DNA would load inside the pores in the silica core. 
The second cargo was a red fluorophore Dextran tetramethyl rhodamine (DexRHO) 
with a MW of 10,000 (Figure A.13 B). It is a hydrophillic polysaccharide composed of α-D-
1, 6 glucose molecules to which a tetramethylrhodamine fluorophore is linked. The molecule 
has an overall negative charge. It has been determined that 1-2 tetramethylrhodamine groups 
are conjugated to each 10,000 MW of Dextran polymer.252 Calculations of the planar bond 
length of the DexRHO component without the dextran polymer show the width to be ~.983 
nm and the height ~.576 nm. Considering the very large size of the entire DexRHO polymer, 
the molecule would most likely load by adsorption to the surface of the positively charged 
protocell core. In fact because of these physical characteristics, DexRHO was chosen as a 
surrogate molecule for the large 5.9 kb plasmid DNA molecule the final protocell cargo used 
in these studies (Figure A. 13 C).  
Plasmid IL-10 has previously been shown assume a supercoiled state.79 If linearized, 
the length at .34 nm/basepair would be 20060 nm253 and double stranded DNA has a 
diameter of ~2 nm.253 However in actuality, the circular plasmid DNA is supercoiled with 
elastic qualities in “standard aqueous conditions of 0.14M univalent salt”.255 Supercoiled 
DNA assumes many different structures based the linking number or the number of times the 
two sides of circular plasmid cross. The linking number is a function of the twisting number, 
or the total number of turns of the duplex, and the writhing number, the total number of turns 
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of the duplex.256 For size comparison, one bacterial 4361 bp plasmid, pBR322, ~1539 bp 
smaller than pDNA-IL-10, was examined by atomic force microscopy and was ~225 nm 
across.257 Determining the actual dimensions of the supercoil is beyond the scope of this 
dissertation and was not a goal of the studies Chapter 1, but it can be speculated that like 
DexRHO, supercoiled DNA would be too large to load into the pores of the silica core but 
would load by charge interaction with a positively charged silica core and a positively lipid  
such as DOTAP:CHOL 1:1 covering the surface. 
Future studies will most certainly incorporate the newest generation of protocells that 
have larger multi-modal pore sizes and a capacity for pDNA loading94 and show promising 
potential as gene delivery vectors for spinal gene therapy. Another aim will be to reduce the 
size of the pDNA-IL10 to better utilize these second generation protocells.  
4.3 Mesoporous silica-supported lipid bilayers (protocells) for DNA cargo delivery 
to the spinal cord ( re-submitted to the Journal of Controlled Release) 
4.3.1 Investigation of toxicity and biocompatibility of protocells 
Given protocells are novel nanocarriers, their biocompatibility and potential for 
cell toxicity were initially examined. The testing for biocompatibility of MSNs has been 
complicated. Different combinations of materials and differences in synthesis result in 
various MSN characteristics (shapes, pore sizes, chemical composition, surface 
chemistry). Therefore the assessment of toxicity and cellular uptake and responses in 
living systems is not easily generalized to all MSNs.95, 214, 219 As pointed out by Tarn et 
al.,95 most of the toxicity studies in the past century have been related to concerns about 
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silicosis resulting to exposure to both crystalline and amorphous silicon dioxide. The 
authors emphasize that, “ not all silica is created equal”, but can exist in a wide variety of 
forms depending on synthesis and environmental exposure.95 They explain that toxicity is 
mostly related to surface silanol (SiOH) groups that can hydrogen bond to membrane 
components or when dissociated, form SiO,- that can interact with positively charged 
lipid head groups, and may lead to lysis of cell membranes such as red blood cells.95 
Silicate radicals can similarly react with H2O to produce reactive oxygen species (ROS) 
known to damage proteins and upregulate cytokines and inflammatory molecules leading 
to cell death or carcinogenesis.95 In support of the use of silica, these reactive silica 
groups can be modified to reduce or eliminate this problem. In addition, the small 
diameter of the MSN reduces the surface area and exposed hydroxyl groups available to 
react.  
Depending on mode of synthesis, particle or pore diameter and in vivo delivery 
route, toxicity can vary.93 Different cell types also can be more susceptible than others. 
Hudson et al.93 evaluated biocompatibility of two different cell lines, myoblasts and 
macrophages to mesoporous silicates with diameters of ~150 nm, ~800 nm and ~4 µm 
and pore sizes of 3 nm, 7 nm and 16 nm respectively. The particles were synthesized in 
three different processes. All three particles showed increasing toxicity correlating with 
increasing their concentration in mesothelial and myoblast cells but not in macrophages, 
cells important to studies described in this thesis. Interestingly, differing methods of 
MSN delivery had differing toxicity. Mice were injected subcutaneously with 1 ml of 30 
mg/ml, which was well tolerated. Histological examination showed no sign of MSN 
material at 2 or 3 months. Surprisingly, in contrast, mice that received an intra-peritoneal 
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injection of the same dose either died or became distressed after 24 hours and were 
euthanized. Those that received intra-peritoneal doses of 10 mg or 5 mg became ill 30-40 
hours later. However, intraperitoneal injection of a lower dose, 1 mg/ml was not fatal to 
mice. Intravenous injection of 6 mg/ml resulted in rapid death.93 These studies point out 
that careful consideration must be made of not only the dose but the method of delivery 
are extremely important to an assessment of toxicity of nanomaterials in vivo. 
A biocompatibility study by Witsap et al.,220 assessing anionic MSNs in 
macrophages prepared from adult human blood donors, parallels some of the results and 
issues in our studies with protocells that we found to co-localize with spinal 
macrophages. In the Witsap experiments, three different MSNs prepared by calcination 
only, solvent extraction only, or calcinated and covalently loaded with the green 
fluorophore, fluorescein isocyanate (FITC), were evaluated in primary macrophage 
cultures. Viability of macrophage was measured by trypan blue assay and cells remained 
viable at 10 and 100 ug/ml doses after a 6 or 24 hour exposure, similar to the results of 
our experiments with DOTAP and DOPC protocells in mouse macrophage cells (Raw 
274.7) and HEK cells. Interestingly, Witsap et. al reported that the autofluorescent 
properties of MSNs confounded their attempt to use the colorometric 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT) assay for measuring 
mitochondrial metabolic activity. Protocell green autofluorescence similarly confounded 
our initial assays of live cells using the green fluorophore, Calcein-AM, followed by 
analysis using flow cytometry. We found the problem was solved instead by assessing 
dead cells using the red fluorophore, Ethidium homodimer-1. Protocell autofluorescence 
also confounded our examination of protocells in spinal cord slices by standard 
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microscopy, yet was remedied by a switch to the use of spectral analysis to determine 
biodistribution.  
In the Hudson report,93 uptake of MSNs was drastically reduced by an actin-
inhibitor, Cytochalasin-D and a cocktail of endocytosis inhibitors, suggesting that the 
particles were being taken up by macrophages by the actin dependent process of 
endocytosis. The macrophage function was unaffected following internalization of 
MSNS, as the cells readily engulfed apoptosed neutrophils, Jurkat cells and Ig-opsonized 
sheep red blood cells as they would normally. Important to our studies, MSN containing 
macrophages stimulated with LPS produced their usual levels of IL-10, TNF-α and IL1-β 
cytokines.220 These studies support our findings that macrophages appear viable and 
healthy both in vivo in the CNS and in vitro in macrophage cell cultures following 
exposure to mesoporous silicates such as the protocell. The fact that autofluorescence 
confounded their microscopic examination of cells and colorometric viability assays 
supports our similar observations. 
While our studies have shown that 1 mg in 20 µL of both positively charged 
DOTAP:Chol 1:1 and DOPC protocells had no adverse effects when delivered to the 
CNS intrathecally, the issues of early cell stress or even programmed cell death remained 
a concern. The realm of nano-MSNs and their tolerance in living systems remains a 
largely uncharted territory, due to the many variations in synthesis, composition, size 
shape and immunogenicity. Toxicity could be a benefit in some cases, such as in the 
elimination of cancer cells. Conversely, nano-MSNs would be a risk if healthy cells are 
destroyed in the process.  
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4.3.2 Transfection capacity and efficiency of protocells 
Our results show that protocells can be effectively used to deliver pDNA, thus 
their use in this regard will be addressed in more detail below. For an excellent study 
describing their use to deliver anti-cancer therapeutics please refer to the Ashley paper.94 
Due to the deprotonation of surface silanol groups on the protocell core, silica is 
intrinsically negatively charged.95 To avoid repulsion of negatively charged DNA, it can 
be altered to become positively charged.95 This was accomplished by adsorbing 
(layering) the silica with positively charged DOTAP lipid. Lui et al. found that the size of 
the silica core as well as the lipid charge was important for DNA loading.215 Silica 
particles with an 8 nm diameter when mixed with DOTAP continued to have a negative 
charge (negative zeta potential) while larger particles (30, 50, 80, 130 nm diameter) 
assumed a positive charge (positive zeta potential). When a plasmid DNA coding for the 
DsRed fluorescent protein (4.8 kbp) was loaded onto these protocells it was found that 
pDNA loading was dependent not only on particle size, but also on the ratio of particle to 
DNA mass. For protocells of 30 and 80 nm diameter particle, mass of protocells needed 
to be 4X or 16X the DNA mass, while for larger particles of 130 nm diameter, 40X the 
DNA mass was needed.215 The particles in our studies had a diameter of ~150-200 nm 
(data not reported). The studies by Liu et al.215 also demonstrated that in vitro transfection 
efficiency of DOTAP: Chol 1:1 in CHO cells in studies was approximately 30 % of 
transfected cells and equivalent to that of LipofectamineTM 2000. A casual estimate of 
transfection efficiency in the HEK cells used in our studies was comparable. Supporting 
the use of protocells for DNA delivery, Liu’s group demonstrated DOTAP: Chol 1:1 
protocells completely protected the pDNA-IL-10 from degradation in an assay with the 
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DNA specific degradative enzyme, DNAse I, and successfully transfected cells even if 
previously exposed to the nuclease. In a final study, the Liu team used different 
fluorescent labels for the lipid, silica core (50 nm diameter) and DNA and demonstrated 
that all the components remained intact after 2 hours, suggesting that they all entered the 
cell simultaneously. By 12 hours, the DNA was observed in the nucleus while most of the 
silica remained peri-nuclear. Larger particles of 200 nm appeared to remain in the 
endosome. The confocal data in our studies revealed similar peri-nuclear localization of 
protocells around 30 nm in diameter. While the studies of Liu et.al215 demonstrate that 
protocells protect the DNA from degradation and are capable of cellular delivery of a 
fluorescent tagged plasmid, our HEK cell transfection studies (Chapter 2, Figure 2.6) 
are the first to demonstrate that a therapeutic gene such as IL-10, remains fully 
operational and generates functional protein following loading on protocells. 
4.4  Adjuvants to improve pDNA therapy 
4.4.1  Adjuvants defined 
Classically, adjuvant compounds are used with non-pathogen based vaccinations 
such as protein-based vaccines to induce a safer and longer lasting immune response. 
Typically, they are used to enhance the immunogenicity of an antigen-based vaccination 
or to improve efficacy of a vaccination in immunocompromised populations.221 Others 
serve as vehicles to present an immune stimulatory antigen, such as the commonly used 
Complete Freund’s Ajuvant (CFA), which presents antigen in a water-in-oil emulsion.222 
In our studies, adjuvants are being evaluated in an attempt to reduce the dose and number 
of pDNA-IL10 injections required to generate enduring pain relief in the CCI model of 
 137 
neuropathic pain. To be clinically successful, the candidate adjuvant must induce an 
innate response by stimulating antibody production or longer lasting adaptive cellular 
immune responses.221 
There are two basic categories of adjuvant.223 Conventional adjuvants can be 
synthetic, such as lipids, polymers or emulsions, or natural adjuvants, such as those that 
are pathogen-derived, using pathogen associated molecular patterns (PAMPs) from 
bacteria or plants. Interestingly, mannose conjugated glucoproteins are a common PAMP 
on bacterial pathogens. DNA based adjuvants are genetically engineered vectors that 
modulate expression of immune stimulatory molecules such as cytokines, B or T cell co-
stimulatory molecules, complement molecules, transcription factors or heat shock 
proteins.223 The route of inoculation of an adjuvant may be critical to the nature of the 
adaptive immune response. For example, early studies showed that intramuscular 
injections of adjuvant stimulate Th1 responses, while high pressure delivery by a 
pneumatic gene gun, elicited Th2 responses.223  
4.4.2  Adjuvants to prime innate immunity 
4.4.2.1 Stimulating cytokines and antibody immune responses 
Most commonly, adjuvants stimulate innate immunity.221 One such example are 
the CpGs DNA motifs that bind toll-like receptors (TLRs) with activation of patterned 
recognition receptors (PRRs) on antigen presenting cells (APCs), such as macrophage 
and dendritic cells. This binding leads to the presentation of antigen by the specialized 
protein complexes, MHC I and II to B and T cells, with activation of co-stimulatory 
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molecules and up-regulation of antibodies, cytokines and complement proteins. 
Complement proteins coat antigen for improved recognition by antibodies. 
4.4.2.2  Adjuvants to prime adaptive cellular immunity 
A second use for adjuvants is to prime the prolonged adaptive cellular responses 
of adaptive immunity. Presentation of adjuvant antigens by MHCII on APCs to CD4+ T 
cells is critical to the maturation and differentiation of CD4+ T cells. When so activated, 
CD4+ T cells differentiate into two distinct cell types with two different cytokine 
profiles, T helper type (Th1), that primarily release INF-γ and Th2 cells that produce anti-
inflammatory cytokines such as IL-4 and IL-13. A third T helper cell type, Th17, thought 
to regulate the cytokine profiles in the other two, is also differentiated.222 As a 
consequence adjuvants can be designed to polarize T cell populations with a Th1 or Th2 
bias. 222  
Cytokines released by Th2 polarized CD4+ T helper cell populations have the 
potential to influence macrophage polarization, priming a feed forward response in the 
direction of the M2 phenotype, including improved ability to phagocytose a therapeutic 
gene. Therefore, evaluation of intrathecally delivered adjuvant compound for T cell 
responses might be an important future direction for our studies, given T cells and 
MHCII expression have been identified in the DRG and DH of the spinal cord during 
neuropathic conditions. 
Another adaptive immune cell that can be stimulated with adjuvants is the 
dendritic cell.224 Like macrophages, they are continually surveying the extracellular 
environment for antigens resulting from pathogens or tissue damage. They have also been 
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dubbed, ‘Nature’s adjuvant’225 as they process and present antigens to T cells, and in 
doing so, regulate the Th1 or Th2 response to the antigen. For example, current therapies 
have been designed to target DC surface receptors with monoclonal antibody adjuvants to 
facilitate cytotoxic T cell responses against cancer cells or stimulation of specific 
antibody responses by B cells.224, 225 DC cells in mice can be divided into CD8+ DCs, 
that initiate Th1, proinflammatory cytotoxic functions, and CD8- cells. The latter are 
better at activating CD4+ T cells and their differentiation into Th2 and a T17 regulatory 
(T17reg) cells, that are programmed to facilitate an anti-inflammatory cytokine profile.224, 
225 By using antibody adjuvants specific to DC surface receptors, a T cell specific 
population with an anti-inflammatory profile can be generated, leading to M2 
polarization of nearby macrophage with improved gene uptake.224, 225 Excitingly, the 
mannose receptor is highly expressed on DCs188, 192 and its ligand, D-mannose the most 
successful candidate adjuvant used in our present study. Future studies using specific 
targeting of mannosylated protocells as an adjuvant to prime anti-inflammatory 
populations of DC and T cells may further enhance proliferation of M2 polarized 
macrophages and lead to enhanced IL-10 transgene uptake prolonging neuropathic pain 
reversal at lower doses and with only one injection. 
4.5  Improvement of spinal non-viral IL-10 gene delivery using D-mannose as a 
transgene adjuvant to control chronic neuropathic pain (re-submitted to 
Molecular Pain) 
4.5.1 Dexamethasone as an adjuvant 
Dexamethasone (DEX) is a synthetic glucorticosteroid (GC) that has been found 
to be important in the resolution of inflammatory diseases by accelerating the apoptosis 
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of leukocytes, such as the eosinophil cells associated with asthma and potentiation of 
their phagocytosis.226 Glucocorticoids such as Dex, act by binding the Glucocorticoid 
Receptor (GR). This receptor exists in its inactive form as a complex with the heat shock 
protein HSP90 and other chaperone proteins that bind to its cytoplasmic tail. With ligand 
binding, these proteins dissociate and expose a nuclear localization signal resulting in the 
translocation of the GC-GR complex to the nucleus.227 In the nucleus, two GR molecules 
form a dimer that binds to the promoter region of corticosteroid-responsive genes, the 
corticosteroid-response element (GRE). The genes upregulated are mostly anti-
inflammatory, and include IL-10 and the inhibitor of NFκ-B, Iκ B-α.75 In addition, the 
GC-GR acts indirectly on co-activator molecules which have histone acetylation activity 
leading to the activation of other anti-inflammatory genes, and at the same time recruits 
histone deacetylases that result in the deacetylation and down regulation of 
proinflammatory genes.75 In vitro, Dexamethasone has been shown to inhibit pro-
inflammatory IL-1β gene expression by blocking the transcription factor NFκ-B and AP-
1 activation.227 Another report showed that glucocorticoids could induce the 
differentiation of an anti-inflammatory subtype of macrophage.228 Because of its well-
known anti-inflammatory effects and potential to induce M2 polarization in spinal 
macrophage cells, DEX was a logical choice as a candidate adjuvant. 
Surprisingly, when used as an adjuvant to prime IL-10 transgene uptake, DEX 
caused only partial pain reversal in neuropathic animals, and the results were short lived. 
The literature regarding the pharmacokinetics of Dexamethasone, intrathecally injected 
into rats, is scant. One group assessed the stability, bioavailability and safety of 
chronically administered Dexamethasone sodium phosphate using indwelling lumbar 
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catheter in naïve Sprague-Dawley rats. Free dexamethasone, within 40 minutes and at 
low doses of 12.5 ng/hour, produced no side effects of neuropathy.229 However, there 
were signs of inflammation observed in the lumbar sub-arachnoid space, when a higher 
dose of 125 ng/hour was administered in the same manner.229 This study was used as to 
establish the dose of Dex used in the studies in Chapter 3. We injected 62.4 ng or 6.2 ng 
(62.4 mg of Dex in 1 gram of powdered compound; Sigma-Aldrich) in a 1st priming 
injection and attributed the observed short-term pain reversal, to inadequate IL-10 
transgene uptake, possibly due to dose issues. If the dose was too high, it may have 
resulted in inflammatory responses of peri-spinal immune cells similar to the effect of 
high doses of Dexamethasone sodium phosphate described above. Alternatively, if the 
dose was too low or the DEX degraded early on, the switch to M2 polarization may have 
failed and thwarted adequate transgene uptake. 
4.5.2 D-mannose as an adjuvant 
4.5.2.1 The sugar 
D-mannose is a 6 carbon sugar that is a C-2 epimer of glucose. In eukaryotic cells 
mannose is required for N-glycosylated glycophospholypid anchor synthesis and the 
source of mannose in eukaryotic cells is mainly derived from glucose. Glucose is broken 
down to fructose-6 phosphate in the Kreb’s cycle and further processed by 
phosphomannose isomerase (PMI) to mannose-6-phosphate.230 The literature on the 
pharmacokinetics of D-mannose is also scant. One study in mice showed that an 
intravenous injection of [2-3H] mannose showed a clearance half-life of 28 minutes with 
98% of the label cleared after 2 hours.231 In humans given D-mannose orally, blood 
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mannose levels increased in a dose dependent manner with increasing doses of mannose 
(0.07-0.21g mannose/kg body weight). It is possible that D-mannose in CSF would have 
at least a similar or even longer half-life of around 0.5 hours following our i.t. injections, 
long enough to bind receptors on peri-spinal macrophage and dendritic cells. 
4.5.2.2 Structure of the mannose receptor 
The mannose receptor (MR; also known as CD206) is a glycoprotein with one 
transmembrane domain and a cytosolic domain, with a single tyrosine residue that 
mediates receptor internalization and recycling but contains no domains involved in 
intracellular signaling.76 The MR exists in both membrane bound and soluble forms.232 It 
is highly expressed on dendritic and macrophage cells and in the lymph organs, liver and 
to some extent on smooth muscle and endothelial cells. It contains three different 
extracellular domains an N-terminal cytosine rich domain (CR) that can bind sulfonated 
sugars ending in SO4-3-GAL or SO4-3/4-Gal NAc, a fibronectin-like domain, involved in 
collagen binding and eight tandemly arranged C-type lectin-like domains (CTLDs) that 
bind sugars terminating with D-mannose, L-fructose or N-acetyl glucosamine in a Ca2+ 
dependent manner.76 Carbohydrate moieties containing these sugars are often found on 
the surfaces of pathogens and self-antigens. Thus the receptor plays an important role in 
the innate immune response and the internalization and processing of antigens by 
APCs.76,233 Studies in transgenic knock out (k.o.) mice have shown the receptor is 
necessary for clearing mannosylated enzymes and proteins involved in inflammation and 
wound healing from the blood.23 70% of the receptor is localized internally in the early 
endosomal compartment while the other 30% is localized on the cell surface and is 
constantly recycling back and forth between the two via clathrin coated vesicles.234 
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Fluorescent microscopy has shown that MR is dominantly expressed in early endosomes 
and late endosomes which suggests that MR might be transported with its ligand to 
compartments involved in antigen presentation by MHC I or class II.76 These studies 
support MR involvement in ligand-receptor internalization and antigen presentation by 
macrophage and dendritic cells with the potential to polarize both innate and adaptive 
immune cells in the direction of anti-inflammatory M2 polarization.  
4.5.2.3 Receptor function 
While the role of MR in clathrin-dependent endocytosis has been clearly 
demonstrated, the role of the receptor in phagocytosis remains controversial.76, 77 
Phagocytosis is an actin-mediated process involving formation of pseudopodia or 
extensions of cytoplasm that surround and engulf material in a large vesicle known as a 
phagosome. After the material is taken into the cell, the actin depolymerizes and the 
phagosome moves into the cell entering the endosomal pathway.76 Non-phagocytic CHO 
cells, transfected with a hMR cDNA to express MR, failed to phagocytose zymosan, a 
yeast derived particle, mannosylated latex beads, or Mycobacterium kansasii but they 
were able to endocytose mannosylated glycoproteins in a clathrin-dependent manner. 
Transient expression of hMR in two human cell lines also failed to phagocytose.235 The 
authors suggest that while the receptor itself is not responsible for phagocytosis, binding 
of ligand such as D-mannose, may cause recruitment of other cell surface receptors, 
which activate phagocytic processes beyond clathrin dependent endocytosis. 
Notably, the MR lacks signaling domains in its cytoplasmic tail even though the 
receptor has been shown to contribute to down stream signaling events. Thus it appears to 
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require assistance form other receptors to accomplish signaling and modulation of 
cytokines.76 It has been suggested that MR activation by ligands such a D-Mannose, 
reduces pro-inflammatory cytokine production by upregulation of IRAK-M. This 
inhibitor of TLR signaling acts by preventing the dissociation of the kinases, IRAK1 and 
4, from the My88 adaptor molecule, preventing the downstream binding of NFκ-β to its 
promotor, thus preventing upregulation of pro-inflammatory molecules.76 Tachado et 
al.236 demonstrated that MR required assistance from another receptor to generate one 
cytokine, IL-8. The group transfected HEK-293 cells with cDNA coding for hTLR2 only, 
or hMR only, and found that no IL-8 was released from the cells upon challenge with p. 
carinii (jirovecci). Suprisingly, when both receptors were co-expressed, IL-8 was 
detected. Their co-precipitation studies suggested that ligand binding MR might form a 
functional complex with toll-like receptor 2 (TLR2) on the cell surface.236 TLR2 has been 
shown to stimulate phagocytosis in macrophage cells and may contribute to improved 
transgene uptake.237 A second study by Chieppa et al.192 supports the idea that MR works 
in concert with other receptors. They found that DCs treated with an MR specific 
monoclonal antibody, LAM-1, were unable to release cytokines that stimulate Th1 
recruitment, suggesting the antibody was blocking the receptor. However, cells treated in 
the same fashion were still able to release anti-inflammatory cytokines, IL1r-a and IL-RII 
and recruit Th2 cells. Not all MR ligands generated these effects. Cytokine production 
was not significantly altered when mannan, a well characterized MR ligand was used, but 
changes in T cell recruitment were observed when mannose capped–LAM (man-Lam) 
was the ligand.192 These results support the notion that man-Lam may have been acting 
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through MR in concert with other receptors such as, Dectin-2 and DC-SIGN, both with 
well known signaling capabilities.  
An early study by Raveh et al.238 suggests that Il-1β and IL-4 cytokines, may 
actually work together to enhance mannose receptor mediated phagocytosis. They 
showed that the Th2 cytokine, IL-4, increases both cell surface expression and 
endocytosis-mediated internalization of ligand bound receptor. The Th2 cytokine, IL-13, 
produced similar effects. The Th1 cytokine INF-γ had the opposite effects on 
endocytosis. Surprisingly, when applied together, the normally antagonistic cytokines, 
IL-4 and INF-γ, enhanced receptor mediated phagocytosis, an actin mediated process, 
even though they had had opposing effects on endocytosis.238  
Recently, it has been reported that there are many other receptors in the C-Lectin 
family that are capable of binding mannose on macrophage and DCs, cell types common 
to the meningeal layer. These are macrophage inducible C-type lectin (MINCLE), which 
can up regulate pro-inflammatory cytokines and leukocyte migration, dendritic cell 
immune receptor (DCIR) expressed on DCs and many leukocytes and DECTIN-2, a Syk 
signaling coupled PRR on DCs, and dendritic cell-specific intercellular adhesion 
molecule-3 (DC-SIGN).239 All have signaling motifs in their cytoplasmic tails that may 
be working cooperatively with MR to improve endocytosis and IL-10 transgene uptake 
leading to prolonged reversal of allodynia observed when D-mannose was used as an 
adjuvant to assist in IL-10 gene delivery (Chapter 3, Figure 2). 
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4.5.3  Mannose receptor in the CNS 
In the mouse CNS, the mannose receptor is most highly expressed on peri-
vascular and meningeal and choroid plexus macrophages240 which are demonstrated in 
the current report to uptake FAM-tagged protocells. MR are also found on dendritic cells, 
microglia241,242 and to a lesser extent, on astrocytes.190, 243 All three cell types are 
involved in modulating immune responses, and hence could respond to stimulation by the 
adjuvant D-mannnose. While expressed in some brain areas during development, the MR 
is not expressed on neurons in the adult brain or on oligodendrocytes, although in the 
periphery, they have recently been shown to be expressed on similar myelin producing 
Schwann cells.244  
In summary, MR has been shown to be heavily involved in innate immunity 
through the recognition of mannosylated PAMP ligands. By a process that is not well 
understood, the ligand bound receptor is internalized and adaptive immune responses are 
generated. As previously discussed, the receptor may work in synergy with other 
receptors with active signaling motifs in their cytoplasmic domains to aide this process. 
Different combinations of cytokines may also be involved. The receptor/ligand complex 
is processed after internalization into short peptide antigen fragments that are presented 
on MHC I or II for the stimulation of B and T cells. The release of pro- or anti-
inflammatory cytokines is capable of influencing M1 or M2 polarization of macrophage 
with subsequent effects on IL-10 transgene uptake.  
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4.6  Future directions 
4.6.1 Protocells to deliver adjuvant  
Protocells have excellent potential for multimodal delivery of drug or DNA to 
specific cells because of the high loading capacity of the porous silica core and ease with 
which targeting molecules can be conjugated to the lipid by layer. The in vitro and in vivo 
studies in Chapter 2 demonstrate that IL-10 transgene can be delivered by protocells and 
remain fully functional for gene expression following loading procedures. Allodynic 
reversal was robust and full for around two weeks in neuropathic rats intrathecally 
injected with 10 µg of pDNA loaded on DOTAP:CHOL protocells (Chapter 2, Figure 
2.7). While these results are promising, there is much room to improve efficacy of 
intrathecal IL-10 transgene delivery using protocells. One way to advance these studies is 
to use cell specific targeting of pDNA-IL10 and/or adjuvant loaded protocells to DC or 
macrophages in the meningeal lining or to microglia or astrocytes in superficial regions 
of the spinal cord. In this fashion these cells could be directly stimulated to polarize to an 
alternatively activated M2 phenotype with improved capability for transgene uptake. As 
these studies point out, D-mannose is an excellent adjuvant to prime these responses. By 
conjugating mannosylated protein ligands to the lipid bilayer of protocells and 
simultaneously loading the protocell with D-mannose enduring pain relief may be 
achieved in a single co-injection with a very low dose of pDNA-IL10 (1 µg) that was 
previously shown to be ineffective when given as a single injection. 
An early study Kawakami S et al.,245 points to the feasibility of using mannose 
receptor targeted gene transfer. Cultured mouse peritoneal macrophage cells were 
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transfected with a pDNA encoding the luciferase gene complexed with the cationic 
liposome composed of a mannosylated cholesterol derivative, DOPE lipid or non-
mannosylated cholesterol, DOPE lipsome. Mannosylated cholesterol/DOPE lipid was 
found to have significantly higher transfection as measured by fluorescent intensity of the 
luciferase by a luminometer. In vivo, mice were given intravenous injection of the two 
varieties of lipid/pDNA-luciferase and those with mannose showed 16-fold higher 
expression of luciferase in the liver, an organ well characterized to express high numbers 
of MRs. When mannosylated bovine serum was injected 5 minutes prior to the liposome 
injections to saturate MRs, gene expression in the liver was significantly lower, 
supporting the idea that the improved transfection involved the MR.245 Improved 
transfection efficiency also demonstrated by another group using Mannose-C4-
cholesterol containing liposomes to deliver pDNA luciferase, using the same mouse in 
vitro and in vivo models.246 More recently, Jaing, H. et al.,247 used mannosylated 
chitosan-grafted polyethylenimine (Man-CHI-g-PEI) to transfect Raw 264.7 mouse 
macrophage cells and found that the transfection efficiency of Man-CHI-g-PEI/DNA was 
10948.3 than naked DNA, 9.4 higher than CHI-g-PEI/DNA , and 16.6-fold higher than, 
PEI/DNA complexes. Man-CHI-g-PEI/DNA complexes had a much reduced transfection 
efficiency in the presence of excess free mannose (50 µM) used to saturate MRs in a 
receptor binding competition assay, supporting that the mannosylated complexes were 
being taken up by a MR dependent mechanism.247 Mannosylated cholesterol or PEI 
conjugated lipid bilayers on adjuvant or pDNA loaded protocells might fine-tune the use 
of D-mannose as an adjuvant and exploit the unique features of the protocell, namely, 
high loading capacity and ease of surface modification. This new generation of protocell 
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has great potential for generating safe and long term pain reversal with lower doses of IL-
10 transgene with only one injection.  
4.6.2 PLGA encapsulation 
Studies using FDA approved, biodegradable, poly-lactic-co-glycolic acid (PLGA) 
to encapsulate pDNAIL-10 and/or adjuvant, as outlined in the original aims of this 
dissertation also offer great promise to improve intrathecal IL-10 gene delivery. Our 
studies have already demonstrated, in the CCI neuropathic rat model, that only one 
injection of 10 µg of PLGA encapsulated IL-10 was able to generate pain relief of ~ 3 
month duration while unencapsulated pDNA at that dose had no effect.73 Because the 
double emulsion synthesis process used to make the particles, loading efficiency is very 
poor. It took 1 mg of PLGA to encapsulate 10 µg DNA. The ideal would be to drop both 
the dose of pDNA and PLGA and generate the same pain reversal. One way to do this is 
to adjust the double emulsion synthesis process. The method involves three phases: 1) a 
hydrophyllic water based phase that contains the DNA 2) an intermediate organic phase 
composed of polymer mixed with solvent and 3) an outer water phase containing an 
emulsifying agent. Adjusting any of these phases has the potential to improve DNA 
loading efficiency in our future work and our collaborators are currently working on this 
issue. While plasmid DNA is difficult to load, small single stranded DNA such as 
ODN2006 may load without difficulty. One study planned for the future is to encapsulate 
this ODN or other adjuvant molecules to prime IL-10 gene uptake. Encapsulation in 
PLGA may protect the adjuvant from degradation as it protects DNA from nuclease 
digestion.73 ODNs adsorbed on PLGA particles and co-administered with human anthrax 
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vaccine induced faster and greater immunoglogulin G response than when naked ODNs 
with the vaccine.248 
PLGA may be ideal for delivering adjuvants such as ODNs, as it has a bimodal 
release profile so it would cause an initial burst of adjuvant or priming immune response 
during the sensitization period followed by a sustained release that might generate 
prolonged M2 polarization of peri-spinal macrophage. An in vitro analysis of pDNA-
IL10 performed in our studies showed that 30% was released from PLGA by 3 days with 
a steady release continuing greater than 72 days.73  
 The terminal carboxyl groups on PLGA can be conjugated with other molecules 
for cell targeting but the efficiency is low as there are few of these groups available per 
particle.249 One strategy is to coat the microparticle with another polymer that contains 
higher densities of functional groups of polyamines. Another strategy is to coat the 
particle with avidin to which biotinylated ligands are attached.249 Either strategy might 
allow mannosylation of PLGA and targeted delivery for IL-10. 
4.7 Concluding remarks 
The research and development of therapeutic gene based methods of treating 
chronic neuropathic pain such as those presented here have been progressing for greater 
than a decade. While lumbar delivery of transgene has been shown to successfully to treat 
this problem in a number of animal models,68,73,79,99,131,250 there is much room for 
improvement to achieve greater efficiency. Using synthetic particles is an excellent 
approach to advance the effectiveness of such therapy. 
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The use of synthetic particles for biomedical purposes such as drug delivery, cell-
specific targeting, medical imaging and gene delivery has rapidly expanded in recent 
years. As discussed herein, these particles are advantageous in that they can be 
engineered to be highly stable in physiological conditions, and tuned for release of cargo 
at a certain time or pH. They are readily functionalized with ligands, molecules or 
antibodies for specific cell targeting, loaded with therapeutic drugs and administered to 
the CNS safely.214, 251  
Cell specific targeting is being increasingly used in approaches to treat 
neurodegenerative diseases and cancer, where the BBB and neuronal anatomy have 
limited other gene therapy approaches.91 Specific targeting of adjuvant or pDNA-IL-10 to 
peri-spinal macrophage or DCs, may offer key improvements in delivery of Il-10 
transgene as a therapeutic treatment to relieve chronic neuropathic pain states. Modifying 
biodegradable polymers such as PLGA or non-toxic nanomaterials such as protocell with 
cell specific ligand holds exciting promise to advance the work presented here. It is of 
upmost importance that while improving the efficiency of the gene therapy approach, that 
biocompatibility and safety are maintained and continually monitored. 
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Appendix A: Figures 
 
Figure A.1 Characterizations of protocells. 
(A) TEM image of mesoporous silica nanoparticles; scale bar = 50 nm. (B) Nitrogen sorption isotherm of 
10% aminated silica nanoparticles. (C) Determination of pore size of 10% aminated silica nanoparticles by 
the Barrett-Joyner–Halenda (BJH) method [27]. (D) DOTAP:Chol protocells and (E) DOPC protocells 
examined from 1 – 168 hours in specific pH solutions. The negatively charged fluorophore, dextran 
tetramethylrhodamine (DexRho) loaded into the protocells served as cargo. Dashed line indicates 20% 
release for ease of comparison between groups and conditions. For both DOTAP:Chol and DOPC 
protocells cargo release increased as time and pH increased. A significant interaction between time and pH 
was revealed (DOTAP:Chol: F(35,84)= 2.16, p = 0021; DOPC: F(35,84) = 2.35; p = 0.0008. A trend for 
increased cargo release at pH 4 compared to pH 7.4 from DOTAP:Chol protocells was observed. 
DOTAP:Chol protocells at pH 6 revealed the greatest degree of cargo retention at 3 and 72 hours (p < 
0.05). The pattern of greater cargo retention (~15%) at pH 7.4 and 6.0 in DOTAP:Chol protocells suggests 
that cargo will remain associated with protocells until taken up within the cell and released within the late 
lysosome for optimal cargo delivery. 
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Figure A.2 Cells remain highly viable following application of DOTAP:Chol and DOPC protocells 
containing pDNA-IL-10-GFP. 
Cells were incubated for 24 hours with DOTAP:Chol or DOPC protocells loaded with pDNA-IL-10-GFP 
or blank control protocells (no pDNA) at varying concentrations across a 50-fold dose range, 500, 50, 25 
and 10 ug/ml. Dead cells were identified by flow cytometry after staining with ethidium-homodimer-1. 
Results are representative of the percentage of gated cells (average of 4 experiments) compared to untreated 
control cells, **p < 0.01; ***p < 0.0001. 
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Figure A.3 In vivo subtle differences in biocompatibility are revealed between DOTAP:Chol and 
DOPC protocells. 
Baseline threshold responses of both hindpaws (left and right) between animal groups were similar; at 10 g 
(right y-axis) F(4,14)= 0.3721; p > 0.05). (A, B) Following i.t. injection with either 1 or 0.01 mg of 
DOTAP:Chol or (C, D) DOPC protocells, threshold responses remained unchanged throughout the 
timecourse (0.5, 1, 2, 3, 24, 48 and 72 hrs) suggesting no spinal inflammation. (C, D) For DOPC - treated 
animals, while a decrease in thresholds was not observed across the majority of the timecourse (left- F(24,60) 
= 1.88, p > 0.05; right- F(24, 60) = 1.01 p > 0.05), there was a small but significant decrease at 2 hours in both 
hindpaws (p < 0.05 left and right), indicating a subtle and transient spinal cord inflammation resulting in 
decreased sensory thresholds [35]. All animals exhibited normal feeding, grooming and exploratory 
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behavior throughout the 8-week observation. (E) Body weight gain remains normal following i.t. injection 
with DOTAP:Chol or DOPC protocells. At BL, there was no significant difference in body weight between 
untreated (open triangles) and treated animals that received i.t. DOTAP:Chol (2 wks, solid circles; 4 wks, 
solid diamonds; 8 wks, solid squares) or DOPC protocells (2 wks, open circles; 4 wks, open diamonds; 8 
wks, open squares)(F(6, 14) = 2.837, p = 0.0506), followed by a normal gain in body weight. This normal 
gain in body weight between control animals and those receiving protocells by i.t. injection remained 
consistent over time in all groups of animals (n = 3 per group). 
ll  
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Figure A.4 Histological examination of DOTAP:Chol protocells with DNA cargo. 
 Fluorescent histological examination of spinal cord sections near the lumbar spinal cord injection site 
(segments L3-4) 8 weeks after i.t. injection of DOTAP:Chol protocells loaded with FAM-tagged 18 base 
pair (18bp) DNA oligomer. (A) Protocells containing DNA cargo (green; white arrow) are not colocalized 
with astroglia stained for glial fibrillary acidic protein, GFAP (red). (B) However, protocells are 
colocalized in the pial meninges with activated microglia/macrophage stained for OX2 (red). 
Colocalization of microglia with DNA cargo (green) results is indicated (white arrow). (C) There is no 
evidence of cellular death in the meninges or spinal cord, as indicated by the absence of positive staining 
for the apoptotic marker, activated Caspase 3 (red) while protocell-containing DNA cargo (green; white 
arrow) is clearly present. (D) Confocal image identifying DOTAP:Chol protocell cargo of FAM-tagged 18 
bp DNA (green) in the peri-nuclear area (cell nuclei stained with DAPI; blue) of meningeal macrophage 
cells stained for the classic activation marker, EDI (red; white arrow) in the dorsal spinal cord. Overlap 
reveals yellow cytoplasmic and peri-nuclear staining. All images are at 20X; scale bar = 40 µm. 
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Figure A.5 The spread to brain following i.t. protocell injection is determined by the lipid bilayer 
formulation. 
 Graphs are representative of the key data in the corresponding Table I. Fluorescent spectral signal from 
FAM-tagged 18bp DNA cargo in cryo-sliced tissue sections (n = 4) of DOTAP:Chol or DOPC protocell i.t. 
treated animals is compared to the spectra of background autofluorescence from naïve animals. (A) In the 
brain, after 72 hours, there was no significant signal from FAM-tagged DNA delivered by either 
DOTAP:Chol or DOPC protocells. By 8 weeks, background signal in DOTAP:Chol protocell treated tissue 
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was comparable to that of auto-fluorecence (p > 0.05), while the signal from FAM-tagged DNA delivered 
by DOPC protocells had significantly increased compared to autofluorescence (F2, 6 = 8.60; p = 0.0173. 
(B) At the lumbar spinal cord protocell delivery site, FAM-tagged DNA delivered by both DOPC and 
DOTAP:Chol prototocells was clearly present at both 72 hours and 8 weeks when levels of FAM signal 
analysis was compared to levels from autofluorescence (F(2, 6) = 6.18; p = 0.0348), with the signal at 72 
hours significantly higher than that at 8 weeks (F(2, 6) = 10.71; p = 0.0170). (Table 1) Values (1 X E-04) of 
each anatomical region are an average of computer-generated spectral analyses taken from 4 separate 
images of four 10 µm sliced tissue sections. Yellow boxes indicate those areas in which the signal from 
FAM-tagged DNA cargo reached levels that were significantly higher than control autofluorescence for 
that tissue. Asterisks indicate the amount of significance. Very low levels of DOTAP:Chol protocells were 
detected in the lymph organs, such as thymus and spleen, while DOPC remained in the CNS. *p < 0.05; 
**p < 0.01; ***p < 0.0001.  
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Figure A.6 DOTAP:Chol protocells improve cellular transfection of pDNA-IL10 transgene.  
In vitro transfection of HEK cells with a bicistronic plasmid containing the genes for both IL-10 and GFP 
employing an internal ribosomal entry site results in expression of GFP (A; green). Staining with antibody 
for IL-10 (red) shows colocalization (yellow) in a GFP-positive HEK cell (green), indicating functional 
bicistronic transgene expression (A; insert). pDNA IL-10-GFP (B) or pDNA-IL-10 (C) delivered by 
DOTAP:Chol protocells results in functional transgene expression as measured by IL-10 protein release in 
culture supernatants following a 24 hour incubation. Results are the average of 4 representative 
experiments (F(1, 4) = 24.85; ***p < 0.0001, **p < 0.01). Scale bar = 10 µm in both Figure 6A and insert.  
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Figure A.7 Intrathecal delivery of protocells loaded with pDNA-IL-10 causes therapeutic reversal of 
allodynia. 
(A and B) At pre-treatment baseline (BL) values, no significant differences were observed (ipsilateral and 
contralateral; p > 0.05). Following BL assessment, animals underwent CCI of the left sciatic nerve, and 
threshold values were reassessed 3 and 10 days later. Robust allodynia was observed compared to sham-
treated controls (ipsilateral- F(8, 36) = 4.94; p < 0.0004; contralateral- F(8, 36) = 19.89; p < 0.0001). On day 10 
after CCI, rats then received an i.t. injection with DOTAP:Chol/ pDNA-IL-10 protocells or control 
DOTAP:Chol protocells without DNA. A significant bilateral reversal of allodynia beginning on day 12 
after CCI (day 2 after i.t. injection), and continuing through day 22 was observed (overall treatment effect, 
ipsilateral- F(4, 108) = 44.91; p < 0.0001; contralateral- F(4, 108) = 85.09; p < 0.0001). Each CCI operated group 
(closed symbols) received an i.t injection of DOTAP:Chol protocells loaded with pDNA-IL-10 (squares; n 
= 7) or a non-coding DNA (triangles; n = 5) (10 µg pDNA in 1mg protocells in 20 µl PBS) or PBS vehicle 
(circles; n = 3) (20 µl). Each sham-operated group (open symbols) received an i.t. injection of non- coding 
DNA (triangles; n = 5) (10 µg pDNA in 1 mg protocells in 20 µl PBS) or PBS vehicle (circles; n = 3) 
(20ul). Black arrow indicates i.t. injection; *p < 0.05; **p < 0.01; ***p < 0.0001. Nitric oxide 
concentration was measured in cultured Raw 264.7 cells (C) in LPS (black bar) and non LPS-stimulated 
cells (white bar) and those treated with whole protocells or constituents of protocells; silica core (500 µg) 
or Dotap:Chol lipid (20 µl)(hatched bars); All three treatments resulted in significantly less NO production 
than the LPS stimulated positive control (F(4,14)= 321.8; p < 0.0001). 
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Figure A.8 Dexamethasone for improved pDNA-IL-10 uptake does not create robust pain reversal. 
(a and b) Baseline (BL) hindpaw sensory threshold responses to light mechanical touch were measured by 
the von Frey test with calibrated monofilaments). There were no significant differences observed between 
groups (Ipsilateral, F(3,24) =0.2154; p=0.8846; Contralateral, F(3,24)=0.6930; p=0.5665). Following either 
CCI or sham surgery, behavioral testing continued at the time points indicated on the x-axis. Animals 
receiving CCI surgery developed stable allodynia from day 3 to day 10 compared sham-operated animals 
(day 10: Ipsilateral, F(3, 24)=53.54; p<0.0001; Contralateral, F(3, 24)=71.70; p<0.0001). On day 10 following 
CCI surgery, animals received an i.t. injection of DEX (62.4 ng, n=6 or 6.2 ng, n=6), or equivolume i.t. 
saline (n=7) and sham-operated animals received i.t. equivolume saline (n=6). Three days later, an i.t. 
injection of pDNA-IL-10 (25 µg) or equivolume saline was given. Sham-control animals remained non-
allodynic, while CCI animals given i.t. saline remained allodynic. I.t. pDNA-IL-10 following a priming 
injection of DEX (62.4 ng) revealed a delayed and partial bilateral pain reversal (Ipsilateral, F(3,140) =33.83; 
p<0.0001; Contralateral, F(3,140)=19.7; p<0.0001). Black arrows indicate i.t. injections.  
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Figure A.9 The D-Mannose used to prime M2 polarization for improved pDNA-IL-10 uptake 
reverses allodynia greater than 90 days. 
(a and b) No significant differences in BL responses between groups prior to CCI or sham surgery were 
observed (Ipsilateral, F(4,32)=1.009; p=0.4197; Contralateral, F(4,32)=1.147; p=0.3551). Sham operated 
animals (open triangles; n=6) remained non-allodynic throughout the time course. CCI animals (open 
diamonds; n=7) revealed clear allodynia from day 3 to day 10 compared to shams (day 10: Ipsilateral, 
F(4,32)=32.87; p<0.0001; Contralateral, F(4,32)=37.01; p<0.0001). On day 10, animals received an i.t. 
injection of either D-mannose (50 µg; 5 µg) , or equivolume saline followed three days later by pDNA-IL-
10 (25 µg or 1 µg) or equivolume saline. Following the first priming injection of D-mannose (50 µg; closed 
squares; n=8), a robust reversal was observed, compared to CCI-saline injection (Ipsilateral, F(3, 70)=15.87; 
p=0.0004; Contralateral, F(3, 70)=20.40; p=0.001). Full reversal to BL levels continued for a 3 month period 
beyond the 2nd injection of pDNA IL-10 (25 µg) in those animals given D-mannose (Ipsilateral, F(3, 384) 
=57.46; p<0.0001; Contralateral, F(3, 384) =59.20; p<0.0001). A 2nd injection of a lower dose of pDNA-IL-
10 (1ug: closed triangles; n=5) produced a transient 11-day reversal. Animals pretreated with the lower 
dose of D-Mannose (5 µg) followed by a second injection of pDNA-IL-10 (25 µg) (closed circles, n=7) 
showed partial bilateral reversal for the 3 month time course that was not significant (Ipsilateral, F(3.17)= 
12.71; p=0.0270; Contralateral, F(3, 17)= 14.64; p= 0.002). 
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Figure A.10 D-Mannose generates short-term reversal of allodynia without pDNA-IL-10. 
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(a and b) No significant BL response differences between groups prior to CCI was observed (Ipsilateral, 
F(3,13) =0.4995; p=0.6910; Contralateral, F(3,13)=0.1761; p=0.9099). All animals underwent CCI surgery and 
revealed clear allodynia by day 10 with no significant differences between groups (F(3,13) =0.1897; 
p=0.9010; Contralateral, F(3,13)=0.2234; p=0.8780). On day 10, animals were given a single i.t. injection of 
D-mannose (50, 5, or .5 µg; closed squares, closed circles, or closed diamonds respectively) or an 
equivolume saline only (n=3-4/group). Saline-treated animals (open diamonds) remained bilaterally 
allodynic throughout the time course. Treatment with D-mannose (50 µg, n=3) resulted in bilateral partial 
reversal from allodynia that gradually returned by day 20 following injection (Ipsilateral, F(3,70)=15.87; 
p<0.0005; Contralateral F(3,70)= 20.40; p=0.0001). Black arrows indicate i.t. injection. (c-f) Cultured Raw 
264.7 mouse macrophage cells were pretreated with D-Mannose (100 mM) followed by a 2 hour incubation 
with a combination of D-Mannose (100 mM) and LPS (10 ng). (c) Compared to control treatment (No 
Tx=no treatment; Mann=D-mannose), LPS-stimulated cells given D-mannose treatment resulted in 
significantly increased IL-10 protein production, (d) almost complete ablation of IL-1β levels (e) 
significantly reduced TNF-α protein levels, and (f) reduced NO production. (g) Cultured Raw 264.7 mouse 
macrophage cells were pretreated with D-Mannose (500 mM) for 5 hours followed by a 24 hour incubation 
with D-mannose with or without pDNA-IL-10, or D-Mannose and pDNA-IL-10 alone. Those cells 
incubated with D-mannose and pDNA-IL-10 showed robust and significantly increased exogenous rat IL-
10 production over controls (F(5,17)=69.3; p<0.001)*p<0.05; **p<0.01; ***p<0.0001 
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Figure A.11 Spinal and DRG pro-and anti-inflammatory markers expression. 
(a and b) Verification of animal behavior prior to tissue collection is represented. There were no differences 
between groups at BL prior to CCI or sham surgery (Ipsilateral, F(5,18) =0.2597; p=0.8999; Contralateral, 
F(5,18)=0.4947; p=0.9398). As before, CCI treated animals revealed clear bilateral allodynia to day 10 
compared to sham controls (Ipsilateral, F(5, 18) = 35.54; p<0.0001; Contralateral, F(5, 18)=35.96; p<0.0001). 
On day 10 following sham or CCI surgery, animals were given an i.t. pretreatment with D-mannose (50, 
µg) or equivolume saline injection followed three days later by i.t. pDNA-IL-10 (25 µg; closed squares; 
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n=7) or equivolume saline (closed circles; n=4). Saline-CCI treated animals (open diamonds; n=3) 
remained bilaterally allodynic throughout the time course compared to sham-D-mannose (open squares; 
n=3) or sham-saline (open circles; n=6) treated animals (Ipsilateral, F(3,9)=28.79; p=0.0001; Contralateral, 
F(3,9)=19.7; p=0.0007). These data replicated our earlier results above, and reveal that i.t. pretreatment with 
D-Mannose (50 µg) followed by pDNA-IL-10 (25 µg) causes a full bilateral reversal of allodynia compared 
to CCI-control groups (Ipsilateral F(4,126)= 30.27; p < 0.0001; Contralateral F(4,126)= 35.75; P< 0.0001). At 
day 29 while rats remained fully reversed from allodynia, spinal cord and associated DRG tissues were 
collected and stained for the anti-inflammatory cytokine, IL-10 or the pro-inflammatory cytokine, IL-1β. 
(c) Animals that received D-mannose (50 µg) on day 1 and pDNA-IL-10 on day 3, revealed significantly 
greater IL-10 immunoreactivity (IR) in the lumbar spinal cord compared to those animals injected with 
saline only or saline followed by pDNA-IL-10 (Ipsilateral F(3, 5) =34.23; p<0.01; Contralateral F(3, 5) =2.714; 
p>0.05). (d,e,f). Representative images used for the data analysis are presented (red=IL-10 IR, blue=cell 
nuclei). (g) Adjacent tissue sections revealed significantly less IL-1β IR in the ipsilateral lumbar spinal cord 
compared to non-mannose treated control groups (Ipsilateral F(3,5)=10.67; p<0.05; Contralateral F(3,5)=3.73; 
p> 0.05). (h, i, j). Corresponding fluorescent images of the analyzed data are presented (red =IL-1β IR, 
blue=cell nuclei). (k) In addition, significantly greater IL-10 IR in the DRG is observed in the D-mannose 
primed treatment group compared to both non-mannose treated control groups (Ipsilateral F(3, 5) =10.35; 
p<0.05; Contralateral F(3, 5) =5.73; p>0.05). (l, m, n). Corresponding fluorescent images of the analyzed data 
are presented (red =IL-10 IR, blue=cell nuclei). Data for the contralateral DRG data are not shown. *p< 
0.05; **p< 0.01; ***p<0.0001; all images were taken at 10X; scale bar =100µm 
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Figure A.12 A single co-injection of D-mannose with low dose pDNA-IL-10 produces enduring 
reversal of allodynia. 
 (a and b) No significant BL response differences were observed between groups prior to CCI or sham 
surgery (Ipsilateral, F(3, 32)=0.8932; p=0.4973; Contralateral, F(36, 32)=1.393; p=0.231). As before, CCI 
treated animals revealed clear bilateral allodynia through day 10 compared to sham controls (Ipsilateral, 
F(3,32) =32.07; p<0.0001; Contralateral, F(3, 32)=38.78; p<0.0001). On day 10 after testing, sham rats received 
a single i.t. saline injection (open triangles; n=8) or D-Mannose (50 µg; closed triangles; n=4), and CCI rats 
received a single i.t. co-injection of D-Mannose (50 µg) with pDNA-IL-10 (1 µg; closed squares; n=10), 
pDNA lacking the IL-10 gene (control pDNA; open circles; n=7), or equivolume saline (open diamonds; 
n=6). Sham-saline and CCI-saline or CCI-control pDNA resulted in no change from bilateral allodynia 
throughout the time course, D-mannose co-injected with a low-dose of pDNA-IL-10 (1 µg) (closed squares, 
n=5) resulted in a significant and full reversal of allodynia throughout the 3 week time course (Ipsilateral 
F(3, 238)= 60.23; p<0.001; Contralateral =F(3, 224)=22.18; p< 0.001). 
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Figure A.13 Schematic showing theoretical loading of 3 protocell cargos 
A) This cargo is a negatively charged, 18 bp DNA oligomer with an approximate length of 6.12 nm and a 
diameter of ~2. It is tagged with a negatively charged fluorophore, FAM which has a MW of 473.4 and an 
approximate planar length of .139 nm and  height of .722 nm, as calculated by bond lengths. FAM-tagged 
DNA may load directly into the silica pores (~3 nm diameter). B) Negatively charged dextran tetramethyl-
rhodamine (DEXRHO) is composed of a dextran polymer with a MW of 10,000 conjugated with tetra-
methyl rhodamine groups. The tetramethyl-rhodamine group has an approximate planar length of .983 nm 
and height of .576 nm as calculated by bond lengths. This very large molecule is thought to load onto the 
protocell by adsorption with the positively charged DOTAP:CHOL 1:1 lipid bilayer and positively charged 
10% aminated mesoporous silica core. C) Negatively charged plasmid encoding the gene for IL-10 most 
likely assumes a supercoiled structure and is thought to load by adsorption in a manner similar to 
DEXRHO. During the synthesis process each cargo was mixed with the silica and rinsed 3xs with PBS 
before the liposomes were added.  
 
